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ABSTRACT
Objectives: 1) To perform a quantitative comparison of proteins released to media on
combination with cytokine (IL-1p or TNF-a) and Injury as compared to either treatment
alone, and to thus identify proteins which may be responsible for the synergism seen
between cytokine and injury in causing catabolism of cartilage in vitro. 2) To identify
proteins which contribute most to some commonly observed phenotypes on treatment of
cartilage with cytokine or injury or both.
Methods : Cartilage explants from calves were treated with (i)IL-1 (10 ng/ml), (ii)TNF-
a (100 ng/ml), (iii)Injurious compression (50% strain at 100%/sec) and IL-1p (10 ng/ml)
or (iv)Injurious compression (50% strain at 100%/sec) and TNF-a(10 ng/ml), cultured for
5 days post treatment, and the pooled media collected, labeled with one of four iTRAQ
labels and subjected to nano-2D-LC/MS/MS on a quadrupole time of flight instrument.
Peptides were identified and quantified using Protein PilotTM, and MATLAB scripts used
to obtain protein ratios. These results were analyzed using different statistical techniques.
Data from two iTRAQ experiments were combined to generate data for all possible
injury and cytokine treatment conditions, and proteins on which injury and cytokines
acted synergistically identified. PLSR analysis was performed using Unscrambler@X
software with the combined data set to determine which proteins are most relevant to
some observed phenotypes. The phenotypes chosen were sGAG released to media in 5
days post treatment, proline and sulfate incorporation rates on day 6 post treatment, and
nitrite accumulation in media in 5 days post treatment
Results and Discussion: TNF-a+injury and IL-1p +injury treatment conditions show a
very high correlation with each other. Most cytosolic, ER lumen and nuclear protein
levels are highly elevated with both cytokine+injury conditions, while ECM proteins are
either highly down regulated or marginally elevated. Many collagen telopeptides are
down regulated, possibly indicating reduced anabolism. However, attempts at repair
exist, as shown by increased levels of TGF- and activin A, and reduced levels of
LTBP1. Also, biglycan and lumican, SLRPs known to be involved in early development
are significantly increased, possibly indicating repair attempts. Other SLRPs such as
PRELP and chondroadherin are also highly elevated, with one or both injury+cytokine
treatments. While MMPs are mildly down regulated or remain the same, ADAMTS1
increases with TNF-a+injury, indicating increased catabolism. Among ECM structural
proteins, COMP shows high down regulation with TNF-a+injury, possibly due to
reduced synthesis. Proenkephalin, a signaling molecule possibly involved in tissue/repair
and apoptosis, AIMPI, a multifunctional proapoptotic, inflammatory and pro-repair
cytokine and Annexin A5, a protein indicating mineralization and apoptosis are all
highly elevated with cytokine+injury indicating heightened apoptosis and/or repair.
When results of two 4-plex iTRAQ experiments are combined to obtain data for all
possible combinations of injury and cytokine, we again find a very high correlation
between TNF-a+injury and IL-1 +injury (-95%), slightly higher than the correlation
between TNF-c alone and IL-1$ alone (-90%), and much higher than the correlation of
either cytokine+injury condition with cytokine alone (-70%) or injury alone (-75%).
This shows that IL-1P and TNF-a in combination with injury act through very similar
pathways in chondrocytes to produce their effect on cartilage tissue. TNF-a and injury
were seen to act synergistically in a positive fashion on aggrecan, CILP-2, COL6A3 and
histone H4, and in a negative fashion on SPARC and IGFBP7, suggesting that these
proteins may be involved in causing synergism between injury and cytokine in releasing
sGAG to the media. A PLSR analysis shows that SPARC and IGFBP7 project close to
proline and sulfate incorporation, and far away from sGAG, indicating that SPARC and
IGFBP7 may be proteins involved in anabolism. The highest phenotype-protein positive
correlations obtained using PLSR are sGAG with Perlecan, SAA3, Complement factor B,
CILP-2 and pleiotropin, indicating that all these 5 proteins are associated strongly with
catabolism and can serve as markers of catabolism. The correlation of inflammatory
proteins SAA3 and complement factor B with sGAG indicates the role of inflammation
with catabolism.
Conclusion: The combination of injury and cytokine affects tissue differently at a
molecular level as compared to either chemical or mechanical stresses alone. Increased
catabolism and increased attempts at tissue repair are observed due to a combination of
injury and cytokine, and a combination of injury and cytokine may thus serve as a useful
model to study OA in vitro.
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INTRODUCTION
1.1 Arthritis: An Overview
The word "Arthritis" literally means inflammation of joint, and encompasses
more than 100 different rheumatic diseases and conditions. It is the leading cause of
disability in the US 1. Arthritis affects around 21.6% of the US population, and limits the
2
activity of -40% of people having the disease . It is projected to affect nearly 67 million
people by 2030 3. Osteoarthritis (OA) is the most common form of arthritis and is
estimated to affect nearly 27 million people currently 4. It poses an immense societal and
economic burden, with OA alone estimated to cost $185.5 billion annually 5.
1.2 Osteoarthritis: Pathology, Symptoms and Treatment
Osteoarthritis is a condition representing an imbalance between degradation and
repair involving the whole joint and its component parts, with secondary inflammatory
changes in the synovium 6. Pathological features of OA include degradation of hyaline
cartilage leading to loss of joint integrity, elevation in bone density at areas of cartilage
loss (bony sclerosis), subchondral cyst formation and endochondral ossification
(osteophyte formation). The synovium, ligaments and neuromuscular apparatus may also
show pathological changes. Symptoms of OA include joint pain, swelling and stiffness of
joint and loss of mobility. Several factors increase the risk of OA, including body weight,
age, gender, physical activity, bone mineral density, injury and genetic factors 6
Pharmacological treatment of OA is usually symptomatic, with analgesics, NSAIDs and
neutraceuticals like glucosamine and chondroitin sulfate used to combat inflammation
and pain. Non-pharmacological interventions including rest, physical therapy and
lifestyle changes seem to help, however, surgery is usually the only option in end stage
disease. Common surgical procedures are osteotomy (joint realignment), arthroscopy
(removal of loose bodies and inflamed synovium, and smoothing irregular joint surfaces),
arthrodesis (joint fusion) and arthroplasty (joint replacement). Total joint replacement is
the recommended procedure for older patients experiencing significant pain and highly
impaired mobility, however, the life time of the joint may not be more than 10-15 years.
No permanent cure currently exists for OA.
1.3 Articular Cartilage
Articular cartilage is a thin, smooth and stiff layer covering bone surfaces in
synovial joints. It consists of an extensive hydrated extracellular matrix (ECM),
maintained by a population of specialized cells, the chondrocytes, which can occupy as
little as 2% of the total cartilage volume. It serves as a low-friction surface between the
bones of the diarthrodial joint, and is responsible for load support, load distribution and
joint motion. Cartilage is avascular, alymphatic and aneural, and the major source of




The major components of the ECM in cartilage are collagens and the large
aggrecating proteoglycan aggrecan. Collagen accounts for two-third of the dry weight of
cartilage, while collagen type II fibrils are responsible for the tensile strength of cartilage,
extensive cross linking of the collagen fibrils is responsible for the mechanical strength of
cartilage (for review 7). Collagen fibers also help counteract the swelling caused due to
hydration of proteoglycans. Several different collagen types have been identified. In
articular cartilage, Collagen types II, IX and XI form a fibrillar network which constitutes
the structural framework of cartilage, in the form of an anisotropic and inhomogeneous
mesh of fibers. While collagen type II is the predominant fibrillar collagen, collagen IX
molecules have several cross-linking sites through which they interact with collagen type
II and other collagen type IX molecules. Collagen Type XI on the other hand is believed
to form a template which constrains the lateral growth of type II collagen heterofibrils 8
Two predominant classes of proteinases are known to degrade collagens, the matrix
metalloproteinases (MMPs) and the cathepsins, and cleavage of collagen by MMPs is an
important feature of OA 9. Collagen type II synthesis is much lower in adult tissue as
compared to immature cartilage; however, synthesis is seen to significantly increase after
injury 10
Cartilage can be divided into four different depth dependent zones, superficial or
tangential, intermediate, deep or radial and calcified, all of which have different
orientations of their collagen fibrils. The inherent inhomogeneous nature of collagen
fibrils along with depth dependent variation in their orientation is responsible for the
anisotropic and non linear properties of cartilage in compression and tension
1.4.2 Aggrecan
Proteoglycans are a family of molecules with a central core protein, to which one
or more glycosaminoglycan (GAG) chains are added post-translationally. GAG chains
are large extended structures with highly charged sulfate and carboxylate groups, which
dominate the properties of the proteins to which they are attached. Common GAG chains
include Keratan sulfate (KS) and Chondroitin sulfate (CS). (for review 12). Aggrecan is
the major proteoglycan in articular cartilage, where it associates with hyaluran and link
protein to form large aggregates. The large fixed negative charge of these aggregates (due
to the large number of GAG chains on aggrecan) causes an osmotic imbalance, and draws
water from the surrounding areas, thus keeping cartilage hydrated. This hydration of
cartilage by aggrecan influences nutrient and solute transport in cartilage. The high
negative charge of aggrecan aggregates is the main reason for the compressive stiffness
of cartilage (for review 13)
1.4.3 Other ECM Molecules
Besides the collagens and aggrecan, several other molecules are present in the
ECM, including thrombospondins, matrilins, cartilage intermediate layer proteins (CILP),
fibulins, laminins, SPARC, fibronectin and members of the Small leucine rich
proteins/proteoglycans (SLRP) family. Some of these proteins such as matrilins and
laminins have structural roles, while others such as some thrombospondins and SPARC
are involved in modulating cell function, tissue development and remodeling. The latter
set of proteins are termed as matricellular proteins 1
Thrombospondins (TSPs) are multidomain proteins containing either three (TSP
1,2) or five (TSP 3,4 and 5) identical subunits. The thrombospondins identified in
cartilage are TSP-1,3 and 5, of which TSP-5 (COMP) is dominant (for review 15). TSP-1,
TSP-2 and TSP-5 (COMP) function at the interface of the ECM and cell surface, thus
regulating cellular behavior and hence can be said to be members of the class of
16,17
matricellular proteins 1,. To accomplish their roles in ECM remodeling as matricellular
proteins, TSPs 1,2 and 5 interact with a wide variety of proteins and proteoglycans. TSP-
1 is the only thrombospondin which can activate TGF-, which leads to synthesis of
collagens and other molecules. It is known to bind to heparin, perlecan, syndecans-1,3
and 4, versican, Collagen type V, fibrinogen and decorin. It also inhibits several proteases
including MMPs and Cathepsin G 17. Cutaneous wounds in TSP-1 null mice showed
delayed wound healing, reduced levels of active TGF-3, decreased collagen and reduced
inflammatory response 18.
TSP-3 is expressed in early proliferative zone and hypertrophic zone in cartilage.
Its function has not yet been elucidated, while single knockouts of TSPs does not affect
stature, mice that lack TSP-3,TSP-5 and Type IX collagen have 20% lesser limb length,
19suggesting a role for TSP-3 in ECM function 1
COMP, made of five identical domains, is one of the major non collagenous
proteins composing cartilage ECM and comprises up to 1% cartilage wet weight.
Mutations in the COMP gene can cause inherited osteochondrodysplasias such as
seudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED) 20. COMP has
been shown to bind to Collagen type I and II 2 and aggrecan 22. It is also known to
23 24 25interact with Type IX collagen , fibronectin and matrilins . Its interactions with
several ECM structural molecules may serve to organize cartilage matrix and regulate the
load bearing function of cartilage. COMP interacts with BMP-2 to regulate mesenchymal
chondrogenesis in vitro 26. It aids chondrocyte attachment through interaction with
integrins 27. Thus, it has roles in chondrocyte attachment, differentiation and ECM
assembly.
SPARC is a matricellular protein expressed highly in developing tissue compared
to mature, and increased SPARC production is associated with adult tissue remodeling. It
can bind to several different collagens, including collagens I, III, IV and V, and is
possibly involved in ECM assembly and turnover 28
Perlecan is another molecule which plays an important role in the organization of
the ECM through its interaction with many ECM molecules including fibronectin,
nidogen-1 and nidogen-2, PRELP, collagen types XIII and XVIII (for review 29). It also
plays a crucial role in cartilage development, possibly by interacting with and altering
distributions of several growth factors 30
A family of non collagenous ECM proteins which may be involved in structural
roles are the matrilins. There are four matrilins known currently, of which Matrilin-1 and
3 are almost exclusively present in cartilage (for review 31). In the adult knee, all
matrilins are present in the growth plate and peripheral areas of articular cartilage.
Matrilin-1 binds to aggrecan and associates with collagen type II containing fibrils.
Matrilins -1, -3 and -4 form complexes with SLRPs biglycan and decorin 32 and bind to
COMP 25 . Matrilin-3 additionally interacts with collagen type IX 33. Matrilin-3 mutations
have been associated with skeletal disorders such as Multiple epiphseal dysplasia (MED)
34 and bilateral hereditary micro-epiphseal dysplasia (BHMED) 35
Cartilage intermediate layer proteins 1 and 2 (CILP-1 and CILP-2) are two related
structural proteins found in articular cartilage. CILP-1 is a monomeric glycoprotein
predominantly expressed in the intermediate zone of cartilage 36. CILP-1 forms a
functional feedback loop with TGF-, with TGF-p inducing CILP-1 mRNA expression,
and CILP-1 in turn binding TGF- 37. CILP-2 is a protein which exhibits -50%
homology with CILP-1, and its function is not yet clear 38.
Another set of proteins involved in collagen fibril formation are members of the
Small leucine rich proteoglycan (SLRP) family (for review 39). Studies by Vogel et al 40
were among the earliest to show that small dermatan sulfate proteoglycans inhibited
fibrillogenesis in both Type I and Type II collagen from tendon and cartilage respectively
in vitro. Since then, various SLRPs have been identified, including biglycan, decorin,
PRELP, chondroadherin, osteoadherin, fibromodulin and lumican, and probably have
unique functions in collagen assembly, as knockout of any SLRP cannot be compensated
by other SLRPs. SLRPs can also be categorized as matricellular proteins as different
members of this family interact with different molecules in the ECM, and thus help in
remodeling the ECM 41. Recent studies have identified that MMPs can cleave some
SLRPs at precise sites, and it has been postulated that the metabolites thus released may
42
serve as bio-markers to monitor the progression of OA
1.4.4 Matrix proteases
Degradation of the ECM by various proteolytic enzymes is a primary feature of
OA. These proteinases can be classified based on the chemical group which participates
in hydrolysis of the peptide bond. The primary extracellular proteinases are the
metalloproteinases and the serine proteinases, both of which act at neutral pH. The
metalloproteinases are distinguished by a highly conserved motif containing three
histidines that bind zinc at the catalytic site, and a conserved methionine turn beneath the
active site zinc. Metalloproteinases can further be divided into different groups based on
structure, of which MMPs and the ADAMTSs are the most active in the cartilage ECM
43
The Matrix metalloproteinases (MMPs) are a family of enzymes that digest
components of the ECM. Most MMPs have three domains, a prodomain which must be
removed to activate the enzyme, a Zn** containing active domain where the substrate is
catalyzed, and a hemopexin-like C-terminal domain which determines the substrate
specificity of the enzyme 44. Members of the MMP family can be broadly divided into
four groups based on their substrates and cellular location: (i) The collagenases (MMP-1,
-8, -13) cleave major fibrillar triple helical collagens into characteristic %/ and 1/4 length
fragments. (ii) The gelatinases (MMP-2, -9) have high activity against gelatins (denatured
component chains of collagen) and Type IV collagen, the predominant constituent of
basement membrane. However, they have broad substrate specificities and can also
cleave fibrillar collagens and other ECM molecules such as fibronectin and decorin (iii)
The stromelysins (MMP-3,10,11) cleave a wide variety of ECM and non ECM substrates
including aggrecan, laminin, fibronectin, etc and (iv) The membrane type MMPs (for
review 9). It is highly likely that MMPs are responsible for digestion of collagens in vivo
in OA, as MMPs digest collagens in vitro, are expressed in OA tissue at the correct time
necessary to cause degradation, and activities altering expression of MMPs alter the
progression of OA 44. However, MMPs may have more complex roles than pure
catabolism in normal and OA cartilage, as they are known to regulate matrix biology by
means of varied functions including release of growth factors, enhancing/inhibiting
45angiogenesis and modification of the cell-ECM interface
A second important group of proteinases involved in cartilage remodeling are the
ADAMTSs (A disintegrin and metalloproteinase with thrombospondin repeats) (for
review 46). ADAMTS proteins can be categorized into different subgroups based on
sequence similarities and substrates, if known. ADAMTS-1,4,5,8 and 15 form a subgroup
called "aggrecanases" as they all cleave aggrecan, though with different efficiencies.
Some aggrecanases can cleave other proteoglycans such as versican47 and brevican48 as
well. ADAMTS-4 and 5 are the predominant aggrecanases in human OA4 9 , these cleave
aggrecan at the Glu 373-Ala 374 bond in the IGD region, and also at four other distinct sites
between the G2 and G3 domainssosi. Aggrecanases may also have roles besides aggrecan
degradation, with ADAMTS-1 being implicated in growth and development, organ
52morphology and fertility . While aggrecanase mediated degradation is probably more
destructive to cartilage than MMP mediated degradation 53, cartilage may have the ability
to recover better from aggrecanase degradation than from MMP degradation 54
Another major group of ADAMTS proteins involved in cartilage remodeling are
the procollagen N-proteinases (ADAMTS-2,3,14) . As the name suggests, these are
involved in the removal of N-terminal propeptides of procollagen 55-57, and hence are
anabolic in nature.
Regulation of metalloproteinases can happen at different levels. MMP activity in
vivo can be controlled by regulation of gene expression, activation of the pro-enzyme
form and inhibition of active enzymes by inhibitors 58. Tissue inhibitor of
metalloproteinases (TIMP) refer to the family of proteins which inhibit active MMPs by
binding to them (for review 59). Four TIMPs (TIMP 1-4) have currently been identified in
vertebrates. Mammalian TIMPs have two domains, a larger N-terminal domain and a
smaller C-terminal domain, each having three disulfide bonds. All active MMPs are
inhibited by TIMP, however, the four TIMPs differ in affinity for different MMPs.
TIMPs may also form non-inhibitory complexes with proMMPs, with TIMP-2 known to
60form a tight complex with proMMP-2 to activate it . ADAMTS proteins are also
inhibited by TIMPs. TIMP-3 seems to be the strongest inhibitor of the ADAMTS family,
inhibiting ADAMTS-4 and 5 with Ki values in the sub nanomolar range 61. TIMP-1
shows some inhibitory activity against ADAMTS-4 62 and TIMP-2 and TIMP-3 against
ADAMTS-1 63. TIMPs have also been shown to be involved in regulation of cell growth,
migration and apoptosis, either through inhibiting metalloproteinases, or by directly
binding to cell surface receptors 64
1.4.5 Other molecules
Several signaling molecules, such as annexins A2 and A5, proenkephalin,
pleiotropin and many others play important roles in tissue morphogenesis and
differentiation, and their expression levels are significantly altered in diseased state 65-67
1.5 Post-traumatic OA
OA is broadly classified into two forms, primary and secondary. Primary, or
idiopathic OA, is the common age-related onset of the disease, with no obvious cause. In
contrast, secondary OA has clear identifiable causes, such as trauma or a congenital or
developmental abnormality 6. Post-traumatic OA, a type of secondary OA, refers to joint
degeneration, dysfunction and pain which develop after joint injuries. Unlike primary OA
which affects aged people, post traumatic OA affects younger individuals primarily, as
they are more prone to joint injury 68. A study by Gelber et al 69, for example, found that
cumulative incidences of knee OA by 65 years was 13.9% for participants who had an
injury during adolescence and young adulthood, and 6% for those who did not. Joint
impact loading; tears in the meniscus, ligament and joint capsule, intraarticular fractures
and joint dislocations all increase the risk of posttraumatic OA 70. In vivo joint injury
causes immediate mechanical damage to cartilage, followed by an acute inflammatory
phase which can last up to two months, and a chronic phase which eventually leads to
OA like symptoms 7 1
1.5.1 In Vitro Cartilage Injury Models
The stress distribution of articular cartilage in vivo depends on several factors,
including contact force, surface geometry, tissue properties, and cartilage thickness 72,
thus making it extremely difficult to quantify and study the effect of mechanical injury on
cartilage biochemical properties. In vitro models enable precise application of load, and
accurate measurements of the stress and strain profiles thus generated, which can then be
correlated with cellular and biochemical changes in cartilage. Usually, high stress/stress
rate mechanical compression is applied, and the resulting maximal strain measured or
vice versa. Also, mechanical compression injury can either be confined or unconfined.
The extent of damage to cartilage by blunt trauma in vitro depends on the magnitude of
stress applied 73 , the orientation of load relative to the articular surface 74 and the rate of
loading 7. Injury immediately affects the collagen network, which in turn reduces the
tensile load carrying capacity of cartilage 76, affects compressive and shear stiffness 77
and causes increase in matrix water content 73 and cartilage swelling because of reduced
ability of damaged collagen to withstand swelling pressure of the GAGs. Rapid GAG loss
to the media post injury occurs, possibly due to mechanical disruption of the ECM78
Kurz et al showed that injury lowers biosynthetic rates of chondrocytes immediately, and
biosythesis remains impaired even after 3 days post injury '7. Within 24 hours of a single
injurious compression, gene expression of MMP -1,-3,-9,-13; TIMP-1 and ADAMTS -
4,5 increase significantly 79. Pooled media for 5 days post injury show that MMP -1,-3,-
13 are highly up regulated, and MMP-9,TIMP-1 and TIMP-2 mildly up regulated at the
protein level 80 . Injurious compression also causes chondrocyte cell death by a
combination of necrosis and apoptosis, with necrosis occurring earlier at the site of injury
and apoptosis responsible for subsequent spread of chondrocyte death beyond the initial
impact area 81,71 The extent of apoptosis is directly related to the load applied, and
apoptosis seems to occur at stresses lower than that required for matrix degradation . it
is however unclear if apoptosis drives matrix degradation or whether matrix degradation
causes apoptosis in vivo. Apoptosis of chondrocytes subsequently reduces the ability of
cartilage to repair itself and contributes to the evolution of an OA like phenotype.
1.6 Cytokines in OA
Cytokines such as IL-1$ and TNF-a are key mediators in the post traumatic
inflammatory phase. These cytokines are produced by the synovial membrane, diffuse
through the synovial fluid into cartilage, and activate chondrocytes, which in turn
produce pro-inflammatory cytokines and proteases 83. Therefore, these cytokines act in an
autocrine and a paracrine fashion. IL-1p and TNF-a are present in OA cartilage, but not
in normal 84. Also, both IL-1$ and TNF-a have been isolated from the synovial fluid of
patients undergoing ACL rupture, with the concentrations of IL-1 and TNF-a
proportional to the severity of chondral damage 85,86
1.6.1 IL-1p in cartilage damage
IL-16 is synthesized as a 31 kDa precursor, which is then cleaved to form the
active 17.5 kDa protein 87. IL-1$ acts upon cells through specific cell surface receptors,
type I and type II, of which type I IL-1 receptor is elevated in OA cells, and is mainly
responsible for signal transduction by IL-16 in OA 87. Direct injections or gene
transfection of IL-IRa, a soluble receptor antagonist of IL-1, reduce the progression of
experimental OA in animal models 88.
IL-1 promotes collagen degradation 89 by stimulating metalloproteases 90. IL-iP
causes strong up regulation of MMP-1, MMP-3 and MMP-13 at both the mRNA 91 and
the protein levels 80 in vitro. It causes aggrecan degradation by stimulating aggrecanases
in vitro, but it is unclear whether ADAMTS-4 or ADAMTS-5 is the predominant
aggrecanase responsible for this. Species specific differences may be possible, with
ADAMTS-4 the predominant aggrecanase in cultures of human OA chondrocytes
stimulated by IL-la 92, and ADAMTS-5 in murine cartilage explants stimulated by IL-la
. IL-1 also decreases proteoglycan and collagen synthesis in cartilage in vitro 4
Exposure of cartilage to IL-1f also affects physical properties of cartilage, causing an
increase in hydraulic permeability and decrease in streaming potential and equilibrium
modulus, possibly due to the degradative activities of MMPs and aggrecanases 96
1.6.2 TNF-a in cartilage damage
TNF-a is synthesized as a type II transmembrane protein arranged as
homotrimers, which is then released by proteolytic cleavage to form the homotrimeric
soluble form. It activates cells through two kinds of receptors, TNF-R1 and TNF-R2, of
which TNF-R1 is the type present in several kinds of tissues including cartilage. TNF-R1
is responsive to both the soluble and membrane trimeric forms of TNF- 97 , and is over
expressed in OA cartilage on the surface of chondrocytes located near sites of high GAG
loss 98. Like IL-1P, TNF-a also causes aggrecan degradation by stimulating aggrecanases
99,100, and suppresses proteoglycan synthesis, though less efficiently than IL-1 01. TNF-a
also highly up regulates several MMPs including MMP-1, MMP-3, MMP-13 and MMP-9
80. Additionally, TNF-a stimulates IL-6 production 101, which in combination with its
102
soluble receptor can contribute to further proteoglycan catabolism
1.6.3 Comparison between IL-1 and TNF-a in cartilage damage
103TNF-a exerts effects similar to IL-1, and can also act synergistically to IL-1
however, animal models of RA indicate that TNF-a and IL-1p may have distinct
functions, with TNF-a important in initiating joint swelling, and IL-1 playing a role in
subsequent inflammation and cartilage erosion 104. Chondrocytes stimulated by IL-1
alone or IL-1 in combination with TNF-a produce inflammatory molecules such as
inducible nitric oxide synthetase (iNOS), cyclooxygenase-2 (COX-2) and phospholipase
A2 (sPLA2). Molecules such as nitric oxide and E-series prostaglandins produced by the
activity of these enzymes have further anabolic/catabolic roles downstream 105
1.6.4 Anti-Cytokine Therapies for OA treatment
In spite of the fact that IL-1 and TNF-a seem to be key molecules involved in the
pathogenesis of OA, the inhibition of IL-1 and TNF-a using IL-iRa and anti-TNF alpha
106therapies in OA patients is not very successful , generating the need for further
investigation of the roles of these cytokines and better therapies.
1.7 In Vitro Models combining injury and cytokine
Therefore, to get a more realistic in vitro model of post traumatic OA, we need to
capture the effect of cytokines as well. Patwari et al used an in vitro model where
cartilage explants from newborn bovine and human knee tissue were subjected to a single
injurious compression followed by incubation with exogenous cytokines IL-la and TNF-
a for three days 107. They found that incubation of injured bovine cartilage with cytokines
increased sGAG loss to the media greatly, from a mean of -7% sGAG loss from injured
cartilage without exogenous cytokine, to a mean of 60% and 54% sGAG loss for injured
cartilage incubated with 10 ng/ml IL-la, and 100 ng/ml TNF-a respectively. Interaction
between injury and cytokine in both cases was highly significant, with P<0.001 by two
way anova. IL-la and TNF-a showed synergism with injury for human knee tissue
explants too, though the magnitude of synergism was far lower. Sui et al found that anti-
IL-6 Fab reduced the amount of sGAG loss caused by synergism between TNF-a and
injury in newborn bovine cartilage explants, but did not completely eliminate it,
suggesting that the synergism between TNF-a and injury is at least partly mediated by
IL-6 produced by chondrocytes 108. Further, addition of exogenous IL-6 along with its
soluble receptor (sIL6R) increased the synergism between exogenous TNF-U and
mechanical injury in newborn bovine and in human knee and ankle cartilage explants.
1.8 Thesis Objectives
Injury and cytokines both play a significant role in the progression of post
traumatic OA, and interplay between these two factors possibly drives OA progression in
vivo. Therefore, an in vitro model system in which injured cartilage explants are
incubated in IL-16 or TNF-a is used to try to elucidate the mechanism by which injury
interacts with cytokines to drive OA. A proteomic profile of media released from
cartilage under different treatment conditions (injury, cytokine and combination of injury
and cytokine) is generated using a quantitative iTRAQ 2D-LC-MS-MS approach. The
levels of several different proteins under different treatment conditions are compared, and
proteins on which injury and cytokine act synergistically, in a positive or a negative
fashion are identified. This approach thus helps understand the mechanism by which
injury and cytokine interact with each other in driving the pathogenesis of OA.
The next part of our study uses a partial least square regression (PLSR) approach
to relate protein ratios across different treatment conditions with measured phenotypes
across the treatment conditions. This approach removes redundant data, and determines
which proteins contribute most to specific observable phenotypes. Using this approach,
we are able to see hidden associations between proteins, between phenotypes and
between proteins and phenotypes.
Thus, using a simplistic in vitro model, the overall goal of this project is to
determine molecules which may be important to OA disease progression, and may serve
as biomarkers or possible therapeutic targets for OA.
METHODS
2.1 Overview
Equal volumes of cartilage were treated in equal medium volumes with one of the
following treatments (i) 10 ng/ml IL-i I3 (ii) 100 ng/ml TNF-a (iii) unconfined mechanical
compression to 50% strain at 100%/sec followed by incubation with 10 ng/ml IL-l $3 (iv)
unconfined mechanical compression to 50% strain at 100%/sec followed by incubation
with 100 ng/ml TNF-a. Medium was pooled, deglycosylated by chondroitinase ABC and
digested with trypsin. A 4-plex iTRAQ labeling strategy was used, with sample from
each treatment condition labeled with one of the four iTRAQ labels as follows: IL-1 :
iTRAQ 114; TNF-a : iTRAQ 115; IL-1f +injury : iTRAQ 116 and TNF-a +injury :
iTRAQ 117. The samples were then combined, fractioned by SCX chromatography,
subjected to RP-LC/MS/MS and analyzed using ProteinPilot TM (ABI). Matlab scripts
were used to generate protein ratios from the peptide summary reports of protein pilot.
These data were subjected to subsequent analysis. To study the effect of biological
variance, all steps are performed on biological replicates, replicate 1 consisting of
cartilage from a set of three animals, and replicate 2 from a different set of three animals.
2.2 Cartilage Explantation, Mechanical Injury and Cytokine Treatment
Cartilage explants were obtained from the femoropatellar groves of 2-3 week old
calves as described previously 109. Briefly, cartilage was cored and punched to obtain
disks (1 mm thick X 3 mm diameter). Between 8-12 disks (explants) from each of 3
animals were used for each treatment condition for biological replicate 1, and the same
procedure followed for biological replicate 2 with 3 different animals. These disks were
equilibrated for 5 days prior to start of treatment in 1% ITS (high glucose (25 mM))
DMEM medium supplemented with 10 mM HEPES, 0.1 mM non essential amino acids,
115 uM ascorbic acid, 400 uM L-proline, 100 U/ml penicillin, 100 ug/ml streptomycin,
0.25 ug/ml amphotericin B powder (PSA for tissue culture) and 1 mM sodium pyruvate.
On treatment day, location matched explants were placed in four different groups and
cultured in 2 ml medium without ITS supplementation.
Cartilage explants meant to be treated with cytokines alone were placed in
medium without ITS containing 10 ng/ml IL-1p or 100 ng/ml TNF-a. The explants were
then cultured for 120 hours with 10% medium removal and supplementation every 24
hours. Cartilage explants meant to be treated with cytokine+injury were individually
injured first by mechanical compression in a custom designed, incubator housed
110,79,108apparatus as described previously . Explants were subjected to a single
unconfined compression at a strain of 50% and strain rate of 100%.second. After injury,
they were placed in medium without ITS containing 10 ng/ml IL-1 IP or 100 ng/ml TNF-a,
and cultured for 120 hours, with medium removal and supplementation as before. After
treatment, explants and cartilage were stored at -80 C
2.3 sGAG Removal, Trypsin digestion and iTRAQ labeling
3 ml of the medium from each condition (for biological replicates 1 and 2 each)
was supplemented with 5 mM EDTA, 100 ug/ml PMSF and 5 mg/ml iodoacetamide. The
samples were dialyzed for 3 hours against a buffer with 10 mM Tris acetate, 40 mM
NaCl and 5 mM EDTA, mixed with 70 milliunits of Chondroitinase ABC (the
deglycosylation agent and the internal standard) and left to dialyze and deglycosylate
overnight at 37 C. The samples were further dialyzed against 2 mM TEAB and 0.5 mM
EDTA for 8 hours, and then against 500 mM TEAB. The samples were then frozen,
concentrated 10 fold, and then further concentrated to a final volume of 150 ul. Samples
were then reduced by 2 mM TCEP (in 100 mM TEAB) for 2 hours, and alkylated by 5
mM iodoacetamide (in 100 mM TEAB) for 2 hours. The samples are then precipitated by
6 volumes of ice cold acetone and then centrifuged at 15000 x g for 30 min at 4C. The
pellets were re-suspended in 25 ul of 50 mM TEAB containing 0.1% SDS. Trypsin (0.1
mg/ml in 50 mM TEAB) was added to each sample in the ratio 1:37.5. Sample volume
was increased by addition of water and acetonitrile to 40 ul, following which samples
were incubated at 37 C overnight, speedvae'd to dryness, and resuspended in 500 mM
TEAB.
The peptides were then iTRAQ labeled according to manufacturer's instructions.
Briefly, iTRAQ labels were equilibrated at room temperature, diluted with ethanol,
vortexed and centrifuged at 16000 x g for 1 minute. The iTRAQ reagent was then added
to 100 ug peptides from each sample. The samples were then vortexed for 1 minute,
sonicated for 5 minutes, centrifuged at 16000 x g for 1 min, and equilibrated at room
temperature for 55 minutes. Following this, samples were diluted to 200 pl total volume
with water and combined in equal proportion according to volume equivalents. The
combined sample volume was reduced to 50 ptl, further combined with 1% phosphoric
acid and 1 ml of strong cation exchange buffer A (10 mM Potassium phosphate pH 2.8,
25% acetonitrile), made to pH 3.5 and diluted with 3 ml SCX buffer A.
2.4 SCX Chromatography and LC/MS/MS
The combined labeled sample was injected onto a 2.1 mm X 100 mm strong
cation exchange column on an Agilent 1100 HPLC at a flow-rate of 250 ul/min; with
100% Buffer A for 20 minutes, 0 to 40% gradient SCX buffer B (10 mM phosphate
buffer pH 2.8, 400 mM KCl, 25% acetonitrile) for the next 40 minutes, 40 to 90%
gradient SCX buffer B for the next 5 minutes and finally 95% buffer B for the next 5
minutes before returning to starting conditions (Total run time ~ 80 minutes). Peptide
elution was monitored by UV absorption at 214 nm. Fractions were collected every 0.5
minutes and stored at -80 C. Fractions were then concentrated by speedvac and desalted
by zip tip. Desalted factions were loaded onto a 75 um x 160 mm column with 10 um tip
packed in house with Vydac protein/peptide C18 packing material. Peptides were loaded
at flow-rate 250 nl/min at 2% buffer B (1.2% acetic acid in 90% acetonitrile) for 12.5
minutes, eluted with 2 to 40% buffer B gradient for 147.5 minutes and washed out with
40 to 60% buffer B gradient for 20 minutes. This was followed by holding at 60% B for 5
minutes, returning to 2% B over 15 minutes and equilibrating at 2% B for 60 minutes.
The Buffer A is 1.2% acetic acid in water. Following LC, mass spectrometry was
performed using QStar, a Quadrupole time of flight mass spectrometer (ABI) with a
nanospray source. Precursor ions between m/z 400 and 1600 with a charge state between
two and four were selected with Analyst 1.1. Each cycle (10 sec) consisted of an MS scan
followed by 3 data dependent MS/MS scans (m/z 100-1600), with ions excluded for 100
seconds after a single spectra. All fractions from the first replicate were run first, before
running samples from the second replicate.
2.5 Data Analysis
Data were analyzed using the Paragon and Pro Group algorithms of
ProteinPilot TM Software 2.0.1 (ABI). The variable modifications allowed were NH 2
terminal iTRAQ labeling, iTRAQ labeled lysine, iTRAQ labeled tyrosine and oxidized
methionine. The number of missed trypsin cleavages was restricted to 1. The search was
conducted against the NCBInr bovine database assembled in June 2008.
The peptide summary report generated is then exported into excel, and scripts are
written using Matlab (Mathworks) to calculate mean protein ratios, standard deviation
and standard error, and p values for the null hypothesis that the protein ratios are different
from 1. The Matlab script also makes sure that only peptides which are identified by
Protein Pilot with confidence greater than 90%, which are quantified well for both labels
in the ratio under consideration (i.e. the ratios generated from protein pilot are not 0 or
9999), and whose spectra are manually verified are chosen for calculating protein
information. All proteins identified by less than two peptides satisfying all the above
criteria are discarded. All mathematical operations for calculating mean, standard
deviation, standard error, p value, etc are done using log transformed ratios to make sure
that ratios lesser than and greater than one are treated identically. The means and standard
1deviation are calculated using ( ) listed by protein pilot as weights. The weighted
%Error
mean, the weighted standard deviation and the weighted standard error in the log space






Where X w is the weighted mean of the log transformed peptide ratios Xi , Wg is the
1
weight of the peptide i (calculated as ), N refers to the number of well quantified
%Error
manually verified peptides identified with confidence > 90%, Sdw is the weighted
standard deviation, and SEW is the weighted standard error.
Normalization of the protein ratios thus obtained was done using the weighted
mean of chondroitinase ABC, the enzyme used for glycosylation. This protein is a non
mammalian protein and can thus serve as an internal standard 80. Also, the ratio of this
protein is almost 1 in all cases, thus illustrating that the levels of this protein do not get
affected by treatment, as expected. To obtain the p values for the null hypothesis that log
transformed protein ratios were different from zero, the normality of log transformed
peptide ratios was first checked using Lilliefors test for normality in MATLAB, if the log
transformed ratios were normal, a paired t test was used, if not, the Wilcoxon sign rank
test was used. To correct for multiple comparisons, the Benjamini Hochberg procedure
m was used and false discovery rate (FDR) controlled at 0.1. The Benjamini Hochberg
procedure was performed for each ratio (i.e. 115:114, 116:114 and 117:114) separately.
2.6 Comparison of biological duplicates and final protein list
compilation
To test whether there exists significant variation between biological replicates, for
proteins identified in common between biological replicate 1 and 2, histograms of the
difference between log transformed ratios from biological replicates 1 and 2 are plotted,
and the mean and standard deviation of this difference computed, for each ratio.
A final protein list is then compiled for use in further analysis. To do so, a list of
proteins which satisfy Benjamini Hochberg procedure across all three ratios from the first
biological replicate is selected. This is supplemented with proteins identified from the
second biological replicate alone which satisfy Benjamini Hochberg procedure across all
three ratios, after correcting for any major inter experimental bias. This correction is done
using the difference between the means of log transformed ratios from replicates 1 and 2
obtained by comparing the biological replicates in the previous step. A total of 199
proteins are thus chosen for the final compiled list, for each of which we have ratios for
three conditions, TNF-ax:IL-1p, IL-1f +injury:IL-1 and TNF-a +injury:IL-1p.
2.7 Global Proteomic Analysis and Clustering
A correlation matrix is generated using MATLAB between different ratios (TNF-
a:IL-1p, [IL-1f+inj]:IL-1p and [TNF-u+inj]:IL-1p) using the compiled protein list. K-
means clustering analysis was done using the statistics toolbox in MATLAB on the
compiled protein data set. This methodology partitions the 199 proteins into k clusters, by
minimizing the sum of distances between each protein and the centroid of the cluster the
protein is partitioned into. The number of clusters is chosen such that the mean of the
silhouette values is the maximum. The Mann Whitney U test or the Unpaired t test is
used to check for the uniqueness of each cluster.
2.8 Merging data between two iTRAQ experiments
We seek to combine data from two iTRAQ experiments, an earlier experiment 80
and this experiment. The earlier experiment has ratios (IL-1 IP:untreated), (TNF-
a:untreated) and (injury:untreated), while the current experiment has ratios (TNF-a:IL-
1p), (IL-1p +injury:IL-1p) and (TNF-a +injury:IL-1p). By merging data from both
experiments, we hope to obtain data for all possible ratio combinations with respect to
untreated control (i.e. IL- 13 :untreated, TNF-a:untreated, Injury:untreated, IL-l$
+injury:untreated and TNF-a +injury:untreated). Before doing so, we need to compare
data for proteins found in common between these two experiments to ensure that there is
no significant inter experimental error. The comparison is done only between proteins
which satisfy Benjamini Hochberg procedure across all ratios at FDR 0.1 in both
experiments. 74 proteins are thus found in common between both these experiments, a
histogram of the difference between the log transformed (TNF-a /IL- 10) ratios from both
these experiments is plotted, and the mean and standard deviation of this difference
computed.
If there is no significant inter experimental error, we merge data from both these
experiments to obtain data for all five treatment conditions for 74 proteins. A correlation
matrix is generated using Matlab to ascertain how these five conditions (IL-1p, TNF-a,
injury, IL- 11 +injury and TNF-a +injury) correlate to each other.
2.9 Finding proteins on which injury and cytokines act synergistically
We want to identify proteins on which injury and cytokine act synergistically in
either a positive or a negative fashion. To do so, if the ratio of (cytokine:untreated) were
RI, the ratio of (injury:untreated) R2 and (cytokine+injury:untreated) R3 for a given
protein, if all the three conditions R3>R1, R3>R2 and R3>R1*R2 are satisfied for any
protein, injury and cytokine are determined to exert positive feedback on that protein. On
the other hand, if the three conditions R3<R1, R3<R2 and R3<R1*R2 are satisfied for
any protein, injury and cytokine are determined to exert negative feedback on that
protein.
2.10 Partial Least Square Regression (PLSR)
We want to find out which protein ratios contribute most to observed phenotypes.
We take the compiled protein list consisting of log transformed protein ratios for 74
proteins across 5 conditions, and eliminate two proteins because they act as outliers and
add noise to the PLSR model. We thus have an independent 72*5 data matrix (X)
consisting of log transformed protein ratios across five treatment conditions. For the
dependent Y matrix, we choose phenotypes for which data are already available for all
the five treatment conditions. The phenotypes thus chosen are amount of sGAG loss to
the medium during the 5 day treatment regime, amount of nitrite accumulation in medium
during the 5 day treatment regime, proline incorporation rate on the 6 th day post start of
treatment and sulfate incorporation rate on the 6th day post start of treatment 11
We thus create a (4*5) matrix Y, with each element of the matrix = log -Ilj , where
P is the value of the phenotype i on receiving treatment j, and Pe is the value of the
phenotype i on receiving no treatment. (For example, Pj may be sGAG released to the
medium on treatment with TNF-a, with PI, the sGAG released to the medium on absence
of treatment)
PLSR 114 is used to find a relation between Y and X, by choosing dimensions
(latent vectors) such that superfluous information in X and Y is eliminated, and the
maximum possible co-variation between X and Y is captured in the first few latent
vectors. Both the X and Y matrices are mean centered and set to unit variance along the
columns (i.e. proteins and phenotypes respectively) before performing PLSR.
PLSR is performed using the NIPALS algorithm 115 with The Unscrambler @ X Version
10.0.1 (Camo) software. The PLSR model is trained and validated by cross-validation,
where portions are omitted from the input matrix in turn, omitted data predicted from the
remaining data in the matrix, and predicted data compared to actual omitted data. Once
the latent vectors are determined, the proteins, phenotypes and treatments are projected
on the first few latent vectors, this enables one to reduce the dimensionality of data and
see relationships between proteins, phenotypes and treatments which were previously
hidden.
RESULTS
3.1 Reproducibility between biological replicates
We want to check whether the methodology and our data are sufficiently robust as
to show reproducibility between biological duplicates (Unlike technical replicates which
are designed to show variability in the process, biological replicates capture variability in
both the target population and the process) . For this, only protein ratios whose p values
satisfy Benjamini Hochberg procedure at FDR 0.1 are chosen, for each ratio separately.
Proteins identified in common between the two biological replicates are compared
by dividing the geometric mean of the peptide ratios for any protein in the first biological
replicate (ratiol) by the geometric mean of the peptide ratios for the same protein in the
second biological replicate (ratio2). These ratios of ratios (ratiol/ratio2) are log
transformed and plotted as histograms for each treatment condition (Figure 1) We expect
to see a mean of zero and negligible standard deviation for these histograms if biological
replicates were perfectly reproducible. We note that the mean +/- standard deviation is
0.1010 +/- 0.3015 for log2(ratiol 115:114/ratio2 115:114), 0.0807 +/- 0.3134 for
log 2(ratiol 116:114/ratio2 116:114), and 0.4317 +/- 0.4292 for log2(ratio1
117:114/ratio2 117:114). The huge error (43.17%) between 117:114 ratios is probably
due to incomplete protein digestion in the sample from biological duplicate 2 containing
the 117.1 m/z label (a white precipitate was seen in this particular sample). To correct for
this error, 0.4317 was added to log 2(ratio2 117:114) for all protein readings obtained
from the second biological replicate. The % variation observed in the other two cases
(10.1% and 8.07%) is well within the 25% variation found between biological replicates
and the 23% variation between experimental replicates (variation due to different iTRAQ
experiments) in the study by Gan et al 116
3.2 Global proteomic analysis
A total of 199 proteins identified by either iTRAQI or iTRAQ2 or both and which
satisfies Benjamini Hochberg procedure at FDR 0.1 across all ratios were used to perform
a systems level analysis of the effect of the combination of injury and cytokine on the
cartilage sample. A matrix of correlation coefficients between the log transformed protein
ratios is shown in Table 1. (All ratios are expressed with respect to IL-1P because a
4-plex iTRAQ analysis (using 4 labels) were chosen). A high correlation of ~ 91.4% was
seen between the two (Cytokine+Injury) combination conditions indicating either that the
proteins were affected similarly by the two cytokines in combination with injury or that
the effect of injury was much higher than the effect of cytokines , thus dominating the
overall (Cytokine+Injury) response. This high correlation between the two
(Injury+Cytokine) conditions is verified by a plot between log2(IL-1p +inj/IL-1p) and
log2(TNF-a+inj/IL- 1p ) (Figure 2) , which shows a linear relation with R2 equaling
0.8353.
3.2.1 K-means clustering analysis
K-means clustering was used to cluster the proteins into groups which would
enable better understanding of how groups of proteins varied with treatment. Silhouette
plots were used to determine that 3 clusters yielded optimum inter-cluster variation as
compared to intra-cluster variation. Figures 3a-d represent the proteins in 3D space and
their projections on 2D planes. The proteins are determined to be well separated into
three clusters by means of unpaired t test (All p values are << 0.001). Figure 4 shows
how the centroid of each cluster varies with treatment. Broadly, cluster 2 proteins are
depressed by all conditions wrt IL- 13, and additionally depressed in the (TNF-a +injury)
condition. Cluster 1 proteins are almost unchanged with all treatments, showing a mild
increase on treatment with injury and cytokine. Cluster 3 proteins are in general elevated,
and show increased elevation on treatment with injury and cytokine.
3.2.2 Effect of Cytokine+injury on proteins based on cell location
Proteins are sorted by location and average ratios are found out for all proteins
belonging to a particular cellular location. We observe that proteins inside the cell
(Including the cytosol, ER lumen and nucleus) all show highly elevated levels in response
to both (TNF-a +injury) and (IL-1P +injury) (p<0.05) (Figure 5). ECM proteins and
membrane protein levels remain almost the same on treatment with (cytokine+injury).
Secreted proteins are down regulated to a greater extent with TNF-a alone than with
(cytokine+injury).
3.3 Effect of combination of cytokine and injury on specific proteins
In cartilage, a few collagens are synthesized in a procollagen form and require
processing by removal of N- and C-terminal propeptides to form mature collagen. The
release of C-terminal propeptides is hence an indicator of collagen synthesis. From
Figure 6a, we see that C-terminal propeptide levels of many collagen chains are mildly
to moderately down regulated with IL-1 +injury, and moderately to highly down
regulated with TNF-a +injury, indicating reduced synthesis. When we examine other
major structural proteins found in the ECM, we find that fibronectin is highly down
regulated with TNF-a treatment alone or (TNF-ct +injury) and COMP is highly down
regulated with (TNF-a + injury) (Figure 6b). All the Matrilins are down regulated with
TNF-a or (IL-1 p + injury), but elevated with (TNF-a + injury), with Matrilin-3 showing
the most significant down regulation (Figure 6b). Aggrecan shows marginal down
regulation with all three treatments with respect to IL- 1P. Members of the Small leucine
rich proteoglycan (SLRP) family respond significantly to the combination of treatment
and injury, with chondroadherin, biglycan, lumican and PRELP all showing significant
up regulation with (TNF-a + injury) (Figure 6c). Biglycan also shows up regulation with
(IL-IP + injury).
We next look at proteases which are known to be important in ECM degradation
(Figure 6d). Both MMP 2 and MMP3 are highly suppressed with TNF-a compared to
IL- 1p, but only very mildly so on treatment with a combination of cytokine and injury
MMP 13 is down regulated with (IL-1P + injury) treatment. ADAMTS-1 is the only
ADAMTS protein found in our study, it is up regulated with (IL- 13 + injury) and more
significantly with (TNF-a + injury). The metalloproteinase inhibitor TIMP-2 is
marginally up regulated on treatment with IL-1 I and injury, but not so with TNF-a and
injury.
The next figure (Figure 6e) shows the effect of the combination of cytokine and
injury on members of the TGF- super family and their inhibitors. TGF- family
members are known to be anabolic and to stimulate proteoglycan synthesis by
chondrocytes. While TGF-p2 itself is up regulated significantly with (Cytokine + injury)
for either cytokine and especially for (TNF-a + injury), inhibin PA shows extremely high
elevation with (Cytokine + injury) treatment for both IL-1 and TNF-a. Among the
LTBP's , proteins known to help in TGF-p secretion, LTBP1 and LTBP2 are both down
regulated with all three treatments, LTBP1 down regulated more with (TNF-a + injury)
and (IL-1 I3 +injury) than with TNF-a; and LTBP2 more with TNF-a. Connective Tissue
Growth Factor (CTGF) is significantly down regulated with (TNF-a +injury) , while (IL-
1f +injury) does not seem to have much effect. TGF-p inhibitor vasorin is almost
unchanged with all treatments, while BMP inhibitor chordin-like 2 is highly down
regulated with cytokine+injury.
IGF is also an important anabolic agent. IGF binding proteins (IGFBP) show
varied response to (Cytokine+Injury) (Figure 6f). While IGFBP7 is down regulated on
treatment with both (IL-1 B3 +injury) and (TNF-a +injury), IGFBP5 is up regulated with
(TNF-a +injury) but not with (IL-1 +injury). IGFBP3 is elevated with (IL-1 P +injury)
and (TNF-a +injury), and IGFBP6 is marginally down regulated with (IL-I P +injury) and
(TNF-a +injury)
Figure 6g looks at proteins involved in the innate immune response. Complement
factors C3, Cis, Clq and C1r all show mild down regulation in the presence of (IL- 1
+injury). C3 and Cir show significant down regulation in the presence of (TNF-a
+injury), while Clq is mildly up regulated. C1 inhibitor and PGLYRP2 show significant
down regulation with (IL-1p +injury), but remain almost the same with (TNF-a +injury).
Lactotransferrin shows mild down regulation with all treatments, while
Lipopolysaccharide binding protein (LBP) is highly down regulated with TNF-a alone,
and moderately with (IL-1p +injury) and (TNF-a +injury). CD14 shows significant down
regulation with (IL- 1P +injury), and mild down regulation with (TNF-a +injury)
We next look at some proteins involved in signaling including cytokines (Figure
6h). Proenkephalin shows the highest response to the combination of injury and cytokine,
with eight and thirteen fold elevation to (IL-1f +inj) and (TNF-a +inj) respectively.
Calcium binding proteins annexin A2 and annexin A5 are also elevated significantly by
injury and cytokine. Angiopoietin-like 7, on the other hand, is depressed by both the
injury+cytokine conditions. Pleiotropin shows mild elevation with (IL-I P +inj) and
(TNF-a +inj) treatments. Granulin shows a more than two fold depression with (TNF-a
+inj) alone. The membrane protein CD44 is significantly depressed by (IL-1p +inj), and
mildly by (TNF-a +inj).
3.4 Effect of combination of injury and cytokine as opposed to either
treatment alone
Data from a previous iTRAQ experiment in our lab 80 are used in combination
with data from this experiment to generate all the information necessary to perform this
study. To combine data from both the experiments, we first verify that there is no
significant experimental error/bias between both these experiments.
3.4.1 Comparison between two iTRAQ experiments
We want to check whether there are no major sources of variation between the
results of both these iTRAQ experiments. As earlier, this is done by first identifying
proteins found in common between experiment A (the current experiment) and
experiment B 8. (The final data set used for comparison from experiment A is the set of
199 proteins identified by merging proteins identified by either or both of the biological
duplicates and which satisfy Benjamini Hochberg procedure at FDR 0.1; similarly, the
final data set used from experiment B consists of 136 proteins found in either or both
technical duplicates combined which satisfy Benjamini Hochberg procedure across all
ratios at FDR 0.1). 74 proteins are thus found in common between Experiments A and B.
We compare reproducibility between exp A and B by taking the ratio of (TNF-c /IL-1 )
ratios for proteins in both experiments ((TNF-a /IL- 1P) is the only ratio in common
between experiment A and experiment B). This ratio of (TNF-a /IL- 1P) ratios is log
transformed and a histogram is plotted (Figure 8). The mean+/- standard deviation is
seen to be 0.1067 +/- 0.2191. There thus seems to be good reproducibility between
experiments A and B with variation of around 10.7%.
3.4.2 Correlation coefficient matrix between different conditions
Since variance between experiment A and B is around 10.7% only, the data for
the 74 proteins identified in common between both these experiments are fused.
Experiment A data which are ratios wrt IL-i I are converted to ratios wrt untreated
control by multiplying with (IL- 1 P:untreated) data from experiment B. Thus, all possible
ratios i.e. (IL- I :untreated), (TNF-a:untreated), (injury:untreated),(IL- 13
+injury):untreated and (TNF-a +injury):untreated are obtained for these 74 proteins. A
matrix of correlation coefficients is generated from log transformed ratios (Table 2).
Around 90.3% correlation between TNF-a and IL-1$, and around 95.3% correlation
between (TNF-a +injury) and (IL- 1P +injury). There is very little correlation between
injury and cytokine treatment, and both injury and cytokine show almost equal
correlations with (cytokine+injury). Curiously, TNF-a shows greater correlation with (IL-
1 P +injury) than with (TNF-a +injury).
3.4.3 Proteins on which injury and cytokine act independently
If the effect of injury and cytokine were almost independent on a protein, we
would expect that the effect of the combination of injury and cytokine would be a product
of the effect of injury and the effect of cytokine. Therefore, if the ratio of
(cytokine:untreated) were R1 and the ratio of (injury:untreated) were R2 for a given
protein, if cytokine and injury acted independently, the ratio of
(cytokine+injury:untreated) (R3) would be R1*R2. We therefore check for all proteins
for which
log 2(R1*R2) -0.1 <= log 2(R3) <= log2(R1*R2) + 0.1
The addition and subtraction of 0.1 is to specify error range.
Under this criteria, we observe that IL-13 and injury act almost independently on
aggrecan, CILP-2 and SPARC. TNF-ax and injury act almost independently on Collagen
VI alpha II, MMP-2 and C-type lectin domain family 3 member A.
3.4.4 Positive and negative feedback by cytokine and injury
If the effect of combination of cytokine and injury is greater than that of cytokine
alone, injury alone and the effect obtained if cytokine and injury acted independently,
cytokine and injury positively reinforce each other, in other words, exert a positive
feedback on the protein. Similarly, if effect of combination of cytokine and injury is
lesser than that of cytokine alone, injury alone and the effect obtained if cytokine and
injury acted independently, cytokine and injury exert a negative feedback.
To formulate the above statements as equations, if the ratio of
(cytokine:untreated) were R1, the ratio of (injury:untreated) R2 and
(cytokine+injury:untreated) R3 for a given protein,
If R3 > R1, R3 > R2 and R3 > R1*R2, a positive feedback is seen.
If R3 < R1, R3 < R2 and R3 < R1*R2, a negative feedback is seen.
Under these criteria, TNF-a and injury are seen to show positive feedback for aggrecan,
collagen VI alpha III, histone H4 and CILP-2. TNF-a and injury show negative feedback
for SPARC and IGFBP-7.We do not see any protein for which IL-l $3 and injury show
positive or negative feedback.
3.5 Partial least square regression (PLSR) between protein ratios and
phenotypes
We want to find out how protein ratio under different treatment conditions (the
independent variables) causes changes in various observed phenotypes under the same
treatment conditions (the dependent variables). The phenotypes available to us for the
treatment conditions IL-i I3, TNF-a, injury, IL-1P +injury and TNF-a +injury are: amount
of sGAG released into medium at the end of five days post treatment, amount of nitrite
accumulation at the end of five days, and rate of proline and sulfate incorporation
measured on the sixth day (Table 5). We thus want to find out a simple relation between
the protein ratio matrix (a matrix consisting of log transformed protein ratios as rows and
treatment conditions as columns) and the phenotype matrix (a matrix consisting of log
transformed phenotype ratios wrt control as rows and treatment conditions as columns).
Since there exists a lot of redundancy in the protein ratio matrix, we perform PLSR in
order to find a set of components (called latent vectors) which explain as much as
possible of the co-variation between the protein ratio matrix and the phenotype matrix.
First, from Figures 8a and 8b, we see that two latent vectors (factors) seem to
explain most of the variation in both X (the protein matrix) and Y (the phenotype matrix).
Therefore, a projection of the treatment conditions on the first two latent vectors is shown
in Figure 8c. From this, we see that both the cytokine only conditions are relatively
close, both the (injury+cytokine) combination are also close to each other, whereas the
injury alone condition lies away from the other conditions. This tallies with the
correlation matrix in Table 2. Figure 8d shows the projection of the phenotypes and
proteins on the first two latent vectors. Proline and sulfate are seen to project nearby,
corresponding to the fact that protein and proteoglycan synthesis are related.
Complements C3,B and C1r cluster together in the second quadrant. Cytoskeletal
proteins such as beta actin, vimentin, actinin alpha 4, alpha actinin and fascin are all
found close together in the fourth quadrant. Both the histones H2B and H4 are in the third
quadrant. A matrix containing the correlation shown by each protein with each phenotype
is generated.
In Table 4, the protein-phenotype pair showing the strongest positive and
negative correlations are listed. Perlecan-sGAG, pleotropin-sGAG, serum amyloid A3-
sGAG, CILP2-sGAG and complement B-sGAG are the pairs showing the highest
positive correlation. The pairs which show the highest negative correlation are Perlecan-
sulfate, perlecan-proline, pleiotropin-sulphate, pleiotropin-proline and cathepsin B-
sGAG.
Figure 1: Comparison of the first and second biological replicates. Proteins are identified
in common between the first and second biological replicates and their mean ratios after
internal standard correction compared. Only ratios whose respective p values satisfy
Benjamini Hochberg procedure at FDR 0.1 are chosen for the respective plot. Histograms
of log 2 transformed ratio of ratios (i.e. log2(ratiol/ratio2) ) are plotted for each of the
ratios 115:114 (A), 116:114 (B) and 117:114 (C). The Mean +/- standard deviation is
0.1010 +/- 0.3015, 0.0807 +/- 0.3134 and 0.4317 +/- 0.4292 for A, B and C respectively.
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Table 1: Matrix of correlation coefficients. Correlation coefficients are found between
TNF-a only, combination of IL- 1s and injury and combination of TNF-a and injury
treatments. Log transformed protein ratios obtained from iTRAQ experiments for the
corresponding treatments are used as vectors to calculate these coefficients. Only
proteins, the p values of all whose ratios satisfy Benjamini Hochberg procedure at FDR
0.1 are chosen.
log 2(TNF-a/L-1 p) Iog 2(IL-1 P+inj/L-1 p) log2(TNF-a+inj/L-1 p)
log2(TNF-a/IL-1 P) 1 0.6786 0.6957
log2(IL-1 p+inj/IL-1 p) 0.6786 1 0.9139
1og 2 (TNF- a+iinj/IL-1p) 0.6957 0.9139 1
Figure 2: Expresses the relation between effect of cytokines IL-1$ and TNF-a in
combination with injury on proteins. Log 2(IL- 1p +Injury/IL- 1p) (x axis) is plotted against
Log2(TNF-a +injury/IL-1 [) (y axis). Figure 2 has been fitted to a line with a slope of
1.0729, y-intercept of 0.1353 and an R2 value of 0.8353. This indicates a highly
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Figure 3: Figure 3A is a plot of proteins in three dimensions with log transformed ratios
as axes, the x, y and z axis representing log 2(TNF-a /IL- 1$), log2(IL- 1p +Injury/IL- 1p)
and log2(TNF-a +injury/IL- 1p) respectively. Colors represent protein clusters as
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Figure 4: Profiles of the means of the three clusters identified by K-means clustering.
Error bars represent standard error of the mean. The clusters are well separated (p<0.001,
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Figure 5: Profiles of means of log 2 transformed ratios of proteins sorted by location.
Error bars represent standard error of the mean. Asterisks indicate p<0.05, the null
hypothesis being that means of log transformed ratios are 0. Significance is measured by
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Figure 6: Figure 6 shows the behavior of different sets of proteins to the combination of
Injury and Cytokine. All data represent mean log transformed ratios of the respective
treatments wrt IL-1p +/- standard error. The proteins whose effects are measured are (A)
C-terminal propeptides of Collagens. (B) Key structural proteins belonging to the ECM.
(C) Members of the SLRP family, key structural molecules in the ECM. (D) Proteases
including members of the MMP family and ADAMTS 1, and MMP inhibitors. (E)
Members of the TGFp super-family and their inhibitors. (F) IGF binding proteins. (G)
Proteins involved in the innate immune response. (H) Key signaling molecules. Asterisks
represent ratios whose p values are significant. Significance is measured by Wilcoxon
sign rank test or paired t-test under the null hypothesis that protein expression does not
change under treatment. Multiple comparisons are corrected for using Benjamini





















































Figure 7: Comparison of iTRAQ data generated from this experiment (experiment A)
with iTRAQ data generated from previous experiment performed in our lab (experiment
B) 80. Proteins are identified in common experiments A and B and mean (TNF-a /IL-1p)
ratios from experiment A compared with mean (TNF-a /IL-1p) ratios from experiment B.
Only ratios whose respective p values satisfy Benjamini Hochberg procedure at FDR 0.1
are chosen for the respective plot. Histogram of log 2 transformed ratio of ratios (i.e.
log2(exp B (TNF-a IL- 1p) / exp A (TNF-a /IL-i ) is plotted.The Mean +/- standard
deviation is 0.1067 +/- 0.2191
-3 -2 -1 0 1 2 3
log2( expB(TNFIL1) / expA(TNFAL1))
Table 2: Matrix of correlation coefficients. Correlation coefficients are found between
IL-1p only, TNF-a only, injury only, combination of (IL-l p and injury) combination of
(TNF-a and injury) conditions. Log transformed protein ratios obtained from combining
data from experiments A and B and converting to untreated basis are used as vectors to
calculate correlation coefficients. Only ratios whose p values satisfy Benjamini Hochberg
procedure at FDR 0.1 are used in this calculation
log 2(IL-1 P/untreated) log2(TNF-a/untreated) log2(inj/untreated) log 2(IL-1 P+inyuntreated) Iog2(TNF-a+inyuntreated)
log2(IL-1p/untreated) 1 0.9028 0.1416 0.6839 0.5944
log2(TNF-a/untreated) 0.9028 1 0.3473 0.7707 0.7046
log2(inyuntreated) 0.1416 0.3473 1 0.7581 0.7486
log2(IL-1 P+inyuntreated) 0.6839 0.7707 0.7581 1 0.9574
Iog2(TNF-a+inj/untreated) 0.5944 0.7046 0.7486 0.9574 1
Table 3. List of proteins showing positive and negative synergism. The columns are
protein name, log 2(TNF-a /untreated), log2(injury/untreated), expected log2(TNF-a
+injury/untreated) if injury and cytokine acted independently, actual log2(TNF-a
+injury/untreated), and percentage synergism (A). Lists proteins showing positive
synergism. If the maximum ratio among log 2(TNF-a/untreated), log2(injury/untreated)
and expected log2(TNF-a+injury/untreated) were called R1, the percentage positive
synergism is calculated as
(( actual log2(TNF-a+injury/untreated) - R1)/R1 )*100 (B). Lists proteins showing
negative synergism. If the minimum ratio among log2(TNF-a/untreated),
log2(injury/untreated) and expected log2(TNF-a+injury/untreated) were called R2, the
percentage negative synergism is calculated as
(( actual log2(TNF-a+injury/untreated) - R2)/R2 )*100
A
log2(1NF-a/untreated) log2(injury/untreated) Expected Actual log2(TNF- % hi gher than
log2(TNF-+ a+injury/untreated) maximum of
injury/untreated) if [TNF-a, injury,
independent TNF-m+injury if
indep endent]
Aggrecan 1.014 -0.111 0.903 1.059 4.377%
Col6A3 0.468 0.684 1.152 1.389 20.588%
Histone H4 0.931 0.941 1.873 2.379 27.032/o
replacement-like
CLP-2 0.406 -0.147 0.259 0.735 81.115%
B
log2(TNF-aluntreated) log2(injury/untreated) Expected Actual 1og2(TNF- % lower than
log2(TNF-m+ a+injury/untreated) minimum of
injury/untreated) if [TNF-a, injury,
independent TNF-a+irnjury
if independent]
SPARC -0.765 -1.084 -1.849 -3.599 94.631%
IGFBP7 -0.644 -1.110 -1.754 -2.141 22.025%
Figure 8: Figure 8 is obtained by performing Partial Lease Square Regression (PLSR)
between protein ratios and phenotypes (sGAG loss into medium in five days post
treatment, nitrite accumulation in five days post treatment, rate of proline incorporation
and rate of sulfate incorporation on the 6 h day post treatment). X represents matrix of log
transformed protein ratios under five different treatment conditions, and Y matrix of log
transformed phenotype ratios (wrt control) under the same conditions. The matrices X
and Y are mean centered and set to unit variance before PLSR (A) Percent variation in
the protein ratio matrix (X) explained by 1,2 and 3 Principal components (factors). Each
vertical line represents a single protein (B) Percent variation in phenotypes explained by
1,2 and 3 principal components. The blue line is the training data set, and the red line the
validation data set. In both (A) and (B), two factors explain the variation very well. (C)
Projection plot of the five treatment conditions on the first two principal components. (D)
Projection plot of proteins (blue) and the phenotypes (red) on the first two principal
components. Points close to each other are positively correlated, and in opposite
quadrants are negatively correlated. The Unscrambler @ X Version 10.0.1 used for
generating plots A-D
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Table 4: List of protein-phenotype pairs showing (A) The top five positive correlations
and (B) The top five (in magnitude) negative correlations, as generated by PLSR.




serum amyloid A3 sGAG release
CILP-2 sGAG release
compl B sGAG release
Top 5 negative correlations
Protein phenotype
pleiotropin proline incorporation




Table 5: Effect of injury or cytokine treatment or both on different phenotypes. Rows
represent treatment conditions and columns represent phenotypes. This data matrix forms
the Y matrix in the PLSR analysis.
nmol proline
microg sGAG per set nmol sulphate incorporation lincorporation / nmol Nitrite
of 4 explants (in 120 day (Measured at the 6th day (Measured accumulation (in
Experimental Condition hrs) day) at the 6th day) 120 hrs)
Control 194.7035484 139.4045 68.32229 9.397892
injury 199.7683616 85.85213 50.74262 10.31592
L-1p 1045.690457 58.85496 37.03414 71.23021
L-1p+ injury 1164.124135 36.51318 28.51041 34.39866
TNF-a 829.7448476 66.59978 41.7247 104.7924
TNF-a + injury 2080.996078 34.77035 32.56093 152.8823
DISCUSSION
The aim of this study is to understand the molecular basis behind the synergism
seen between cytokine and injury in causing sGAG loss to medium from cartilage
explants as observed by Patwari et al' . With this aim in mind, we generate a
quantitative profile of proteins released to medium on treatment of cartilage explants with
cytokine (IL-1p or TNF-a), injury or a combination of cytokine and injury. By doing so,
we hope to identify those proteins whose expression values differ most on combination of
injury and cytokine, as compared to either treatment alone. Since we used a 4-plex
iTRAQ labeling strategy, we could analyze only four treatment conditions at a time.
Therefore, in the first part of this study, we divided cartilage explants into four groups,
and subjected each group to one of the treatments: IL-1f alone, TNF-a alone, IL-1p and
injury and TNF-a and injury. Medium from each group was collected, iTRAQ labeled
and a 2D-LC/MS/MS analysis performed. iTRAQ ratios from this experiment were
specified with respect to IL-1p alone values and proteins whose levels differed
significantly on treatment with cytokine and injury, as compared to IL- 13 alone screened.
Clustering and correlation analyses were performed to observe which proteins and which
treatment conditions behaved similarly.
The next part of this study combined data from this experiment with earlier
iTRAQ experiments in our lab 80 which contained treatment conditions not present in the
first experiment (ie injury alone, and a control without any treatment). Data from both
these experiments were combined after suitably correcting for inter experimental bias.
This helped generate all possible ratios for several proteins with respect to control (ie IL-
1p:control, TNF-a:control, Injury:control, IL-1f +injury:control and TNF-a
+injury:control). These ratios were used to determine the proteins on which injury and
cytokine acted synergistically, in either a positive or a negative fashion. These proteins
thus identified are probably the proteins involved in causing synergistic sGAG loss to the
medium at a macro level.
Since we have protein levels for several proteins across 5 treatment conditions
with respect to control (IL-1:control, TNF-a:control, Injury:control, IL-1
+injury:control and TNF-a+injury:control), we have a huge data matrix in which we
expect to see a lot of redundant information. To get the core non redundant information
from this highly "collinear" data matrix, we next use a PLSR (partial least square
regression) analysis, to determine those combinations of protein ratios (latent vectors)
which contribute most to some observed phenotypes. The phenotypes used in our PLSR
model are sGAG loss to the media in 5 days post treatment, rate of proline incorporation
on day 6 post treatment, rate of sulfate incorporation on day 6 post treatment, and total
nitrite accumulation in 5 days post treatment. Since redundant information is eliminated
by this analysis, PLSR helps unearth non-obvious groupings of proteins which behave
similarly on treatment, and proteins which are most responsible for an observed
phenotype. For example, because sGAG loss to media is directly indicative of
catabolism, and proline and sulfate incorporation rates of anabolism, the choice of these
phenotypes in the PLSR model helps to identify proteins which closely correlate with
catabolism and anabolism.
4.1 Methodology for correcting for multiple comparisons - The
Benjamini Hochberg procedure
Instead of correcting for multiple comparisons by controlling the Family wise
error rate (FWER) using Bonferroni correction, we opt to adopt the procedure adopted by
Benjamini and Hochberg 112 to control the False Discovery Rate (FDR). The advantage of
this methodology over the Bonferroni correction is that Bonferroni correction is
exceedingly stringent and hence a lot of protein ratios which represent real differences
may not be counted. Using the Benjamini - Hochberg procedure thus ensures fewer false
negatives and more "hits" than the Bonferroni correction 117 . A FDR of 0.1 is chosen for
our analysis.
4.2 Variation between biological replicates
The LC/MS/MS analysis was done on biological replicates. The source of
variation between any two experiments can be broadly classified as technical,
experimental and biological 116. Briefly, technical variation measures the variation
observed by repeated tests on the same test subjects under identical conditions. In the
iTRAQ experiment, this includes all steps from protein extraction till quantification.
Experimental variation in the context of iTRAQ experiments refers to variation caused
due to repetition of an identical iTRAQ experiment. Biological variation measures
biological variability in the test subject. Since the biological replicates in our experiments
are also subjected to separate iTRAQ experiments using a different set of labels, the
source of variation between these replicates is biological as well as experimental. We
observe that log(ratiol/ratio2) for proteins identified in common between experiments 1
and 2 (only proteins which satisfy Benjamini Hochberg procedure are used in this
comparison) has a mean of 10.1 % for the 115 label and 8.07 % for the 116 label (Figure
1). Both these are lesser than the 23 % average variation between experimental replicates
and 25 % average variation between biological replicates as reported in an earlier iTRAQ
16study with a different model system 116. The log(ratiol/ratio2) for the 117 label however
shows a difference of 43.17 % . This huge difference is possibly due to incomplete
digestion in the iTRAQ2 117 label sample, where a white precipitate was observed after
trypsin digestion. This implies that only a part of all proteins released to medium is
subjected to LC/MS/MS analysis, and hence quantitation of this sample is naturally
inaccurate. To correct for this difference, for all proteins identified in biological duplicate
2 alone and not in biological duplicate 1, 0.4317 is added to log transformed 117:114
ratios alone. For proteins identified by biological duplicate 1 alone or in common by both
experiments, experiment 1 values are used for further analysis.
4.3 A global proteomic analysis of the effect of Cytokine+injury
4.3.1 Correlation between IL-1p +injury and TNF-a+injury treatment conditions
It is highly interesting that a global proteomic analysis between different
treatments yields a very high correlation between the two cytokine+injury treatments,
with a correlation coefficient of 0.914 (Table 1). (Only proteins whose p values suggest
good quantification across all ratios are chosen for all global analysis). This implies one
of two things, either that TNF-a and IL-1 interact similarly with injury and activate
similar pathways in the cell, or that the effect of injury dominates over the effect of
cytokine. To confirm which of these two hypothesis is right, we require data representing
the effect of injury alone on cartilage, if the injury alone condition were to show a high
correlation with both the (cytokine+injury) conditions, it would imply that injury
dominates over cytokine; if not, it would imply that both the cytokines act on the cell
through very similar pathways, thus causing very similar change in protein levels. This
study is performed later in this discussion when we combine results from two iTRAQ
experiments.
4.3.2 K-means clustering of proteins
K-means clustering is performed on the data matrix, comprising 199 proteins with
3 conditions, and the optimum number of clusters was chosen as three. Figure 3a shows
a 3D plot of log transformed protein ratios, with the three treatment conditions as three
axes, and clusters differentiated by color. The centroids of these three clusters are plotted
versus treatment in Figure 4, to better illustrate the differences between the clusters.
Broadly, cluster 1 proteins show a mild elevation with (cytokine+injury), cluster 2
proteins are significantly depressed and cluster 3 proteins are highly elevated. A closer
examination of the proteins present in each cluster reveals that about 73% of the proteins
present in cluster 3 are cytoplasmic proteins. Therefore, most of the cytoplasmic proteins
are highly elevated on treatment with (cytokine+injury). This is presumably because of
lysis of the cell membrane caused by mechanical injury, and subsequent release of
proteins in the cytosol to the medium .This is consistent with the study by Stevens et al
118 which also finds a high proportion of cytosolic proteins to be released to the medium
on treatment with injury alone. We also find that all ECM proteins identified are present
in either cluster 1 or 2 (i.e. slightly increased or highly depressed with (cytokine+injury)).
The structural proteins aggrecan, matrilin-1, matrilin-2, matrilin-3; the SLRPs
chondroadherin, fibromodulin, epiphycan and biglycan all cluster together in cluster 1.
While collagens III, VI, XI and XII cluster together in cluster 1, collagens I and II cluster
together in cluster 2. MMPs 2, 3 and 13 also cluster together in cluster 2, and are
depressed by cytokine+injury.
4.4 Effect of Cytokine + Injury on specific protein classes
We next look at specific classes of proteins in greater detail, to find out how these
key proteins vary with (cytokine+injury), to find out how (cytokine+injury) affects
catabolism and synthesis. From this, we try to see if this in vitro model is representative
of OA.
4.4.1 The Collagen Family
Collagen accounts for two-thirds of the dry weight of adult articular cartilage, and
collagen fibers provide cartilage with the ability to withstand tensile and shear forces.
Fibrillar collagen chains are generally synthesized as procollagens, and formation of
mature collagen fibrils requires cleavage of the N and C terminal propeptides of
procollagens (for review 119). The cleavage and release of Collage C-terminal propeptides
to the medium is thus indicative of the ability of cartilage to synthesize new collagen, and
is a useful marker of the anabolic state of cartilage. In Figure 6a, we see that both
(cytokine+injury) treatments inhibit collagen synthesis of several collagen chains, with
TNF-a+injury inhibiting collagen synthesis to a greater extent than IL-1 +injury. This
suggests that the combination of injury and cytokine reduces anabolic activity in the cell,
and impairs the ability of cartilage to recover from damage.
4.4.2 Aggrecan
Aggrecan is the major proteoglycan present in hyaline cartilage, and is
responsible for compressive stiffness of cartilage (for review 13). The core protein of
aggrecan has a modular structure, with three disulfide-bonded globular domains G1, G2
and G3 and an extended central portion between G2 and G3 for GAG attachment
(chondroitin sulfate (CS) and keratan sulfate (KS)). G1 and G2 are separated by an inter-
globular domain (IGD) 120. Depletion of aggrecan due to its degradation is an important
characteristic of OA. This occurs due to increased proteolytic cleavage of the core protein
by MMPs'21 123 and primarily aggrecanases 2. In our study (Figure 6b), we find that
aggrecan levels remain almost constant on treatment with (injury + cytokine) with very
mild down regulation (<0.5 difference on log 2 scale)
4.4.3 Other structural and matricellular molecules
Besides collagen and aggrecan, several other molecules are present in the ECM.
These either aid in structural roles, such as collagen fibril formation and collagen cross-
linking, or in remodeling of ECM. Thrombospondins are multi-domain, calcium binding
ECM proteins which have a high affinity to collagen (for review' 5 ). There are five
thrombospondins currently discovered. We identified all five in our study (Appendix),
but only Thrombospondins 1 and 5 were quantified well across ratios (Figure 6b). We
see that while thrombospondin-1 is only slightly elevated with (TNF-a + injury), COMP
(Thrombospondin-5) is highly down-regulated with TNF-a + injury. COMP is cleaved
by ADAMTS-4 and MMP-19 and 20 1'1 and elevated levels of COMP/COMP
fragments in the serum and the synovial fluid have been correlated with OA severity and
joint injury 12,127 . However, a decreased amount of COMP remains in OA cartilage and
the distribution also changes, with higher COMP in the fibrillated superficial zones, and
almost no COMP in the middle and deeper zones 128. Since we are measuring proteins
released to medium from cartilage explants, we would expect elevated levels of
COMP/COMP fragments on treatment with injury + cytokine, due to diffusion of newly
synthesized COMP unanchored to the matrix due to proteoglycan loss; and cleavage with
proteases respectively. Hence, it is surprising to see that (TNF-a + injury) decreases
COMP released to the medium significantly compared to IL-1 alone. One possible
reason is that synthesis of new COMP is reduced. Since we did not observe ADAMTS-4
among our proteases (Figure 6d) , it is possible that the COMP we observe released to
the medium is not due to degradation of existing COMP, but due to synthesis of new
COMP. Hence, if synthesis were reduced, we would observe reduction in COMP levels
released to medium. Further studies have to be undertaken to find out if the COMP
released is due to synthesis (i.e. whether the COMP released to medium represent intact
COMP) , and if so, reason out why COMP synthesis is reduced on treatment with (TNF-
a+injury).
Among the matrilins, Matrilin-1 and 2 are almost unchanged with (injury +
cytokine) (< 0.5 on the log scale). Matrilin-3 is moderately down regulated with (IL-1 +
injury) alone. Matrilins are proteins thought to play a role in the formation of filamentous
networks in the ECM through interacting with collagen and other molecules 31. A
mutation in Matn3 gene was found to be linked to hand OA in a genome wide linkage
analysis 129. While Ko et al 130 found Matrilin-3 deficient mice to have no skeletal
malformations and normal life spans , Van der Weyden et al 131found an expanded
hypertrophic zone of the growth plate in the embryonic stage due to premature
chondrocyte differentiation and a higher predisposition for severe OA in one year old
animals. An examination of the collagen architecture of Matn3- knock-out mice with
electron-microscope showed mild abnormalities with slightly increased collagen fibril
diameter and collagen volume densities 132. In view of these studies, the decrease in
Matrilin-3 we observe with (IL-1p +injury) may indicate premature differentiation of
chondrocytes, with impaired collagen fibril network structure resulting in altered
mechanical properties.
4.4.4 Small leucine rich proteins (SLRP)
Since SLRPs have been postulated to serve as biomarkers of OA 42, we next look at how
these ECM proteins respond to treatment in our in vitro model. SLRPs are currently
classified into four classes. Our study (Figure 6c) identifies decorin and biglycan (class
I); fibromodulin, lumican, PRELP and osteoadherin (class II); epiphycan and osteoglycin
(class III); and chondroadherin (class IV).
Decorin shows mild up regulation with IL-1 +injury (not attaining statistical
significance) and moderate down regulation with TNF-a+injury. Disruption of the
decorin gene in mice leads to fragile skin with markedly reduced tensile strength, with
collagen fibrils thicker than wild type mouse, indicating that decorin may have a role in
inhibiting fibrillogenesis. 133 . Decorin has a role in connecting fibrillar collagens such as
collagens I or II with minor collagens such as collagens VI, XII and XIV 32,134,135
As opposed to decorin, Biglycan is highly over expressed with IL-1P +injury and
moderately with TNF-a+injury. This is similar to the result obtained by Robbins et al 136
who found that mechanical injury up regulated biglycan in tendons. The precise
interaction of biglycan with collagen is unclear; with some studies claiming that biglycan
binds collagen 1137 and others that biglycan does not 138. Besides connecting collagen VI
to collagen II, biglycan also appears to organize collagen VI microfibrils into a hexagonal
network in vitro 139,32. Biglycan is known to be cleaved by MMP-13 at a specific location
140, but this is not the reason for increased biglycan levels with (cytokine + injury) in our
study, as MMP-13 levels are seen to decrease with (cytokine + injury) (Figure 6d)
Biglycan and decorin differ in their pattern of temporal expression in corneal stroma
development. While decorin was expressed at high levels in all stages of development,
biglycan was expressed highly in early stages of development, decreasing until expressed
141
at very low levels in mature cornea
Looking at Class II SLRP's, fibromodulin and osteoadherin does not change
much with treatments. Lumican is slightly over expressed with IL-1p + injury, and highly
with TNF-at + injury. PRELP is moderately over expressed with IL-1 + injury, and
highly with TNF-ca + injury. Fibromodulin has two sites of different affinities at which it
binds to collagen, and lumican has one site. The lumican site and the low affinity
fibromodulin sites are homologous and compete in binding collagen I, but fibromodulin
has a higher affinity to collagen I because of the presence of an additional high affinity
site 12. During tendon development, lumican is expressed earlier and fibromodulin later,
with lumican deficient mice showing distorted fibril morphology earlier, and
fibromodulin deficient mice later. This could possibly be because lumican aids in
forming early thinner fibrils, and once fibromodulin levels rise later in development, it
displaces lumican, and helps join the thin fibrils to form thicker fibrils 39.
It is highly interesting that both lumican and biglycan, both of which are
expressed earlier in development show high expressions with cytokine and injury. This
possibly indicates an attempt to repair tissue damage by development of new collagen
fibrils.
Also, our results for decorin, biglycan, fibromodulin and lumican are identical to
the results obtained by Young et al in a sheep model of OA (143. They found increased
mRNA levels of lumican and biglycan, decreased decorin levels and unchanged
fibromodulin levels, identical to what we observe at a protein level in our in vitro model
of injury. This indicates that the changes in protein levels we observe are probably the
result of new protein synthesis of SLRPs which again suggests an attempt to repair
cartilage. This also shows that the combination of injury and cytokine shows a
remarkably similar SLRP profile as compared to OA tissue, and hence this in vitro
treatment condition approximates OA reasonably well.
PRELP is highly up regulated with cytokine+injury in our study. While most
SLRPs have amino terminal domains with acidic properties, PRELP has a basic amino
terminal region. It also has no GAG chains. PRELP is capable of binding heparin and
heparin sulfate containing proteoglycans such as perlecan through its amino terminal
region, and collagen type I and type II through its Leucine rich repeat region. Hence, it
possibly connects the basement membrane (rich in perlecan) to the underlying connective
144 145tissue . PRELP is expressed highly in cartilage 4. Over expression of PRELP in skin,
where it is normally present at low levels, results in a structural change, with decrease in
collagen fiber bundle content and size, and decreased thickness of hyperdermal fat layer
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. However, the collagen fibrils obtained are of normal structure. It is not clear what the
high up regulation of PRELP with (cytokine+injury) means, and further knowledge about
PRELP and its functions is necessary to interpret this result.
Among class III SLRPs, epiphycan shows moderate up regulation with (IL-1p +
injury), and is not changed much with (TNF-a + injury). Epiphycan-deficient mice
generated by disrupting the epiphycan gene in mouse embryonic stem cells developed
OA, and male epiphycan-deficient mice had shorter femurs than wild type mice. Also,
epiphycan-biglycan double deficient mice developed OA earliest suggesting possible
interaction between both in vivo 47 Osteoglycin does not show statistically significant
change with (cytokine + injury).
The class IV proteoglycan chondroadherin shows high up regulation with TNF-
a+injury, and is not changed much with IL-1p + injury. Chondroadherin is particularly
enriched in cartilage, but also found in bone. It binds to collagen type II 148 , and also to N
and C terminal globular domain of collagen type VI 32. It binds to integrins on the surface
of cells, and causes intracellular signaling through tyrosine phosphorylation of factors
like ERK 149. Like PRELP, chondroadherin too has a heparin binding domain via which it
can bind to perlecan and cell surface receptors carrying heparan sulfate proteoglycans 15.
The elevation of chondroadherin with (TNF-a+injury) may thus indicate an attempt to
repair the collagen type II network. Chondroadherin elevation may also cause changes in
synthesis of other proteins through intracellular signaling via cell surface receptors.
4.4.5 Matrix proteases and their inhibitors
A healthy cartilage lies in equilibrium between synthesis and degradation. Matrix
degrading proteases such as collagenases and aggrecanases play a crucial role in
maintaining this equilibrium 151; however, aberrant regulation accompanied by over
expression of these proteases result in a shift of the cartilage away from equilibrium
towards degradation resulting in degenerative diseases such as OA 9. It is believed that
aggrecanases act in early stage OA, and collagenases in late stage OA. A study by
Karsdal et al 54 shows that aggrecanase mediated aggrecan degradation in cartilage can be
reversed by anabolic stimuli, provided catabolism has not been too severe. However,
MMP mediated collagen and aggrecan degradation impaired the repair capacity of
cartilage, and was irreversible.
MMP-13 is thought to be the major collagenase in OA 152 and is highly over expressed in
OA cartilage. Mice knockout experiments showed significant protection against OA in
ADAMTS-5 single knockout and ADAMTS-4/ADAMTS-5 double knockout mice, but
lack of protection in ADAMTS-4 single knockout mice 153,154. A study by Kevorkian et al
155 profiling several MMP, ADAMTS and TIMP (Inhibitors of MMP and ADAMTS) in
end stage hip OA cartilage found increased genetic expression of the gelatinases MMP2
and MMP9, MMP13, ADAMTS2 and TIMP3 and decreased expression of MMP1, MMP3,
ADAMTS1, TIMP1, TIMP4 and ADAMTS5 at various levels of statistical significance.
However, MMP1 was increased in knee cartilage indicating differences in regulation of
MMP1 between hip and knee. Another global study by Swingler et al 156 which profiled
expression levels of several genes in hip OA and compared them to normal cartilage
found an increase in expression of MMP13, MMP3, MMP9, ADAMTS2, MMP2 and a
decrease in expression of ADAMTS9, ADAMTS1, MMP1 among others at P<0.01
Figure 6d shows the response of members of the MMP, ADAMTS and TIMP
families to the combination of cytokine and injury. Several MMPs identified in our study
(MMP's-1,2,3,9) show very mild down regulation with (IL-1 +injury) as compared to
IL-13 alone, with MMP-2 alone showing moderate down regulation with (TNF-
a+injury). The gelatinases MMP-2 and MMP-9 seem to be almost unchanged .MMP-13
alone shows high down regulation with (IL-1 +injury), and a mild down regulation with
(TNF-a+injury), both showing statistical significance. This is contradictory to studies
which show that MMP-13, whose main substrate is Collagen 1I, is the major collagenase
involved in OA 1.57 It is surprising that the collagenases (MMP-1, MMP-13), the
gelatinases (MMP-2, MMP-9) and stromelyin-1 (MMP-3) all mostly mildly down
regulated with (cytokine+injury) with respect to IL-1. With the mild down regulation
possibly due to apoptosis of some cells due to injury, this means that addition of injury to
cytokine does not change the expression of MMP as compared to cytokine in general.
Therefore, addition of injury to cytokine does not increase catabolism due to MMP.
However, ADAMTS-1, the only ADAMTS identified in our study, shows significant up
regulation with (cytokine+inury) for both IL-1p and TNF-a. ADAMTS-1 does not cleave
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any member of the collagen family, but cleaves aggrecan and versican
Among the TIMPs, both TIMP-1 and TIMP-2 were identified. TIMP-1 shows
decrease with TNF-a+injury, without reaching statistical significance. TIMP-2 on the
other hand is moderately up regulated with IL-1 and injury, and not changed with TNF-
a+injury. TIMP-1 has previously been shown to be significantly down regulated and
TIMP-2 up regulated in OA hip cartilage 155. The up regulation of TIMP-2 might be an
attempt to inhibit ADAMTS-1, which is seen to be up regulated, and against which
TIMP-2 has inhibitory activity.
4.4.6 Members of the TGF-p superfamily and their inhibitors
The TGF-P superfamily refers to a large family of growth factors which are
predominantly anabolic in nature and includes the TGF-3 subfamily, the activin/inhibin
subfamily, bone morphogenetic proteins (BMP) and some other members 158 . TGF-p
causes net synthesis of the ECM by inhibiting collagenases and up regulating TIMP 159.
Treatment of chondrocytes with TGF-p1 is known to down regulate mRNA levels of
MMP-1 and MMP-13 and also reduce mRNA levels of IL-1 and TNF receptors 160, thus
moving the chondrocyte towards an anabolic state. TGF-p also increases net proteoglycan
synthesis as measured by sulfate incorporation in vivo 161. TGF-1 and TNF-a are known
to increase their own mRNA levels and reduce each others', resulting in an autocrine
feedback loop shifting between anabolism and catabolism.
Connective tissue growth factor (CTGF) is a growth factor, known to be inducible
by TGF-, which synthesizes collagen and fibronectin in fibroblasts 162. It is involved in
fibrotic diseases, characterized by excessive collagen deposition. CTGF null mutant mice
develop cartilage which has impaired mechanical properties due to reduced aggrecan and
link protein production 163. CTGF has previously been identified in human osteoarthritic
cartilage 164 , but at very low levels. CTGF synthesis as measured by mRNA levels has
been found to reduce in a sheep model of OA 143
Cartilage derived morphogenetic protein - 2 (CDMP-2) is a bone morphogenetic
protein belonging to the TGF-3 super-family. Along with CDMP-1 and CDMP-3, they
form a distinct subgroup within the BMP family 165 Expression patterns of CDMP-2 in
bovine cartilage indicate that it is involved in terminal differentiation of chondrocytes and
at the earliest stages of endochondral bone formation, including angiogenesis and
osteoblast differentiation. CDMP-2 implantation subcutaneously or intramuscularly is
known to induce bone or cartilage; or tendon, depending on the degree of mechanical
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stimulus, higher mechanical stimulus leads to bone formation, and lower, tendon'
Activin and inhibin are two closely related members of the TGF- superfamily which
have opposing functions. While activin enhances FSH biosynthesis and has roles in cell
proliferation, differentiation, apoptosis, inflammation, fibrosis and wound repair 167,168.
inhibin down regulates FSH synthesis 169. Activin consists of inhibin P chains alone,
while inhibin contains both inhibin a and inhibin p 1. Proinhibin PA and mature inhibin
PA were detected in all OA samples but only in half the control samples in a study by
Hermannson et al 164 indicating presence of activin A in OA cartilage. Hermannson et al
also found that activin A was induced in chondrocyte monolayers by IL-13, TGF-31,
FGF-2, PDGF,EGF and activin A itself. Also, it is seen to induce TIMP-1 production in
culture medium, and thus acts as an anabolic factor.
Members of the TGF-$ superfamily such as TGF-, BMPs and activin are
regulated at several different levels (for review 1. LTBP (Latent TGF-p binding
proteins) are proteins, which as the name suggests, bind to TGF-p and another protein,
called Latency associated proteins (LAP), thus maintaining TGF-3 in an inactive form.
Cleavage of LTBP is necessary for TGF- to be active. LTBPs are also involved in
assembly, secretion and targeting of TGF-p to its site of action. (for review 172). MMP-2,
MMP-3 and MMP-9 have been shown to cleave LTBP, thus releasing active TGF-p 41
LTBP-3 null mice develop craniofacial abnormalities and eventually develop
osteoarthritis. 73
Looking at other inhibitors of the TGF- superfamily, the ECM proteins decorin
and biglycan have been seen to inhibit TGF- activity 174175. Chordin and gremlin are
soluble extracellular inhibitors of BMPs 176. Chordin-like 2 is a protein structurally
similar to chordin which inhibits BMP in vitro and in vivo. It is specifically up regulated
in the middle zone of OA cartilage and may delay chondrocyte hypertrophy, thereby
ameliorating cartilage degeneration7 Vasorin is a type 1 membrane protein which is
observed to directly bind to TGF- and inhibit its action 178. Follistatin is an autocrine
glycoprotein whose primary function is the inhibition of activin 79. Follistatin-like protein
1 is a secreted glycoprotein sharing a characteristic structural molecule (the FS domain)
with follistatin. It has a role in inflammation and has been shown to both be highly over
expressed in early arthritis, leading to up regulation of pro-inflammatory cytokines like
IL-1 and TNF-a 180; and contradictorily to ameliorate arthritis severity in a mouse
model' 81 .
In our results, looking at members of the TGF-P superfamily (Figure 6e), we see
that TGF-2 itself is highly elevated with TNF-a + injury, and moderately with IL-1f +
injury. LTBP-1 is highly down regulated for both the (cytokine + injury) conditions.
Down regulation of LTBP implies that TGF-p is activated from its latent form, thus
increasing net synthesis and moving towards anabolism. Inhibin BA is extremely elevated
with the (cytokine + injury) treatments. Only inhibin PA is found and not inhibin a,
which implies that activin A which is a homodimer of inhibin PA is up regulated with
cytokine+injury. This again indicates a shift towards anabolism, and tallies with the fact
that activin A is found to be upregulated in OA samples 164. Follistatin-like 1 is also
moderately down regulated with (TNF-a + injury), which could mean reduced
inflammation, this tallies with the high levels of activin A observed.
CTGF is extremely down regulated with (TNF-a + injury), indicating cartilage with
impaired mechanical properties. However, its levels don't change much with (IL-1p +
injury). One possible reason why CTGF is inhibited is the sequestering of TGF- by
SLRPs like biglycan which show increased levels with (cytokine+injury) (Figure 6c).
However, it is unclear why CTGF levels are unchanged with (IL-1p + injury) if this be
the case, as biglycan levels are increased both with (IL-1P + injury) and (TNF-a +
injury). Other inhibitors of the TGF-6 superfamily such as chordin and gremlin remain
almost the same with (cytokine + injury) treatment.
4.4.7 Insulin-like Growth Factor Binding Proteins
IGF (Insulin-like growth factors) are ubiquitously expressed mitogens showing
high sequence similarity to insulin and which affect cell growth and metabolism. They
are predominantly anabolic in nature and known to stimulate DNA synthesis, protein
synthesis, proteoglycan synthesis and glycosaminoglycan synthesis 1 82 . There are two
forms of IGF, IGF-1 and IGF-2. In cartilage, IGF-1 acts as an enhancer of matrix
synthesis and a growth promoter, and IGF-2 acts as a growth stimulator in a non-
differentiated state 183. Their actions are mediated by IGF receptors. IGFBP (IGF-binding
proteins) are soluble proteins which bind to IGF in biological fluids. They have higher
affinity for IGF than IGF receptors, and thus act as carriers of IGF and also modulators of
IGF availability and activity (for review182,184). IGFBPs also have actions independent of
IGF. For example, IGFBP-5 administration increased bone formation parameters both in
vitro and in vivo with a magnitude comparable to IGF-1185 and IGFBP-7 plays a potential
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tumor suppressor role in colorectal carcinogenesis186
In our study (Figure 6f), four IGFBP's were identified, IGFBP-3,5,6 and 7.
IGFBP-3 is moderately up regulated with (IL-13 +injury), and up regulated with (TNF-a
+ injury) without approaching statistical significance. This represents a move towards
catabolism, as IGFBP-3 will sequester IGF and prevent IGF mediated anabolism. IGFBP-
3 has previously been found to be higher in severe OA cartilage as compared to mild OA
in a statistically significant manner, but difference between mild and intermediate or
intermediate and severe does not approach statistical significance 187. A regression done
in the same study between OA score and IGFBP-3 levels show a very weak but
statistically significant dependency. The up regulation seen in IGFBP-3 may be because
of increase in IGFBP-3 in either matrix or in cytoplasm or nucleus of chondrocytes,
where it is seen to localize 188. This might be because of a role of IGFBP-3 independent
of IGF.
IGFBP-5 is highly up regulated with (TNF-ct + injury) in our study, but the level
remains the same with (IL-1 + injury). This possibly represents an attempt to repair
cartilage as increase in IGFBP-5 has previously been seen to increase IGF-1 and thus
improve joint architecture during OA development 89. IGFBP-5 is also increased in
chondrocytes and bone matrix during arthritic joint deterioration 90. IGFBP-5 is degraded
by complement component Cis. Figure 6g shows that complement component Cis is
mildly down regulated with both the (cytokine + injury) conditions. This mild down
regulation might partly explain the elevation of IGFBP-5 in the (TNF-a + injury)
condition, but it isn't known why the same down regulation of Complement Cis in the
(IL-13 + injury) condition does not cause an increase in IGFBP-5.
IGFBP-6 is one of the predominant IGFBP's found in bovine cartilage, and not
found much in human 191,192. We find IGFBP-6 to be mildly down regulated in both the
(injury + cytokine) conditions.
IGFBP-7 is moderately down regulated with (IL-1 +injury), and highly with
(TNF-a + injury). This protein is discussed in greater detail in a later section. It is
difficult to say with certainty how change in levels of IGFBPs are affected/affect any
roles of IGFBP independent of IGF, as these roles are yet unclear.
4.4.8 Proteins associated with the innate immune response
The complement system has traditionally been associated with the innate immune
response, functioning in host defense against invading pathogens (for review 19. It does
this through the release of inflammatory mediators and has been implicated in the
pathogenesis of several autoimmune, ischemic and vascular diseases 194 '195. The
complement system also serves as a vital link between innate and acquired immunity196
Complement component C1 triggers the classical component pathway. It is a complex
formed by association of the recognition protein Clq with two copies of two proteases
Cir and Cis. Clq binds the target, thus triggering self-activation of C1r, which converts
pro-enzyme Cis into a protease which cleaves C4 and C2, thus activating the classical
component pathway197 . The component Clq is also known to bind to, and induce
clearance of apoptotic cells198 .
The complement system is also involved in functions very different from its
traditional role in the immune response. It may be involved in the replacement of
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cartilaginous matrix by endochondral bone in early fetal development' . The
complement component C3 may be involved in osteoclast development by potentiating
M-CSF dependent proliferation of bone marrow cells and induction of osteoclasts 200
Complement proteins C3, B, C5, C9 and properdin are localized to distinct areas in the
developing endochondral bone, suggesting that complements proteins are involved in the
cartilage cell death, vascularization and hence the transformation of cartilage to bone 201
A significant role for the complement system exists in rheumatoid arthritis (for
review 202). Complement component C3 and C4 are drastically reduced relative to total
protein in the synovial fluid of patients with RA. Genetic deletion of complement
component C5, C3 or factor B in arthritis susceptible DBA/1 mice resulted in each case
in mice resistant to collagen induced arthritis (CIA)203,204. Wu et al 205 found complement
components such as complement factor B, complement component 4 binding protein,
complement 9 and complement factor H-related protein 5 to be over expressed in OA
cartilage compared to normal cartilage.
We identify complement factors B, I, components C3, C4-A, and subcomponents
C1r, Cis, and the A, B and C subunits of subcomponent Clq in our study (Figure 6d).
Cl-inhibitor is also present. Factor B is moderately down regulated with (IL-1P + injury)
and almost unchanged with (TNF-a + injury). Factor C3 is highly suppressed with both
(cytokine + injury) conditions. Injurious compression of cartilage is known to induce
apoptosis82. Since both factor C3 and B are known to be increased with inflammatory
cytokines such as TNF-a20 6 , it is likely that the combination of injury with these
cytokines results apoptosis of some cells, thus causing reduced levels of complement B
and C3 production. Subcomponents Cis, Cir and Clq are mildly downregulated with
(IL-13 + injury), and CIr moderately down regulated with (TNF-a + injury). C1 inhibitor
is highly down regulated with IL-1 + injury, but almost remains the same with (TNF-a +
injury). Deficiency of C1 inhibitor is associated with autoimmune diseases such as
systemic lupus erythematosus207
Peptidoglycan recognition proteins (PGLYRP) are innate immunity proteins
which recognize bacterial peptidoglycan and function in antibacterial immunity and
inflammation (for review 208). Four mammalian PGFLYRP's (PGLYRP 1-4) have been
identified. While human PGLYRPs have the highest affinity for peptidoglycans, bovine
PGLYRP1 has the highest affinity for LPS (Lipopolysaccharide) and LTA (Lipoteichoic
acid). PGLYRP2 plays a pro inflammatory role in a model of peptidoglycan-induced
arthritis in mice, with PGLYRP2- mice resistant to peptidoglycan induced arthritis and
inflammation209 PGLYRP1 on the other hand has an anti inflammatory effect. In our
study, we identify both PGLYRP1 and PGLYRP2. PGLYRP1 is down regulated mildly
with IL-13 + injury and moderately with TNF-a + injury compared to IL-1 alone.
PGLYRP2 on the other hand remains almost the same with (TNF-a + injury) (without
attaining statistical significance) and is highly down regulated with (IL-1B + injury). It is
curious that both PGLYRP1 and PGLYRP2 are down regulated with (IL-1P + injury),
since they have anti and pro inflammatory activities respectively. Since PGLYRP2 is
down regulated to a greater extent than PGLYRP1, this might imply an attempt to reduce
inflammation and repair tissue. Since IL-1 and TNF-a are pro-inflammatory cytokines,
we would expect that IL-1 alone/TNF-a alone would increase PGLYRP2 and decrease
PGLYRP1 compared to [IL-13 + injury]/[TNF-ax + injury], unless mechanical injury
increases chondrocyte access to the cytokines in the combination treatment. Some as yet
undiscovered function of the PGLYRPs may account for the way their levels change with
(cytokine + injury).
CD14, a membrane protein commonly found on monocytes/macrophages, is
critical for activation of the innate immune system by lipopolysaccharides2".
Lipopolysaccharide binding protein (LBP) binds to LPS on bacteria and transfers it to
CD14 on macrophages. CD14 and LBP are necessary and sufficient for the activation of
the Toll-like receptor system211. CD14 is moderately down regulated with IL-1P + injury
and very mildly with TNF-a + injury. LBP is moderately down regulated with both the
(cytokine + injury) conditions. The down regulation of CD14 and LBP with both the
(cytokine + injury) conditions as compared to IL-1 alone signifies that the inflammation
and macrophage activation caused by cytokine alone conditions is reduced on addition of
injury.
4.4.9 Signaling molecules
Proenkephalin is one of the proteins whose expression changes the most with
(cytokine + injury) in our study, showing -8 fold increase and -13 fold increase with IL-
1p + injury and TNF-a + injury respectively as compared to IL-1P alone (Figure 6h).
Proenkephalin is the precursor of enkephalin, opioid peptides which are
neurotransmitters, neurohormones and neuromodulators. Initially associated with the
nervous and neuroendocrine systems, proenkephalin was found to be highly elevated in
non-differentiated cells of diverse mesodermal lineages in the process of development
into adult tissues, including cartilage mm. It was, however, almost undetectable in
differentiated tissue, suggesting a role in cell proliferation/differentiation. Proenkephalin
expression was closely associated with cell proliferation and stimulated by TGF- in
chondrocytes. While very few primary chondrocytes express proenkephalin mRNA, a
high proportion of subcultured cells do . Rosen et al hypothesize that a small proportion
of undifferentiated cells in differentiated tissue retain the ability to synthesize
proenkephalin, and do so in situations demanding repair 66. Recent studies by McTavish et
a12 15 show that proenkephalin assists stress activated apoptosis by transcriptional
repression of p53 and NF-KB gene targets. Therefore, the high elevation of proenkephalin
with cytokine+injury could indicate an attempt to repair damaged tissue. It could also
help assist in apoptosis of cells, which has been observed with mechanical injury8 2
AIMP1 (p43) is another signaling protein highly elevated with (cytokine+injury).
AIMPI was first identified as a factor associated with a macromolecular tRNA synthetase
complex in mammalian systems 216. It was later found to be secreted and acts on diverse
target cells such as endothelial cells, macrophages and fibroblasts to control
angiogenesis, inflammation and dermal regeneration respectively. It is seen to activate
MAPK and NF-KB, and activates cytokine and chemokine genes involved in
inflammation such as TNF-a, IL-1p, IL-8, macrophage inflammatory proteins MIP-la
(CCL3), MIP-2a, MIP- 13 (CCL4) and RANTES (CCL5)m. It promotes endothelial cell
death by apoptosis at high dose 218, but also promotes fibroblast proliferation and wound
repair2. AIMPI has not been identified in cartilage in any study so far. The up
regulation of AIMPI with cytokine+injury might indicate inflammatory response, but it
is doubtful that cytokine+injury might have such highly elevated levels of inflammation
compared to cytokine alone (as the cytokines IL-1 and TNF-ax are highly pro
inflammatory themselves, and addition of injury would not increase inflammation). It
could represent an attempt to repair tissue, in line with its role in dermal wound repair, or
it could be involved in apoptosis caused by injury. Since AIMP1 seems to be a highly
multi-functional protein with different domains contributing to different functions220, it
could play any of these roles here, and further studies are needed to clarify the role of
AIMPI in stressed cartilage.
Annexins A2 (II) and A5 (V) show high elevation with TNF-a + injury. Annexin
A5 is also highly elevated with IL-1 + injury, and Annexin A2 moderately. Annexins
are a family of proteins with the ability to bind to acidic phospholipids in the presence of
Ca*. Three annexins, 1I, V and VI are known to be highly expressed in calcifying
cartilage and bone 2. Annexins II, V and VI are major components of matrix vesicles
(MV), particles released from plasma membrane of hypertrophic chondrocytes or
osteoblasts, which initiate mineralization of cartilage. These annexins form calcium
channels in MV's and mediate rapid influx of Ca** into the vesicles which serves as the
start of the mineralization process. Annexin mediated Ca"* influx also leads to terminal
differentiation and apoptosis of growth plate chondrocytess,222 . The up regulation of
Annexins II and V in our study with (cytokine+injury) therefore indicates the onset of
mineralization, terminal differentiation and apoptosis in cartilage, which are features of
OA cartilage as well. SPARC (osteonectin) shows high down regulation with (TNF-a +
injury), and is discussed in greater detail later in this discussion.
4.5 Comparing the effect of combination of cytokine and injury as
opposed to either treatment alone
4.5.1 Combining data from two iTRAQ experiments
Since we used a four-plex iTRAQ experimental design, we chose iTRAQ
114,115,116 and 117 labels to represent IL-1 alone, TNF-a alone, IL-1 + injury and
TNF-a + injury treatments respectively. Since we had only four labels available to us, we
could not introduce an untreated control, and a sample for injury alone treatment.
However, for a true study of whether there exists synergy between injury and either
cytokine in their effect on protein levels, we require data for six treatment conditions,
namely untreated control, IL-1 alone, injury alone, IL-1 + injury, TNF-a alone and
TNF-a + injury. Therefore, we combine data from this experiment with a previous
experiment done in our lab (which had untreated control, IL-13 alone, TNF-a alone and
Injury alone treatment sample data8 0) to generate all possible ratios with respect to
control.
4.5.2 Variation between the two iTRAQ experiments
We first check for reproducibility between the two iTRAQ experiment data, by
looking at the only common ratio between the two experiments, TNF-a/IL-1. To do this,
we first identify proteins which are found in common between experiment A (this
experiment) and experiment B 80, and which are quantified well across all ratios. We
identify 74 such proteins. The log of ratio of (TNF-a/IL-1P) ratios from experiment A
and B for these proteins has a mean of 0.1067. This variation of 10.67% is again lesser
than the 23% and 25% variation seen between experimental and biological replicates in
an earlier iTRAQ study1 1 6. Therefore, for these 74 proteins, data from both experiments
are merged and converted to ratios with respect to untreated controls.
4.5.3 Correlation between cytokine alone, injury alone and cytokine+injury
treatment conditions
A matrix of correlation coefficients is thus generated for these 74 proteins for the
five ratios (IL-1 I:control), (TNF-a:control), (injury:control), (IL-1 IP+injury:control) and
(TNF-a+injury:control) (Table 2) . We see that while IL-1 alone and TNF-a alone have
a correlation of -90.2%, (IL-1 + injury) and (TNF-a + injury) have a 95.7% correlation.
It is highly interesting that in the presence of injury, the two cytokines show an even
higher similarity in their effect on proteins than in the absence of injury. This shows that
while IL-1 and TNF-a themselves have very similar effects on cells globally, the
addition of injury further augments this similarity. This high similarity between the two
(cytokine+injury) conditions is not due to the effect of injury masking the effect of
cytokine, as the correlation between injury alone and (cytokine+injury) (-75%) is much
less than the 95% correlation between the two (cytokine+injury) conditions. One possible
hypothesis to explain higher correlation the (cytokine+injury) treatments (as compared to
correlation between cytokine alone treatments) is that the combination of injury with IL-
1p and TNF-a may activate some new pathways in the chondrocyte, in addition to
pathways activated by cytokine alone and injury alone, and that these new pathways
activated are common for both (IL-1 + injury) and (TNF-at + injury).
4.5.4 Proteins on which injury and cytokine act in a synergistic fashion
To identify proteins on which injury and cytokine act synergistically, we look at
proteins for which the effect of (injury + cytokine) is greater than that caused by injury
alone or cytokine alone. If the ratio of (injury + cytokine) for a protein is greater than the
injury alone ratio, the cytokine alone ratio, and the product of injury alone and cytokine
alone ratios (the ratio expected if injury and cytokine act independently), injury and
cytokine are identified as exerting a positive feedback on each other's action (positive
synergism) for that protein. On the other hand, if the ratio if (injury + cytokine) is lesser
than the injury alone ratio, the cytokine alone ratio, and the product of these ratios, injury
and cytokine are said to exert a negative feedback on each other's action for that protein.
By having such a stringent criterion, we make sure that we pick only proteins on which
injury and cytokine truly act synergistically, and avoid artifacts due to quantitation error,
and any error in combining data from the two experiments.
When we thus look at proteins which satisfy this criterion, we find that among our
list of 74 proteins, for no protein does IL-1P and injury exhibit positive or negative
feedback. However, we identify a few proteins for which TNF-a and injury act
synergistically. TNF-a and injury exhibit positive feedback for Aggrecan, Histone H4,
CILP-2 and COL6A3 ; and negative feedback for SPARC and IGFBP7 (Table 3).
Aggrecan is almost doubled with (TNF-a) alone, and slightly down regulated with
injury alone, but when injury and TNF-aL are combined, the level rises to more than that
by TNF-ax alone. The percentage synergism is 4.3%. This small synergism may be due to
enhanced transport in the ECM caused by injury, which allows better access of aggrecan
to ADAMTS and MMP, thus causing higher cleavage and greater release of cleaved
fragments to medium, resulting in increased levels.
CILP-2 shows the highest percent positive synergism (81%) among these four
proteins. Cartilage intermediate layer protein 2 (CILP-2) is an isoform of the ECM
protein CILP-1. CILP-1 and CILP-2 are 50.6% identical and around -66% of their amino
acids are conserved 38. CILP-1 has been found to bind to TGF- and act as a negative
regulator of TGF-p in chondrocytes, thus preventing TGF-p induction of aggrecan and
Collagen type I 223. It is also seen to block the ability of IGF-1 to decrease extracellular
inorganic pyrophosphate; however, CILP-2 has no such effect 38. A protein profile of
human OA cartilage yielded CILP-2 fragments, suggesting possible CILP-2 cleavage in
OA 224. The increase in CILP-2 levels we observe due to synergism between injury and
TNF-a may thus be due to cleavage of CILP-2. Further studies on the function of CILP-2
may help in interpreting these results better.
The alpha III chain of Type VI collagen (COL6A3) shows 20.6% positive
synergism between TNF-a and injury. Collagen VI is structurally composed of three
different peptide chains, al(VI), a2(VI) and a3(VI); a3(VI) (260-300 kDa) is much
larger than al(VI) and a2(VI) (both around 140 kDa). It is an ECM protein which forms
a microfibrillar network around or in between collagen type II fibers in cartilage; it is
concentrated in areas surrounding chondrocytes225 226 . It interacts with several matrix
constituents including collagens type Im and type II228 ; SLRP's biglycan, decorin,
chondroadherin 32 , fibronectin 229 and basement membrane Collagen type IV2 . It also
binds to alp1 and u2 1 integrins and thus maybe involved in cell signaling231. Thus,
roles of collagen VI include structural roles such as anchoring the basement membrane to
the connective tissue, and serving as scaffolds for formation of fibrillar collagen
networks; and signaling roles, such as mediating the interaction of cells with the ECM.
Therefore, it could be involved in roles ranging from wound healing to tissue
232development and architecture 2. Thus, the positive synergism displayed between injury
and TNF-a for COL6A3 possibly represents an attempt to form collagen microfibrils to
repair damaged tissue.
Histone H4 replacement-like protein also shows considerable synergism
(27.03%). This protein resembles histone H4, which is one of the basic units of chromatin
architecture in the nucleosome. DNA wraps itself around the nucleosome composed of
histones. Because of this close association with DNA, histones are involved in DNA
transcription, replication, DNA damage and its repair, recombination and overall
chromosomal stability 233. Histones are basic proteins with a globular domain and a
charged NH 2- terminus (histone "tails") protruding from the nucleosome. These tails are
highly involved in modulation of chromatin architecture, either by serving as targets for
chromatin remodeling factors such as Swi/Snf and NURF; or by means of diverse post
translational modifications such as acetylation and phosphorylation (for review2 3 4).
Synthesis of histones is closely associated with DNA replication during S-phase of the
cell cycle, and hence histone gene expression can be used as a marker for
proliferation 235 ,236. Therefore, the synergistic up regulation by TNF-a and injury of
Histone H4 replacement-like protein possibly represents increased cell proliferation due
to repair of damaged tissue.
SPARC and IGFBP7 are the proteins which show reduced expression because of
negative feedback between TNF-a and injury. SPARC is a glycoprotein present in the
ECM which mediates cell-matrix interactions but does not serve structural roles. It is a
Ca** binding protein which acts as a counter-adhesive protein, a modulator of growth
factor activity and a cell cycle inhibitor. It is expressed in high levels in tissues
undergoing remodeling, whether naturally, due to wound healing or due to disease (for
reviewm2 1). SPARC is stimulated by several members of the TGF- super family
including TGF-1, BMP-2 and activin, and inhibited by bFGF, IL-1, TNF-ax,
dexamethasone and LPS 238-240 .
SPARC has been shown to induce production of MMPs 1, 3 and 9241; and also to
activate MMP-2242 It also binds to several collagens including collagen type I, III, IV
and V243. SPARC synthesis is markedly enhanced in arthritic joints (OA or RA), and in
such joints has been hypothesized to induce MMP production in the surface zone, and
modulate chondrocyte proliferation, matrix synthesis and mineralization in the middle
and deep zones 240. A proteomic study by Wu et al 205 found SPARC to be increased in
OA cartilage compared to normal. In this context, it is highly surprising that we observe
negative feedback between TNF-a and injury, resulting in down regulation of SPARC.
We would expect up regulation, both in view of the fact that SPARC elevation has been
reported in OA cartilage, and that IL-1 and TNF-a alone reduce SPARC mRNA levels.
A possible reason could be high levels of apoptosis with injury, leading to a less number
of SPARC producing cells. Increased transport of TNF-a due to increased permeability
caused by injury and subsequent inhibition by TNF-a could be another reason for the
negative feedback. However, it is unclear whether increased transport may suffice to
explain extremely high negative feedback, and further studies need to be carried out to
understand better the reason behind this behavior of SPARC.
IGFBP7 is the other protein which shows down regulation due to negative
feedback between TNF-a and injury. This protein is known to be expressed in OA
articular cartilage. The gene coding for IGFBP-7 is present in chromosome 4q which has
been associated with hip OA susceptibility by linkage mapping, but further studies
indicate that polymorphisms in IGFBP7 gene may not increase susceptibility to hip
OA 244. As IGFBP-7 only weakly inhibits IGF, this significant down regulation is
probably due to an as yet unknown function of IGFBP-7.
In our study, we have thus identified six proteins on which TNF-a and injury act
synergistically. A more complete way to analyze interactions and feedbacks between
Cytokine and injury would be to perform multiple mass spectrometry experiments using
the 8-plex iTRAQ experimental design, and analyze the data using a two way Anova.
However, this study makes a start in trying to understand where the synergism between
injury and cytokine in GAG loss comes from.
4.6 Partial Least Square Regression (PLSR) Analysis
4.6.1 Motivation behind the PLSR analysis and Methodology
Our next aim is to connect what happens inside the cell to variables which can be
observed outside. By performing this study, we hope to find out proteins which are most
relevant in changing some specific measurable phenotypes of cartilage. We thus have two
matrices, X composed of log-transformed protein ratios under different treatment
conditions, and Y composed of phenotypes under the same treatment conditions. We
want to find out how the underlying change in protein ratios manifests as observable
phenotypes, and hence want to find a relationship between Y and X. Since the number of
protein ratios is much higher than the number of phenotypes, we have a problem of multi-
collinearity (one or more protein ratios are highly correlated and hence, the matrix X
contains superfluous information). Ordinary multiple regression can hence not be used.
The commonly used Principal component regression (PCA) eliminates the problem of
multi-collinearity by choosing directions of maximum variance in X and using these to
develop a multiple regression model with Y. PLSR on the other hand chooses those
directions which maximize covariance between X and Y, projects X and Y data points on
these directions, and performs regression. Therefore, PLSR helps generate those
independent variables which contribute most to the relationship between X and Y (for
review 114). In our situation, this means that amongst all the protein ratios we have, we
can identify proteins which contribute most to observed phenotype. From the 74 proteins
for which we have data for all 5 treatment conditions, CLEC3A and CD109 are not
chosen because they increase error in the model. We use log transformed data for the
remaining 72 proteins across 5 treatment conditions as the X matrix. The Y matrix is a
(4*5) matrix consisting of log transformed phenotype ratios with respect to control. The
four phenotypes we choose are sGAG loss to the medium during the five day treatment,
nitrite accumulation in the medium in five days, rate of proline incorporation (indicative
if protein synthesis) on the sixth day (the day after the five day treatment ends), and rate
of sulfate incorporation on the sixth day. The five treatments are the same as for the X
matrix.
It is important to note that any relevant phenotype for which data across all
treatments including (cytokine+injury) are available can be chosen, these four phenotypes
are chosen because of availability of data for all the five treatments including the
(cytokine + injury) treatments. Also, sGAG release and proline and sulfate incorporation
rates are biologically significant phenotypes, as they indicate catabolism (sGAG release)
and anabolism (proline and sulfate incorporation). Choosing these phenotypes therefore
helps understand which proteins contribute most to catabolic and anabolic activities.
4.6.2 Some Observations from the PLSR plots
Figures 8a-b show that four factors (principal components) are able to describe
100% of the variation in the X matrix (protein ratios) and Y matrix (phenotypes). Two
principal components describe 88% variation in the training data set and 70% of Y
variation in the validation data set. This difference may be due to the presence of outliers
in the protein data matrix.
However, for obtaining trends about how phenotypes and proteins relate to each
other, projection on the first two principal components are sufficient. Figure 8c shows
the projection of different treatment conditions on the first two principal components. We
see that the cytokines IL-1p and TNF-a are close to each other, the two cytokine+injury
treatments are close to each other, and the injury treatment is separate from the other two.
Figure 8d shows the projection of proteins and phenotypes on the first two principal
components. Proteins and phenotypes present close together in the same quadrant are
highly correlated to each other, and proteins and phenotypes present in opposite
quadrants and far from each other are inversely correlated. We immediately see that
proline and sulfate incorporation rates, both indicators of synthesis, are highly correlated
as expected. sGAG loss to medium, an indicator of cleavage of proteoglycans, and hence
catabolism, is diametrically opposite to proline and sulfate incorporation rates, again as
expected. Most cytoplasmic proteins cluster together tightly in the fourth quadrant. We
also observe that SPARC and IGFBP7, two proteins which we earlier observed to
synergistically decrease in the presence of TNF-a and injury are clustered close to sulfate
and proline incorporation rates. Therefore, SPARC and IGFBP7 both seem to be
indicators of synthesis or repair, which is seen to reduce on treatment with cytokine and
injury. If the only role for IGFBP7 were in binding IGF, we would expect a negative
correlation of IGFBP7 with synthesis, with an increase in IGFBP7 decreasing free IGF,
and hence decrease anabolism. Therefore, this positive correlation of IGFBP7 with
synthesis suggests a new role for IGFBP7 in repair and merits investigation.
4.6.3 Identification of proteins which contribute most to observed phenotype
From Table 5, we see that the top five positive protein-phenotype correlations are
perlecan, pleiotropin, serum amyloid A3, CILP-2 and complement factor B, all with
sGAG. Since sGAG loss to the medium is an indicator of catabolism, these five proteins
are either key causative agents or key markers of catabolism. Also, the top five negative
correlations are pleiotropin with proline and sulfate incorporation, perlecan with proline
and sulfate incorporation and cathepsin B with sGAG release to the medium.
Perlecan is a large, multi-domain ECM proteoglycan expressed in almost all
basement membranes, and also in mesenchymal organs and connective tissue. It is
involved in a diverse range of developmental and biological processes, including
chondrogenesis, endochondral ossification, angiogenesis and wound healing. Perlecan is
known to interact with and sequester several growth factors, including FGF, VEGF,
CTGF, etc. Knox and Whitelock 30 hypothesize that perlecan performs such a diverse
range of functions by interacting with, and altering distributions of growth factors and
morphogens in developing tissue. Perlecan also interacts with several ECM molecules
including fibronectin, nidogen-1, nidogen-2, PRELP, etc and thus is involved in ECM
organization (for review 29 ). Perlecan deficient mouse embryos die at embryonic day (E)
24510.5 with defective cephalic development, or die just after birth with skeletal dysplasia .
Late stage OA tissue samples showed elevated perlecan mRNA and protein levels in
cartilage adjacent to OA defects246, this suggests that perlecan is either involved in OA
pathogenesis, or is synthesized in OA cartilage in an attempt to repair tissue. Our study
however, shows that perlecan is highly correlated with sGAG release and highly anti-
correlated with both proline and sulfate synthesis, showing that an increase in perlecan
released to the medium is an indication of catabolism, and reduced anabolism. Therefore,
it is probable that the increase in perlecan observed in late stage OA is not due to an
attempt at tissue repair, but rather due to worsening catabolism.
Pleiotropin is a cytokine implicated in tumor cell growth and angiogenesis,
apoptosis and mitogenesis (for review 67). It is undetectable in normal adult cartilage, but
is elevated in the synovial fluid of OA patients in early stages and found rarely in late
stages247. In cultured chondrocytes, pleiotropin reduced MMP-1 and MMP-13, and
increased TIMP-1 and TIMP-2 mRNA levels, indicating a role in repair 248. However, a
study by Tare et al 249 found that over expression of pleiotropin in transgenic mice led to
increased type I collagen synthesis (associated with osteoblasts), and ossification within
articular cartilage. Our result shows high correlation of pleiotropin with sGAG loss, and
high anti-correlation with proline and sulfate incorporation, and suggests a catabolic role
for pleiotropin, contradicting the possibility of a role for pleiotropin in repair. However,
since cartilage catabolism is accompanied by endochondral ossification in OA, the
association of pleiotropin with catabolism might actually imply the role of pleiotropin in
ossification.
Complement factor B and Serum Amyloid A3 are both involved in the innate
immune response. Complement factor B has been discussed earlier, and is implicated in
cartilage cell death and endochondral bone formation20 1 . Serum Amyloid A3 (SAA3) is a
member of the Serum amyloid A family, apolipoproteins associated with HDL. The
SAA3 gene is not expressed in humans 2s; however, LPS stimulated macrophages secrete
SAA3 in a murine model, suggesting a role for SAA3 in local inflammation apart from a
general acute-phase response . The high association of these innate immunity proteins
with sGAG release suggests that catabolism is accompanied by inflammation and innate
immune response.
CILP-2 has been discussed previously earlier in the context of TNF-a and injury
acting synergistically to increase CILP-2 levels. This protein, whose function is as yet
unknown, also appears to be a marker of catabolism.
It is, however, surprising that cathepsin-B, a cysteine protease which cleaves
collagens252 and aggrecan 2 2 and hence plays a part in catabolism, shows such a strong
negative correlation with sGAG release. One possible reason is that in our (injury +
cytokine) model, cathepsin is not the primary collagenase/aggrecanase and does not
contribute to sGAG release, therefore, the anti-correlation of sGAG release with
cathepsin B is an artifact.
4.7 Limitations of this study
To identify the proteins on which injury and cytokine act synergistically, we
combined data from two 4-plex iTRAQ experiments to obtain values for all the
treatments (IL-1, TNF-a, injury, IL-1p and injury and TNF-ax and injury with respect to
control). Because there exists a variation of only -10.5% between the two experiments,
which is less than that typically seen between biological replicates, the data from both
experiments are combined as such without correcting for any experimental bias.
Additionally, when combining data between the two 4-plex experiments, to ensure that
there are no false positives identified, we first shortlist those proteins which are identified
by both iTRAQ experiments, and which have all ratios across both experiments with an
FDR<0. 1. This gives us a list of only 74 proteins, and in this final list we check for
proteins on which cytokine and injury exhibit synergism, ending with only 6 proteins on
which TNF-a and injury show positive or negative synergism, and none for IL-1 IP and
injury. This methodology is exceedingly stringent, and may miss out several proteins on
which cytokine and injury actually exhibit synergism, but are not counted because one or
more of their FDR>O. 1. In other words, we may end up with several "false negatives".
An 8-plex iTRAQ experiment can circumvent both these problems, as we could
label samples from all the treatment conditions simultaneously. This would firstly
eliminate the need to combine data from two 4-plex experiments, and thus ensure no inter
experimental variation. Secondly, conducting an 8-plex experiment would ensure lesser
false negatives, and ensure more than just the 6 proteins we obtained on which cytokine
and injury exhibited synergism.
When we performed the PLSR analysis, we considered only the first two latent
vectors, to enable easy interpretation of how proteins and phenotypes relate to each other.
The first two latent vectors of our PLSR model, however, capture only -88% variation in
the training set, and 70% variation in the validation set. The addition of more latent
vectors would capture more information, but may complicate the interpretation of the
PLSR plots.
CONCLUSION
In conclusion, we have used 4-plex iTRAQ labeling followed by 2D-LC/MS/MS
to study the effect of the combination of cytokine and injury on cartilage explants. A
global analysis of the proteins released revealed a high correlation between (IL-13 +
injury) and (TNF-a + injury) treatment conditions. A k-means cluster performed on the
protein ratios revealed three distinct clusters, cluster 1 containing proteins highly down
regulated, cluster 2 mildly up regulated and cluster 3 highly up regulated with (cytokine +
injury). Most cytoplasmic proteins are present cluster 3 and are highly elevated with
(cytokine + injury), possibly due to mechanical lysis of cells due to injury. ECM proteins
are present in either cluster 1 or cluster 2. Looking at specific protein groups, C-terminal
collagen propeptides of some fibrillar collagen chains are down regulated with (cytokine
+ injury), indicating reduced synthesis of new collagens, and a decrease in the anabolic
ability of cartilage. ECM molecules such as COMP and matrilin-3 were down regulated,
and members of the SLRP family including chondroadherin, PRELP, biglycan and
lumican were highly up regulated with (TNF-a + injury). The elevation of lumican and
biglycan, known to be expressed in early stages of collagen fibril development possibly
indicates signs of repair. Proteases MMP-2, MMP-3 and MMP-9 levels don't change
much with (cytokine + injury), but MMP-13 is highly down regulated and ADAMTS-1
highly elevated with TNF-a + injury. This suggests that ADAMTS-1 may be responsible
for the synergistic sGAG release in the presence of cytokine + injury. An increase in
TGF-62 and activin, accompanied by a decrease in LTBP1 suggests attempts to repair
cartilage. CTGF, known to be induced by TGF-D is highly down regulated with TNF-a +
injury, a behavior similar to what happens in a sheep model of OA at the mRNA level,
although it is unclear why. Proenkephalin, AIMP1 and annexins A2 and A5 show high
elevation with TNF-a + injury and/or IL-1 + injury. The up regulation of proenkephalin
possibly helps in repair and in apoptosis caused by injury, the elevation of annexins
indicates terminal differentiation and onset of apoptosis and AIMP1 may play a yet
undetermined role in this situation.
Next, we combined the results from two iTRAQ experiments to obtain data from
injury alone, cytokine alone and cytokine + injury to find out proteins on which injury
and cytokine acted synergistically. From data combined from both experiments, we find a
very high correlation between (IL-1p + injury) and (TNF-a + injury) (-95.7%), much
higher than that between injury and (cytokine + injury), indicating that the domination of
injury over cytokine is not the reason for the high correlation between (IL-13 + injury)
and (TNF-a + injury). Also, the correlation between the two (injury + cytokine)
conditions is higher than the correlation between the two cytokine conditions (-90.3%),
indicating that while both cytokines act through similar pathways in chondrocytes, the
addition of injury further adds new common pathways. From the 74 proteins identified in
common between both the experiments and quantified well across ratios, we find that
TNF-a and injury exert positive synergism on CILP-2, COL6A3, Histone H4
replacement-like and aggrecan and negative synergism on SPARC and IGFBP7. While
increased transport of TNF-a caused due to mechanical damage might cause a slight
increase in aggrecan cleavage resulting in the small synergism shown for aggrecan,
increase in COL6A3 and Histone H4 replacement-like proteins are much higher and may
result from cellular pathways seeking to repair damaged cartilage.
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A PLSR analysis performed between phenotypes and protein ratios removes
superfluous information and generates interesting associations between protein ratios and
phenotypes. Perlecan and pleiotropin are both highly correlated with sGAG release and
highly anti-correlated with proline and sulfate incorporation rates, indicating that both
these proteins are markers of catabolism. Complement factor B and serum amyloid A3,
proteins associated with innate immunity are both highly correlated with sGAG release,
indicating that local inflammation plays a role in catabolism. SPARC and IGFBP7 are
correlated with proline and sulfate incorporation, suggesting that the negative synergism
between TNF-a and injury for these proteins indicates a reduction in the ability of
cartilage to repair itself. High correlation between CILP-2 and sGAG release suggests
that this protein can also serve as a marker for catabolism. PLSR can thus help find
unique protein-phenotype associations, which may help discover unknown functions of
proteins.
Thus, our study indicates that our in vitro model of injury + cytokine affects
cartilage differently from either injury alone or cytokine alone, and causes both
catabolism and attempts to repair damaged cartilage. This model thus mimics OA
cartilage and may serve as a useful model system to study OA under controlled
conditions in vitro.
Future Work
While bovine cartilage serves as a useful in vitro model system to mimic OA like
conditions using a combination of injury and cytokines, using human cartilage explants in
our in vitro model will help avoid bovine-human differences in response to treatment, and
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will be closer to human in vivo conditions. Also, as mentioned before, an 8-plex iTRAQ
experimental system would yield more proteins on which injury and cytokine exert
synergism, and could provide a better picture of metabolic pathways in the chondrocytes
which are affected by injury and cytokine.
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APPENDIX
Appendix A.1 and Appendix A.2: Profile of proteins released to media
from the first and second biological replicates respectively. Only
proteins identified by greater than 2 peptides with confidence > 90%
and which are well quantified across all ratios are shown here. Protein
ratios are normalized using the internal standard chondroitinase ABC.
Profile obtained using iTRAQ 2D-LC/MS/MS with ProteinPilotTM
Software 2.0.1 (ABI). Matlab scripts are used to calculate the weighted
means and standard deviations. For more detailed information on how
this list was obtained, refer to Chapter 2
Column 1: GI Number of Protein
Column 2: Name of Protein
Column 3: Percent of proteins covered by identified peptides
Column 4: Geometric mean of (TNF-a/ IL- 1p)
Column 5: Standard deviation of (TNF-a/ IL- 1f) in log space
Column 6: p value for the null hypothesis that (TNF-a/ IL-1p) is unity. Obtained by
Wilcoxon Sign rank test or paired t test.
Column 7: Geometric mean of (IL- 1f +inj/ IL- 1p)
Column 8: Standard deviation of (IL-1P +inj / IL-1 ) in log space
Column 9: p value for the null hypothesis that (IL-i I1 +inj / IL- 1f) is unity. Obtained by
Wilcoxon Sign rank test or paired t test.
Column 10: Geometric mean of (TNF-a +inj/ IL- 13)
Column 11: Standard deviation of (TNF-a +inj / IL- IfP) in log space
Column 12: p value for the null hypothesis that TNF-x +inj / IL- 1P) is unity. Obtained by
Wilcoxon Sign rank test or paired t test.
Column 13: Number of peptides used in calculating (TNF-a/ IL-1 3) ratios
Column 14: Number of peptides used in calculating (IL- 1 +inj / IL- 1p) ratios





PREDICTED: similar to heparan sulfate proteoglycan 2 (pedecan) [Bos taurus]
giJ76610126 PREDICTED: similar to fibronectin 1 isoform 4 preproprotein isoform 12 [Bos taurus]
gi|164 4 144 25 collagen, type 11, alpha 1 isoform 1 [Bos taurus]
gi|119900891 PREDICTED: hypothetical protein LOC540664 [Bos taurus]
gi|119890645 PREDICTED: similar to alpha 3 type VI collagen isoform 5 precursor isoform 1, partial [Bos taurus]
gi]41386685 thrombospondin 1 [Bos taurus]
gir30794280 albumin [Bos taurus]
gi|34098396 Chondroitin ABC endolyase 1 precursor (Chondroitin ABC lyase 1) (Chondroitnase ABC) (Chondroitin sulfate endolyase) (Chondrotin ABC elminase)
gi|1 19913814 PREDICTED similar to melanoma-associated chondroitin sulfate proteoglycan 4 [Bos taurus]
gi|119901095 PREDICTED: similar to collagen, type XII, alpha 1 isoform 1 [Bos taurus]
gil119887130 PREDICTED: similar to Collagen, type VI, alpha 1 isoform 1 [Bos taurus]
gi]27806761 aggrecan 1 [Bos taurus]
gi]115495027 heat shock 70kDa protein 5 [Bos taurus]
gij1 19889734 PREDICTED: similar to Collagen alpha-1(XI) chain isoform 1 [Bos taurus]
gi|156120777 nidogen 2 [Bos taurus]
gill10347570 vimentin [Bos taurus}
gi|119892686 PREDICTED: similar to P63 protein [Bos taurus]
gil1 19890597 PREDICTED: similar to alpha 3 type VI collagen, partial [Bos taurus]
gill14051163 collagen. type XI, alpha 2 [Bos taurus]







lamin A/C [Bos taurus]
gil148238040 actnin, alpha 4 [Bos taurus]
gi|95147674 complement factor B [Bos taurus]
gi|119894520 PREDICTED: similar to cartilage oligomeric matrix protein isoform 1 [Bos taurus]
gir9902896
9 
complement component 3 [Bos taurus]
gi]148230374 protein disulfide isomerase-associated 3 {Bos taurus]
gill15497814 nucleobindin 1 [Bos taurus]
gi|116003881 collagen, type Ill, alpha 1 [Bos taurus]
gi|119919153 PREDICTED: similar to AHNAK nucleoprotein [Bos taurus]
gi|77404252 collagen, type 1, alpha 1 [Bos taurus]
gil119888668 PREDICTED: similar to Cartilage matrix protein precursor (Matrilin-1) [Bos taurus
gi]164452943 gelsolin a [Bos taurus]
gi]60592792 heat shock 9OkD protein 1, alpha [Bos taurus]
gij76621011 PREDICTED: similar to Cartilage intermediate layer protein 2 precursor (CILP-2) [Bos taurus]
gil27806501 prolyl 4-hydroxylase, beta subunit [Bos taurus]
gil1 14050715 moesin [Bos taurus]
gil153791660 extracellular matrix protein 1 [Bos taurus]
gi]114326226 protein disulfide isomerase-associated 4 [Bos taurus]
gi]76607158 PREDICTED: similar to Melanotransferrin precursor (Melanoma-associated antigen p97) ]CD228 antgen) [Bootaurus]
gi|156120795 quiescin Q6 sutfhydryl oxidase 1 [Bos taurus]





matrix metalloproteinase 2 [Bos taurus]
gi|119906908 PREDICTED: similar to matrix metalloproteinase-3 [Bos taurus]
gi|7663 014 3 PREDICTED: similar to matrilin-3 [Bos taurus]
gi|122692297 chitinase 3-like 1 [Bos taurus]
gi]77735551 phosphoglycerate kinase 1 [Bos taurus]
gil119921375 PREDICTED: similar to RP11-525G3.1, partial [Bos taurus]
gil1 19901238 PREDICTED: similar to laminin alpha 4 [Bos taurus]
gi]87196501 enolase 1 [Bos taurus]
gil27807263 heat shock protein 90kDa beta, member 1 [Bos taurus]
gi|1 15497900 eukaryotic translation elongation factor 2 [Bos taurus]
gi|156718112 latent transforming growth factor beta binding protein 1 (Bos taurus]
gi|115497210 complement component 1, s subcomponent [Bos taurus]
gil15652
3
168 matrilin 2 [Bos taurus]
gil11991915
7 
PREDICTED: hypothetical protein [Bos taurus]
gi]61845535 PREDICTED: similar to emilin [Bos taurus]
gil164450489 AE binding protein 1 [Bos taurus)
gil27805853 cartilage linking protein 1 [Bos taurus]
gil1 19902010 PREDICTED: similar to LOC512571 protein [Bos taurus]
gi|94966763 haptoglobin [Bos taurus]
gi|62988316 follistatin-like 1 [Bos taurus]
gi]76253709 heat shock 70kDa protein 8 [Bos taurus]
gil147906412 hypothetical protein LOC615490 [Bos taurus]
gi|27805991 latent ransforming growth factor beta binding protein 2 [Bos taurus]
gi1 19918578 PREDICTED similar to vinculin isoform meta-VCL isoform 1 [Bos taurus]
gi|27806781 vitrin [Bos taurus]
gi]41386780 UDP-glucose pyrophosphorylase 2 [Bos taurus]
gi]119903231 PREDICTED: similar to lysyl oxidase-like 3 protein [Bos taurus]
gil1 19903133 PREDICTED: hypothetical protein [Bos taurus]
gi27806477 lysyl hydroxylase precursor [Bos taurus]
gi|61888856 triosephosphate isomerase 1 [Bos taurus]
gil27806257 collagen, type I, alpha 2 [Bos taurus]
gi|154707890 lysyl oxidase-like 2 [Bos taurus]
gi]76682880 PREDICTED: smilar to nucleolin-related protein NRP isoform 1 [Bos taurus]
gill 15498012 glycogen phosphorylase, liver [Bos taurus)
gi|115496702 collagen, type VI, alpha 2 [Bos taurus]
gir120474983 annexin AS [Bos taurus]










PREDICTED: similar to filamin [Bos taurus]
9i)75832054 actin, beta [Bos taurus]
%Cov mean 115: std 115:11 pvalue 115: mean 116 std 116:11 pvalue 116 mean 117: std 117 11 pvalue 117: Nopepll5hopepll
6 
Nopepll7
34.79845 1.005643 0.421889 0.5458818 0.961879 0.315976 0.0001377 1.253084 0.844274 3.39E-15 346 348 370
49.32261 0.435739 0.496027 3.61E-102 1.047484 0.294038 1.60E-05 0.473026 0.639835 1.87E-103 628 682 857
69.60323 0.826267 0.712588 3.87E-24 0.654007 0.542659 0 0.461606 0.860192 1.25E-114 717 719 719
42.53996 0.542485 0.260546 0.0065573 0.894213 0.218261 0.2160647 1.252597 0.216957 0.05788702 4 4 4
53.2872 0.65229 0.494509 6.39E-19 1.192888 0.385784 1.10E-06 1.222695 0.763684 4.86E-05 114 120 123
50.8547 0.815516 0.520715 3.35E-33 1.005309 0.288304 0.7150054 1.347252 0.921421 3.49E-14 347 357 368
85.99671 3.023079 0.45549 3.63E-117 0.867879 0.434132 5.71E-22 1.198459 1.138088 0.00159624 707 688 705
56.51322 1 0.358784 0.0385808 1 0.323575 0.6563822 1 0.342961 0.64236811 238 244 250
32.16904 1.34625 0.355638 0 1.002979 0.413166 0.9146439 1.274493 0.578736 2.86E-06 80 81 83
23.52753 0.852151 0.343306 1.93E-05 1.067136 0.297717 0.021252 1.754255 0.357203 0 87 69 79
53.74878 0.649362 0.44438 1.60E-50 1.015564 0.284613 0.5096392 1.224062 0.499061 5.72E-28 362 371 378
18.99441 0.784089 0.472729 0 0.922274 0.3414 2.97E-21 0.813244 0.913111 5.48E-15 717 728 731
62.13741 1.247723 0.528367 2.90E-05 2.974593 0.72733 2.24E-18 3.541618 0.842243 2.95E-19 83 103 112
42.26747 0.919981 0.486381 0.0339878 0.864302 0.345823 9.03E-10 0.875004 0.656286 0.53356804 188 190 182
37.70115 0.96593 0.410477 0.210661 0.924994 0.360826 0.0007069 1.422424 0.787659 3.27E-08 103 107 114
72.31759 1.432939 0459791 4.74E-09 3.405984 0.487717 0 4.166193 0.508689 0 75 81 82
69.43973 0.999488 0.61657 0.6375414 3.582926 0.769483 0 4.295576 0.831835 0 76 83 83
39.15441 0.689371 0.432873 1.74E-10 1.20587 0.286836 1.99E-07 1.41886 0.289956 0 78 79 84
45.50691 0.637727 0.635712 1.77E-28 1.108789 0.321063 1.06E-11 1.849601 0.658567 1.94E-44 356 368 382
27.42947 1.109722 0.423167 0.0588728 1.798648 0.379839 1.27E-13 2.725651 0.388416 0 31 32 32
74.12587 1.221441 0.41052 1.69E-05 2.590192 0.482542 0 3.48788 0.529756 0 47 49 49
52.68935 1.304351 0.603734 0.0009554 2.917892 0.651177 0 3.617987 0.673506 0 33 39 39
52.69383 0.83096 0.356832 2.95E-11 0.563283 0.33502 0 1.076385 0.635898 0.0006317 110 105 120
63.62434 0.782051 0.332165 7.52E-18 0.939958 0.336537 0.0009198 0.458171 .228831 9.27E-21 134 134 132
34.31668 1.69058 0.440162 2.55E-10 0.554469 0.379337 9.89E-13 0.318933 0.72373 8.84E-13 30 29 29
61.18812 1.161431 0.486953 0.003473 4.180471 0.535 0 4.920994 0.643657 0 84 74 73
58.86076 1.344723 0.34105 4.95E-12 0.98958 0.329008 0.187172 1.061875 0.290694 0.00554071 88 88 91
42.63301 0.848729 0.569953 0.0004671 1.543071 0.529033 4.44E-16 2.050639 0.922916 7.71 E-09 77 78 80
45.49967 1.006412 0.402019 0.952236 3.754362 0.721279 2.14E-07 4.804789 0.687947 1.53E-08 8 14 14
46.27478 0.491396 0.389364 7.44E-14 0.849487 0.354394 0.0036338 0.316493 0.800289 526E-06 28 29 28
68.56618 0.849852 0.480011 5.72E-08 0.753928 0.355448 0 1.395893 0.59142 6.42E-11 137 138 151
45.3265 0.797719 0.305244 1.66E-12 1.46885 0.463886 4.94E-07 1.61193 0.51147 1.18E-08 86 67 70
42.97408 1.212443 0.455201 0.0019861 3.698287 0.533763 0 4.315778 0.486888 0 31 35 36
32.36515 0.858448 0.339405 0.0008235 0.944119 0.324471 0.0694573 0.899322 0.591975 0.52273553 43 43 46
62.94118 1.151039 0.371326 0.0200043 3.291955 0.423177 0 3.828104 0.430247 0 60 60 60
49.74003 1.180499 0.28306 0.0003509 1.976554 0.297421 4.060-14 2.493254 0.284578 2.22E-16 22 22 23
43.13346 0.413906 0.377329 1.68E-14 0.76161 0.247638 0 0571277 1.007268 1.31 E-09 78 80 81
60.34214 1.162803 0.53044 0.0396956 3.152702 0.775665 2.49E-14 4.033919 0.6537D6 0 28 35 36
42.21922 1.369667 0.406137 7.79E-07 1.176319 0.267303 5.62E-05 1.182175 0.58193 011694565 31 31 31
46.56085 0.895843 0.446222 0.0183304 1.744497 0.37099 1.850-09 3.435781 0.606333 0 46 52 61
67.55162 0.971116 0.528762 0.6173109 2.152968 0.440105 0 3.638051 0.545126 2.618-08 38 40 41
52.6475 1.116443 0.415104 0.0007673 0.746375 0.334907 2.25E-08 0.542329 0.732D67 5.690-12 74 70 71
38.36478 0.260787 0.703519 0 0.864888 0.255386 321E-13 0.801977 0.314875 4.440-18 93 97 95
56.79013 0.551502 0.430747 3.47E-19 0.057004 0.4602 4.960-19 1.171390 0.824810 8.990-05 123 122 125
56.26599 0.406649 0.421989 8.99E-141 0.82509 0.28308 1.89E-145 0.59098 0.300093 8.8-143 851 805 087
63.30935 1.224115 0.55838 0.012083 3.746138 0.742322 7.118-15 3.737121 0.626015 1.820-14 28 31 33
29.9373 1.048322 0.352778 0.2546114 0.995253 0.453871 0.8281887 1.218634 0.545084 0.2898089 37 30 39
27.8481 0.862922 0.329199 0.0165747 0.722218 0.334845 2.26E-05 0.818708 0.532575 0.03801338 17 17 17
65.43779 0.960974 0.532531 0.4711225 2.95797 0.564104 0 4819707 0.576677 0 44 52 53
39.42786 1.22407 0.40748 0.0015581 4.12454 0.572235 2440-15 5039212 0.65512 2.448-15 25 20 25
37.41259 1.220731 0.385121 0.0008322 3.683334 0.46267 8.300-56 4.192343 0.455185 0 28 28 26
26.23318 0.632534 0.381765 1.520-08 0369366 0.697547 4.640-10 0.372628 1.428103 8.200-05 24 24 24
32.08633 1.043111 0.262576 0.1327652 0.624724 0.328717 0 0.754675 0.510241 2.020-07 45 45 45
37.47391 0.766229 0.269485 2.200-07 0.873592 0.30648 0.005107 1.209664 0.452606 000295748 25 29 30
34.19483 1.117488 0.472504 0.1588925 2479094 0.453791 2.63E-10 2.841205 0.465213 1.020-11 19 19 20
31.42857 0.898998 0.440236 0.0529203 0.873563 0.298941 0.0008016 0851808 1.105543 0.26924046 26 30 29
25.04274 0.889162 0.35892 0.0144912 1.014537 0.279986 0.822161 1026874 0.520569 0.74987118 30 30 30
49.15254 0.855114 0.327271 1.648-09 0.945667 0.351833 0.2509707 1.694337 1039992 2.620-18 124 128 130
56.15672 1.129493 0.474311 0.0001394 2.974565 0.867531 7.270-07 3229098 0.926168 3.73E-14 37 39 40
63.34165 0.381782 0.428035 5.390-07 0.141562 0.895019 0 0.13D643 1130115 6.66E-16 33 33 33
63.84365 1.240039 0.353315 3.64E-08 0774442 0.289031 7.25E-10 0494301 1,396514 2338-06 54 54 54
49.07692 1.034633 0.448786 0.7556605 2.567655 0.852448 00009766 3.417283 0.649426 3.928-06 9 11 11
42.47191 0.546603 0.490754 2.990-12 0.993797 0.449141 0.399628 1.588508 0.800243 0570-07 8 71 72
21.03923 0.340557 0.618178 00002931 0.679186 0.4041 2.77E-05 0689328 0.904192 0.00193099 17 17 17
36.33157 1.412648 0.572417 00063074 2431227 0.692558 5.210-56 3199324 0.707839 2670-07 14 15 15
33.74233 0.984274 0.502278 0.8109894 1031804 0349224 0.8043618 1.634551 0518398 000035915 28 26 26
50.3937 1.109126 0.574226 0.0864763 3.337236 0.779516 1.508-10 4.325407 0.915289 7.150-11 24 24 24
35.23936 0.885171 0.377162 0.5629179 0.940327 0.321806 0.2134019 0.887358 0.529919 0.19849831 18 18 17
43.21678 0.876185 0.450525 0.1025633 0.711714 0.245211 5030-05 079728 0.921209 0.07190333 29 29 30
33.47107 1.155461 0.325785 1188-05 0.900423 0.353866 0.0014157 1160271 0.532095 0.00256143 57 55 61
77.51004 1.478887 0.521609 4.238-05 2.493635 0.608438 1.20E-08 3.112225 0.706996 0 35 43 49
49.4868 0.702918 0.62236 0.0012565 0.892258 0.21622 0.0014804 0.424701 0.653629 7.368-08 21 21 20
29.84496 0.811225 0.316853 0.0001454 0.834522 0.324703 0.0006167 0.971045 0.821046 0.42906726 23 23 23
48.33333 1.13597 0.366306 0.0968463 3.274319 0.4985 364E-08 4192086 0.533889 8.81 0-09 13 13 13
43.36075 1.201128 0.421419 0.0436801 3690009 0.480869 1.950-09 4.293174 0.420101 3.128-12 13 14 16
41.00327 0.724871 0.545296 1.990-05 1.436954 0.245008 8.398-14 1.584799 0.237539 0 34 34 34
69.47041 0.945781 0.398402 02568198 4.098743 0.506528 0 4.17203 0.53276 0 32 33 33
28.04878 1.023669 0.381426 0.6647152 4.020523 0775478 1.000-12 4.007973 0790645 1468-12 26 26 28
37.40157 1.053964 0.300144 03502808 2.113383 0.407388 2.590-08 2.550005 0.399806 2.31 8-10 15 16 17
18.23834 1.261767 0.382879 00044553 1.967561 0.4281 4.498-07 2936799 0.473249 4.418-09 15 15 1547746667 1.140169 0.450024 0.0056727 3.54527 0.593232 0 4228356 0.848994 0 46 54 54
gi|27806469 peptidylprolyl isomerase B [Bos taurus]
gij61828365 PREDICTED: similar to Tropomyosin 3 isoform 1 [Bos taurus]
gil27806723 calreticulin [Bos taurus]
gi|119887291 PREDICTED: similar to peroxidasin homolog [Bos taurus)
gill 19895885 PREDICTED: similar to EGF-blke repeats and discoidin I-like domains 3 [Bos taurus]
gi|27807437 matrix metalloproteinase 9 [Bos taurus]
gi|114051908 FK506 binding protein 10, 65 kDa [Bos taurus]
gil38566696 serum amyloid A 3 [Bos taurus]
gij77736401 thrombospondin 4 [Bos taurus]
gil27805949 inhibin beta A [Bos taurus]
gil27807207 plasminogen activator inhibitor type 1. member 2 [Bos taurus]
gil27807367 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide [Bos taurus]
gil155371895 sema domain, immunoglobulin domain (1g), short basic domain, secreted. (semaphorin) 3C [Bos taurus]
gi|27806697 chondroadherin [Bos taurus]
gi|27806147 secreted protein, acidic, cysteine-rich [Bos taurus]
gi|119888620 PREDICTED: similar to alpha 1 type XVI collagen [Bos taurus]
gi|41386719 milk fat globule-EGF factor 8 protein [Bos taurus]
gi|76253900 GDP dissociation inhibitor 2 [Bos taurus]
gil27806351 ezrin [Bos taurus]




gil110350683 biglycan [Bos taurus)
gi|156120479 aldolase A [Bos taurus)
gi|134085671 histone cluster 1, Hic [Bos taurus]
gil156121245 insulin-like growth factor binding protein 7 [Bos taurus]
gil27806317 annexin A8 [Bos taurus]
gil115495019 procollagen-proline. 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I [Bos taurus]
gi|99028973 transcobalamin |1[Bos taurus]
gil1 16004023 phosphoglucomutase 1 [Bos taurus]
gil77404273 glyceraldehyde-3-phosphate dehydrogenase [Bos taurus]
gi]40254806 heat shock 70kDa protein 1A [Bos taurus]
gil164420731 transaldolase 1 [Bos taurus]
gi|27806907 clusterin [Bos taurus]
gill 14051756 heterogeneous nuclear ribonucleoprotein A2/B1 [Bos taurus)
gi]51491841 transketolase [Bos taurus]
gi|77404217 phosphogtycerate mutase 1 (brain) [Bos taurus]
gi|119901059 PREDICTED: similar to COL9A1 protein, partial [Bos taurus]
gil30794358 versican [Bos taurus]
gil168804008 tubulin, alpha, ubiquitous [Bos taurus]
gil27806941 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 [Bos taurus]
gi]73853762 annexin I (Bos taurus]
gil119331178 SPARC related modular calcium binding 1 [Bos taurus]
gi|41386727 protein kinase C substrate 80K-H [Bos taurus]
gil 19903961 PREDICTED: similar to Protein disulfide isomerase associated 6 isoform 7 [Bos taurus]
gil27806739 apolipoprotein E[Bostaurus]
gi]77736275 calumenin [Bos taurus]
gill 19900887 PREDICTED: similar to collagen XXVII proalpha 1 chain precursor; preproprotein [Bos taurus]
gi|l 19908661 PREDICTED: similar to Laminin gamma-i chain precursor (Laminin B2 chain) [Bos taurus]
gil41386707 vascular cell adhesion molecule 1 [Bos taurus]
gil1 19912531 PREDICTED: similar to mannose receptor, C type 2 [Bos taurus]
gil157074106 lamin B1 [Bos taurus]
gi]27806489 proenkephalin [Bos taurus]
gi|27805823 dermatan sulfate proteoglycan 3 [Bos taurus]
gil149773543 steroid-sensitive protein 1 [Bos taurus]
gi|119900517 PREDICTED: similar to KIAA11027 protein [Bos taurus]
gi|1 15496928 EGF-containing fibulin-like xtracellular matrix protein 2 [Bos taurus]
gi|27806623 fibromodulin [Bos taurus]
gi|148230364 heterogeneous nuclear nbonucleoprotein D [Bos taurus]
gi|l 15497628 reticulocalbin 2, EF-hand calcium binding domain [Bos taurus]
gil119908681 PREDICTED: similar to superficial zone protein [Bos taurus]
gil156121327 galectin 3 [Bos taurus]
gil66792902 vanin 1 [Bos taurus]
gill 14053121 reticulocalbin 3, EF-hand calcium binding domain [Bos taurus]
gij76253701 decorin (Bos taurus]
gil1 15496400 dihydropyrimidinase-bike 2 [Bos taurus]
gil27806853 lumican [Bos taurus]
gir76670918 PREDICTED: similar to histone H4 [Bos taurus}
gi|115496892 non-metastatic cells 2, protein (NM23B) expressed in [Bos taurus]
gi|1 14051505 serpin peptdase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1 (Boo taurus]
gi|1 14052731 tubulin, beta polypeptide [Bos taurus]
gi|119903031 PREDICTED hypothetical protein [Bos taurus]
gi|119913640 PREDICTED: similar to KIAA0051 isoform 1 [Bos taurus]
gi]78369684 platelet-denved growth factor receptor-like protein [Bos taurus]
gi|78369242 alpha-actin n [Bos taurus]
gi]129277510 superoxide dismutase 3, exracellular [Bos taurus]
giJ68299807 eukaryotic translation elongation factor 1 alpha 1 [Bos taurus]
gi|1 15497328 procollagen C-endopeptidase enhancer 2 [Bos taurus]
gi|115495641 aldo-keto reductase family 1, member Al (aldehyde reductase) [Bos taurus]
gil76635416 PREDICTED: similar to coat protein delta-cop isotorm 1 [Bos taurus]
gi]76613946 PREDICTED: similar to Histone H1.5 [Bos taurus}
gi|31341666 mannosidase, alpha, class 2B, member 1 [Bos taurus]
gi|119912215 PREDICTED: hypothetical protein isoform 2 [Bos taurus]
77.40384 0.966386 0.3585 03520491 1.441514 0390379 4560-08 1.719177 0423647
78.62903 1.216501 0.259127 0.0281599 3321663 0.353157 1.33E-05 3.62064 0.443649
36.45084 1.33925 0.388971 1.50E-05 3.942023 0671703 1780-14 3.62686 0771161
27.04115 0.821375 0.287995 00014648 0764914 0.254156 00001114 1.27309 0.37747
36.77419 0.865865 0.172443 0.0003491 0.859876 0.224315 00001221 0.928577 0.17773
37.2191 0.971629 0.373629 0.7172178 0.785828 0307669 8.210-05 1147188 0.631454
33.27616 1.15534 0.39642 0.046568 4.541796 0872852 2.480-09 4595993 0879052
79.38932 0.511158 0.325391 00001318 0.658872 0.296719 4.570-06 0.835857 022354
28.72008 1.482349 0.771648 0.0160671 0920643 0226488 0.0535164 047494 0922694
47.05882 1.108032 0.432033 0.1934376 3.759034 1190221 6.270-06 6055416 1.259887
52.14106 0.58862 0.400078 9.840-06 1.051048 0312012 0.3067599 1.561361 0.35485
61.63265 1.814499 0.540997 6.97E-08 3.974334 0515406 4.440-16 4638462 0480175
36.08522 0.626223 0.552839 7.390-05 1.833769 0469972 00001064 2.611883 0591251
51.24654 0.578176 0.522216 0 1.113816 0373196 0.0002071 206508 0494707
48.02631 1.268557 0.360931 4340-14 0.477958 0414947 0 0 179124 1.014901
21.38872 1.133376 0.690707 0.3307672 0.796239 0337696 00016794 0754229 0614367
37.00234 0.791304 0.273901 0.0001075 0.619551 0354467 8.520-08 0.628954 0422447
52.58427 1.455453 0.665949 0008821 2.596066 0.420476 1.02E-05 2.653669 0575952
46.64372 1.091578 0.252855 00988308 2241708 0.281875 1.980-09 2642202 0.270054
57.22892 1.178704 0.390814 00287841 2.637623 049076 9960-10 3.071962 0.59957
44.27861 0.635828 0.924922 00159708 1.665717 0.451871 2.200-05 4.118681 1045629
59.62059 1.09486 0.399052 00115285 2.228327 0.503143 3650-14 1.816831 0.487552
45.87912 1.713039 0.466647 6.290-05 2.469162 0060426 1.700-06 3072349 0.599473
64.78873 0.97495 0.404706 0.8458203 1.650374 0481195 0.0294921 8610595 0783553
57.80142 1.094136 0.426337 0.1213981 0.538502 0559197 2.720-08 0.397764 1046779
68.19572 1.438976 0.344794 00018496 2.485153 0432846 1.8005 4.042242 0555698
48.50187 0.882886 0.367268 00679135 2.495708 0.831659 00002931 2.80955 0794449
40.74074 0.555233 0.459658 0002449 0.89322 0.31755 0.1206319 2.086042 0497411
53.20285 1.19411 0.353038 00482391 3.098721 0.547299 6.110-06 3.580732 0574067
51.65165 1.349932 0.412958 5.060-05 469257 0.709112 4220-14 5369332 0.734137
41.65367 1.218518 0.660476 02067183 3.891821 0.221504 5150-11 4.338255 0.207845
53.41246 1.647513 0.78044 0.0085615 4.19667 0.48062 00002441 4465234 0.648436
32.57403 1.370788 0.365556 0 0.532673 0.499506 0 0.603443 0.479738
58.94428 1.269216 0.423061 0.0054606 4.265354 0899902 2.780-08 53571 0.784822
33.22632 1.001777 042484 06601456 2.824623 0490068 1110-06 3972913 0.60178
53.1496 1.420449 0.457248 1.680-05 2.984226 0.47117 3930-14 3.274677 0388514
27.92608 0.624194 0.419346 8.106-05 0.064839 0.225205 0.0215454 0.752822 0.528793
10.85478 1.341758 0.270482 0.0081088 0.71699 0.204008 1.8006 1.023065 0.351439
38.13747 1.128293 0.426549 0.125152 3.777497 0.530255 3.47E-10 5.599331 0.713884
38.94231 0.626197 0.408455 1.03E-06 1.087044 0.370509 0.1216249 0.957381 0.350759
57.80347 0.688388 0.559084 0.801079 1.263143 0.685786 0.0385797 1.638153 0.77381
33.41014 0.729588 0.323378 4.740-06 0.731745 0.242091 6.800-08 0.616842 0729459
21.95122 1.283851 0.412294 0.0045111 3.884186 0.617272 6.300-10 3596102 0.706315
40.67796 1.533899 1.239035 0.0981442 3.564787 0911481 3.030-08 4.920584 1.044945
56.64557 1.054537 0.307699 0.3506565 0628845 0.339228 3080-08 0.648509 0.475921
45.07937 0.883407 0.436466 00494385 2.731974 0.342826 7.710-10 3.035601 0310606
25.86558 0.755179 0.415235 0.00621 0888638 0.36141 08164648 2.123001 0.409484
28.74016 1.08494 0.340788 1 0.827303 0.389165 0.0384872 0.742105 1166543
27.0636 1.583077 0.40522 0.0002906 0.532135 0528182 0.0001742 0.882593 0341505
17.45602 1.25875 0.477965 0.0562236 1.172813 0.242125 00180407 1.253979 0.746504
43.00341 1.07196 0.454305 0.8505681 1.065838 0.308361 00021871 3.308644 0.312812
64.25856 0.952292 0.418135 1 7.706637 1.083169 4330-07 12.92838 1.420231
26.47975 0.869887 0.219256 0.0008093 1.87483 0.286394 1.560-09 1.079035 0.830543
29.24528 0.940334 0.471483 0.5422245 1.337722 0.359504 0.0035578 4.364235 0730059
21.95986 0.828445 0.994186 0.496875 2.306418 0.605184 0.0008231 3.343639 0.889053
37.47178 0.8642 0.253817 0.0109751 0.84039 0295555 0.008025 0.639841 1.00329
35.2 0.961092 0.294838 0.006021 1.173788 0304319 4.840-14 1.285537 0509777
41.17647 1.313532 0.470427 0.0984023 4581735 0.403819 2070-07 5790203 0.396794
30.91483 1.01621 0.59814 08954841 3.288107 0.808578 1.050-06 4.260653 0.758722
24.15186 0.752636 0.778006 0.129217 1.654838 0303415 3790-05 2.538553 0.63436
38.86792 1.084874 0.500628 0.1772784 25512 064266 1.330-15 3928305 0.670743
26.66667 0.388952 0.930631 00001055 1.220544 0.252873 0003363 0881697 0.433523
34.14634 1.847044 0.718336 0.0013333 2.905404 0.856876 2290-06 4.103241 0.641637
49.72222 0.730415 0.440608 4.230-06 1.108696 0413871 00897178 0.694329 0.522041
32.16783 1.377001 0.288088 00027255 3.100286 0.478821 2820-05 3.50074 0.456305
35.67252 0.972895 0.301185 0.4589595 1338501 0257497 6490-10 2.23113 0309532
83.49515 0.82703 0.405577 1.880-09 1.37621 025284 9610-12 2707767 0451848
61.18421 1.105545 0.210209 00468387 3.00549 0607591 2100-06 0408232 0.943364
36,1244 0.848087 0.362412 0.0351232 1481406 0432926 0.0007492 2208003 0.34101
36.93694 1.032283 0.352411 0.7898694 3.855163 0380602 2.720-06 4.388894 0533753
25.41322 1.712802 0.342161 2520-12 3.081876 0.488811 0 3.107097 0.490403
20.07481 0.958993 0.426455 06774568 2.536098 0.811613 00002813 3.587219 0.567402
35.2 0.84085 0.295958 0.0089347 0747438 0.240368 3.220-05 1154384 028933
38.90134 1.389165 0.49615 0.0307261 2.214585 0481167 0.0002806 2.756921 0533143
37.3444 0.909759 0.26464 00382466 0.687629 0.32273 7010-07 0.544909 0.462822
29.87013 1.047109 0.340916 00670238 277265 0.850019 354E-08 3.486767 0.884485
36.29808 0.689359 0.234566 2.890-06 0922919 0292597 0.1495701 1.7825 0.651812
49.53846 1.22208 0.379178 0.0395591 3.068088 0579483 3380-06 3.802311 056824
29.7456 1.08162 0.421572 0.5838214 3.853607 0483844 0.0001858 4.440202 0538426
57.52212 0.819695 0.450096 0.0325495 1149782 059554 0.2488871 4845611 0.88057
23.72372 0.886321 0.446803 0.222994 1.14973 0304272 00627517 1343001 07043



















































































gi|62751849 Parkinson disease (autosomal recessive, early onset) 7 [Bos taurus] 7089947 1.612388 0.31221 2.578-05 3.98492 0400179
9i[139949116 slit-like 2 [Bos looms] 28.52897 1.338105 0429092 00002926 0.904302 0.27225
gi[1561205Dl heat shock 70kD protein binding protein [Bos taurus] 28.18429 1243113 0.239059 0.0227445 2.67794 0.884008
gill1
4 05 26 53 
procollagen C-endopeptidase enhancer [Bos taurus] 41.24188 0.747768 039671 0.0010757 0.907298 0240483
gi27807349 complement component 1 inhibitor [Bos taurus] 2284957 1.93487 0408844 3.788-10 028844 0.842258
gi|27807167 peroxiredoxin 6 [Bos taurus] 58.25 1.574858 0.471361 00005459 3.539818 0.728845
gi|77735541 valosin-containing protein [Bos taurus] 3325082 1155745 1.015324 0.578125 1.982845 0.741708
gil148238309 aldolase C, fructose-bisphosphate [Bos taurus[ 4835185 1.292778 0.681553 0.193125 3.157838 0.899738
gil27807007 insulin-like growth factor binding protein 3 [Bos taurus[ 371134 0.788581 0.778124 0.0288555 1761299 0.338075
gi75812940 phosphabdylethanolamine binding protein [Bos taurus] 6258885 1.289117 030763 0.00282 3.01298 0.489092
gil27806671 cathepsin B [Bos taurus] 31.34329 0.943841 0205782 0.0327489 1.389304 0.258249
gi|119920777 PREDICTED similar to collagen, type IX, alpha 2 [Bos taurus] 2981104 0.54183 0.958949 0.0028995 0.822455 0.288062
gi|119901068 PREDICTED: similar to Collagen, type IX, alpha 1, partial [Bos taurus] 54.0148 0.482305 0,458428 0.0003264 0.758333 0.193313
gi27805999 matrix metalloproteinase 13 [Bos taurus] 2590234 0449574 0.439799 0004883 0.398849 0.248278
gil27806637 fibrillin 1 [Bos taurus] 1605712 1158511 0.333925 0.3125 0850119 0.140244
gil27806617 GDP dissociation inhibitor 1 [Bos taurus] 3534878 1.814872 0.9995 0.0098531 3508770 0.548211
gil27808640 peptidoglycan recognition protein 1 [Bos taurus] 51.05263 045803 0.326152 1.70E-08 0.808319 0.257445
gi|157427782 insulin-like growth factor binding protein 5 [Bos taurus] 50.92251 1181072 0354524 00280809 0.906282 0.48406
gi|119895711 PREDICTED: similar to cytokine-like protein ZCYTO7 isoform 1 [Bos taurus] 2748781 0507187 0.877454 3.35E-06 1.17427 0.37824
gi|78369298 stromal cell derived factor 4 [Bos taurus] 42.25352 0778141 0.33739 0012125 0.85096 0.159828
gi|77735539 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide || [Bos taurus] 24.22998 077955 0452039 005827 2.820207 0.308505
gi|27806197 tyrosine 3-monooxygenase/typtophan 5-monooxygenase activation protein, epsilon polypeptide [Bos taurus] 72.94118 1.358303 0.443855 00002031 3.00073 0.552971
gi|119919662 PREDICTED: similar to LOC539445 protein [Bos taurus} 189 0.585452 0780314 0.0452885 4.897555 0.831237
gi|27805983 leukocyte cell-derived chemotaxin 2 [Bos taurus 642341 0.409485 0331874 7]74E-08 0.990859 0.311931
gi|1 16003813 amyloid beta A4 protein [Bos taurus] 29.06475 1.538547 0.230885 00014379 0.840781 0.298271
gi|129270171 gremlin-1 [Bos taurus] 51.83044 0793555 0.87352 0141028 1.001231 0.337648
gil148228060 stem cell growth factor [Bos taurus] 3240741 0848954 0.267988 00194377 1.002715 0.27112
gi|119915902 PREDICTED: similar to Thioredoxin domain-containing proei5precursorThioredoin-keprotein p465 pEndoplasm c re(dculuo protein Epp446iso)otm 1 [Bar 3947389 1.258969 0.559088 0.0535458 3.870127 0.817854
gi|27806401 secreted phosphoprotein 1 [Bos taurus] 37.78979 0.903294 0.221566 0.0022755 1.915212 0.235771
gi|76613223 PREDICTED: similar to chitinase [Bos taurus] 39.01809 030445 0.493303 00004883 0.209851 0.404558
gi|77404209 eukaryotic translation initiation factor 4A2 [Bos taurus] 3438803 1.233772 0388759 0.2181294 3.109795 0.252134
gil119917871 PREDICTED: similar to serin protease with IGF-binding motif [Bos taurus] 2020849 0.771777 0.243891 8.73E-05 0.081847 0.202598
gil164448628 carboxypeptidase X [Bos taurus] 19.88301 0.788564 0268784 0.001439 1.008874 0.249295
gil113205970 glial fibrillary acidic protein [Bos taurus] 48.83178 1.027088 0483528 0.8502459 2.292389 0.688497
gi178045555 acidic (leucine-rich) nuclear phosphoprotein 32 family, member B [Bos taurus) 28438 1.143311 0510882 0.3222514 3344078 0.476514
gi|1 19895049 PREDICTED: similar to Lamin B2 [Bos taurus] 32.78148 1.343139 0.667012 0.1147527 1.874172 0.482114
gi]27806829 osteoglycin [Bos taurus] 34.78281 0.858085 0.220385 0.0021151 1.021554 0.284641
gi]78045491 fascin homolog 1, actin-bundling protein [Bos taurus] 23.32857 1.334458 0.4889 0.0108301 3.119513 0.442908
gil1 19908208 PREDICTED: similar to Calpain 2, (m/11) large subunit isoform 3 [Bos taurus] 23.83014 0.777731 0.805924 0.2507899 2.057831 0.459223
gi[62751777 cofilin 1 (non-muscle) [Bos taurus] 59.03814 1.249729 0.371271 0.0879952 3.522417 0.42509
gi|78042524 thioredoxin domain containing 4 (endoplasmic reticulum) [Bos taurus] 2508207 0.995942 0.314542 0.833009 2.889886 0.573365
gil27806449 dystroglycan I [Bos taurus] 18.32402 1114704 0.428948 0.1239292 0.989739 0.21681
gi]94966781 eukaryotic translation elongation factor 1 gamma [Bos taurus] 26.59091 1.182179 0847073 0.4509511 3.044482 0.592818
gi|164420791 transforming growth factor, beta 2 [Bos taurus] 30.43478 0742424 0.259859 00022421 1.87391 g.261033
gil 14053333 fibrinogen-ike 2 [Bos taurus] 3850784 1.17009 0309784 0.0467123 0.427778 0.195793
gi[95006989 ribonuclease, RNase A family, 4 [Bos taurus] 57.1428 0804356 0.385366 2.98E-09 0.917848 0.249674
gi]27806081 peroxiredoxin 1 [Bos taurus] 47.7389 1.145655 0.251919 0.1160014 3.559536 0.494199
gi|27806561 lactate dehydrogenase B [Bos taurus] 47.30539 1.217427 0.422007 0.0997833 3.073825 0.570874
gi|77735425 proteasome alpha 7 subunit [Bos taurus] 4508452 1.3595 0.250214 0.0075112 4.311514 0.535948
gi|27806679 colony stimulating factor 1 (macrophage) [Bos taurus] 21.94115 1.5128 0.285552 0.015625 0.008248 0.535002
gi|1 19917542 PREDICTED: similar to tolloid-like 2 protein isoform 2 [Bos taurus] 18.33333 0.558517 0.413338 0.0018358 0.932274 0.44272
gi|115497078 splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing factor) [Bos taurus] 54.83871 1.197937 0.333368 0.0335399 3.03228 0.520847
gi|165905571 leucine aminopeptdase 3 [Bos taurus] 29.28709 1.483983 0514998 0.0425654 2.252881 0.725022
gill4051129 retinoic acid receptor esponder (tazarotene induced) 2 [Bos taurus] 5123457 0668587 0341849 2.548-09 0.705825 0.385304
gil157073966 reticulocalbin 1, EF-hand calcium binding domain [Bos taurus] 33.83686 110571 0.399718 00947473 3.231942 0.338122
gi]27806541 matrix metalloproteinase 1 [Bos taurus] 31.5565 0.272697 0491877 1.30E-05 0.887994 0.145805
gir41386760 CD14anbgen[Bostaurus] 3646113 0.952161 019569 0.2533295 0.378479 0.350338
gill 19915070 PREDICTED: similar to CUB and EGF containing protein [Bos taurus] 14.50151 0 78g134 0409551 0.0356442 0.90833 0.309445
gil27807377 glutamic-oxaloacetic ransaminase 2. mitochondrial (aspartate aminotransferase 2) [Bos taurus] 36.74419 1.406094 0270802 00067711 3.928337 0.298463
gi|7836951 0 ribonuclease/angiogenin inhibitor 1 [Bos taurus] 2939597 1.501005 0325888 0.0070417 4.131356 0.247004
gi|1 18601868 heat shock 90kDa protein 1, beta [Bos taurus] 3991713 1.179283 0338089 0.1518089 3.748732 0.368913
gi|27806825 pepbdylglycine alpha-amidating monooxygenase [Bos taurus] 17.90123 066916 0.256285 0.0026128 0.921522 0.1398
gi|82697375 histone H2B-like [Bos taurus) 73.015g7 0701006 0.441253 00220058 1.387118 0.449981
gi|115497174 3'-phosphoadenosine 5'-phosphosultate synthase 2 [Bos taurus] 299197 1.099204 0395566 0.3926138 3408799 0.393327
gi|119901198 PREDICTED: similar to Man9-mannosidase [Bos taurus] 27.6176 0669272 0337197 00039794 1.227779 042194
giJ28603774 Rho GDP dissociation inhibitor (GDI) alpha [Bos taurus] 46583 1693909 0506794 0.015072 3518611 0682599
giJ71037405 heat shock 27kDa protein 1 [Bos taurus] 50 0.99641 0.516659 0.975981 4.504843 0.777647
giJ27806751 alpha-2-HS-glycoprotein [Bos taurus] 25.90529 0280017 0351435 4939-08 0.44843 0.269395
gi|77735769 complement component 1. r subcomponent [Bos taurus] 2994924 0559876 0.399 0.0093022 0.608092 0477975
gil 19894807 PREDICTED: interleukin enhancer binding factor 3 isoform 2 [Bos taurus] 2095075 1.456753 0582043 0.1058396 2103822 0.172287
gi[94966765 glucose phosphate isomerase [Bos taurus] 29.08438 1.019204 0.584551 09159895 2.748777 0.93774
gi[115496067 nucleobindn 2 [Bos taurus] 2843373 0.977995 0519511 0.8450852 1.283333 0.328989
gi]27805977 keratin 10 [Bos taurus] 23.19392 0794292 0.417656 0.0875888 0.918927 0.357075
gil119901449 PREDICTED similar to PDNP1 [Bos taurus] 20.31873 1122001 0.570995 0.3842895 2.127114 1.082098
gi[77736203 malate dehydrogenase 1, NAD (soluble) [Bos taurus] 30.23952 1620919 0254319 00001127 4.000058 0.345863
gil41386798 poly(A) binding protein, cytoplasmic 1 [Bos taurus] 29.24528 1.241022 0.516059 0.1875 2.920083 0.559438
gil27806881 epididymal secretory protein E1 [Bos taurus] 3087249 0.454079 0.389 0002295 1.695337 0.153522
gil27806415 scinderin [Bos taurus] 2293708 1.30033 0.289782 00434031 2.595421 0.60842
gi|76610312 PREDICTED: similar to neuropilin 2 isoform 8 [Bos taurus] 2915767 1.317935 0334412 00120733 0.788258 0.33126
gil157744500 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypephde [Boo taurus] 51 01215 1.195710 0515928 0.327959 2888529 0.338074
gir27806673 cathepsin L2 [Bos taurus] 3502994 1190907 0253439 0.1028135 1.025708 0.10081


































































































































































gi|76620378 PREDICTED: similar to cytokine-like protein C17 [Bos taurus]
gi|125991942 Sec23 homolog A [Bos taurus]
gi|84579853 lipopolysaccharide binding protein [Bos taurus]
gi|11990114
4 
PREDICTED: similar to malate dehydrogenase decarboxylase (NADP+) [Bos taurus]
gill14051157 complement component 1, q subcomponent, 8 chain [Bos taurus]
gi115497294 canopy 2 homolog [Bos taurus]
gi|76651183 PREDICTED: similar to histone H3 [Bos taurus]
gi|27807523 ribosomal protein P2 [Bos taurus]
gi|156121049 dimethylarginine dimethylaminohydrolase 1 [Bos taurus]
gi|75832065 TIMP metallopeptidase inhibitor 2 [Bos taurus]
gi]61888850 adenylate kinase 1 [Bos taurus]
gi|28875793 thrombospondin 2 [Bos taurus]
gi|119923009 PREDICTED similar to put. HMG-17 protein [Bos taurus]
gi|148232266 fibulin 1 [Bos taurus]
gi|119890932 PREDICTED: similar to Laminin beta-1 chain precursor (Laminin B1 chain) [Bos taurus]
gi|119896006 PREDICTED: similar to mannosidase, alpha, class 2A, member 1 [Bos taurus]
gl155372035 nidogen 1 [Bos taurus]
gi]62460514 angropoetin-ike 7 [Bos taurus]
gil164414726 thymosin beta 4 [Bos taurus]
gi|27806095 protein S, alpha [Bos taurus
gi|45429977 staphylococcal nuclease and tudor domain containing 1 [Bos taurus]
gi|27807209 alpha-2-plasmin inhibitor [Bos taurus]
gill 16004039 peptidylprolyl isomerase C (cyclophilin C) [Bos taurus]
gi|119914274 PREDICTED: hypothetical protein isoform 1 [Bos taurus]
gil27806553 microtubule-associated protein 4 [Bos taurus]
gi45430019 ribosomal protein L12 [Bos taurus]
gil119919151 PREDICTED: similar to AHNAK nucleoprotein isoform 1 [Bos taurus]
gi|119919898 PREDICTED: hypothetical protein [Bos taurus]
gi|1 19908402 PREDICTED: similar to Calsyntenin-1, partial [Bos taurus]
gl157785567 calnexin [Bos taurus]
giJ78369456 nucleophosmin (nucleolar phosphoprotein B23, numatrin) [Bos taurus]
gil119331192 H2A histone family, member X [Bos taurus]
gil27807469 peroxiredoxin 2 [Bos taurus]
gi[77736471 SH3 domain binding glutamic acid-rich protein like 3 [Bos taurus]
gir76611607 PREDICTED: similar to C1QC protein isoform 1 [Bos taurus]
gill18151330 tyrosine 3-monooxygenaseltryptophan 5-monooxygenase activation protein, theta polypepsue 005 taurus]
gi|1 19892706 PREDICTED: similar to chondroitin 4-O-sulfotransferase [Bos taurus]
gil60592767 ribosomal protein, large, PO [Bos taurus]
gi|62751593 proflin 1 [Bos taurus]
gi|78042564 CNDP dipeptidase 2 [Bos taurus]
gi27806625 frizzled-related protein [Bos taurus]
gil1 19901416 PREDICTED: similar to Syncrip protein [Bos taurus]
gil29135295 aspartate aminotransferase I [Bos taurus]
gil110626119 insulin-like growth factor binding protein 6 {Bos taurus]
gi|1 19907521 PREDICTED: similar to NuMA protein [Bos taurus]
gi|155371853 thrombospondin repeat containing 1 [Bos taurus]
gi}1 4052384 heterogeneous nuclear ribonucleoprotein A1 [Bos taurus
gi|1 15495555 endoplasmic reticulum protein 29 [Bos taurus]
gij27806279 caldesmon 1 [Bos taurus]
giJ78042498 phosphoglycerate dehydrogenase [Bos taurus]
gi|27806447 prosaporsin [Bos taurus]
gil27805981 ribosomal protein SA [Bos taurus]
gil155372057 cysteine-rich secretory protein LCCL domain containing 1 [Bos taurus]
gil125630701 collagen triple helix repeat containing 1 [Bos taurus]
gill18151356 angiogenin, ribonuclease. RNase A family, 5 [Bos taurus]
gil28461187 myosin, light chain 6, alkali, smooth muscle and non-muscle [Bos taurus]
gir27805805 fatty acid binding protein 5 [Bos taurus]
gi56119114 purine nucleoside phosphorylase [Bos taurus]
gi|61097917 cystatin E/M [Bos taurus]
gi|1 19888578 PREDICTED: hypothetical protein [Bos taurus]
gi|56710317 keratin 5 (epidermolysis bullosa simplex, Dowing-Meara/Kobner/Weber-Cockayne types] [Bostaurus]
gil119919488 PREDICTED: similar to cathepsin D isoform 1 [Bos taurus]
gi]62751650 poly(rC) binding protein 1 [Bos taurus]
gi|62460494 hemoglobin, gamma [Bos taurus]
gi|116004251 granulin [Bos taurus]
gi|27806813 pleiotrophir [Bos taurus]
gi|30466254 gelsolin-like capping protein [Bos taurus]
gil28461287 hepatoma-derived growth factor (high-mobility group protein 1-like) [Bos taurus]
gil78369458 proteasome (prosome, macropain) subunit, alpha type. 1 [Bos taurus]
gil2780714
7 
C-type lectin domain family 3 member A [Bos taurus]
gil27806139 secreted frizzled-related protein 1 [Bos taurus]
gi|1 15497736 offactomedin-like 3 [Bos taurus]
gi|1 34085635 glyoxalase I {Bos taurus]
gi|119919689 PREDICTED: similar to RNA binding motif protein, X-linked isoform 5 [Bos taurus
gil119892775 PREDICTED: similar to myosin, heavy polypeptide 9, non-muscle [Bos taurus]
gi]6275184
7 
ribosomal protein LlOa [Bos taurus)
gi|164518978 diazepam binding inhibitor [Bos taurus]
gi|77735725 cathepsin H [Bos taurus]
gil1 19926480 PREDICTED: similar to Meteorin, glial cell differentiation regulator-like [Bos taurus]
gil119907290 PREDICTED: hypothetical protein [Bos taurus}
gi]77735597 FK506-binding protein 4 [Bos taurus]
gi|157074098 leprecan 1 [Bos taurus]
52.55474 0.772804 0.448173 00201767 0.914237 0365116 02366615 0617444 0571456
16.92708 1.40908 0.550793 0.1706566 4321113 0.756614 0.011496 4706377 0.624164
23.28482 0.195757 0.44865 0.000302 0.406175 034643 0.0002543 0.329361 0,643969
20.62147 1.467496 0.340693 00106179 4.224115 0.462441 1.671-07 4.233192 0493512
31.17409 1.103934 0.2474 00117622 0.631504 0.3034 0.0002543 1.784666 0.272691
57.14286 1.031638 0.370242 0.7466377 3.754973 0393293 5.045-07 3777664 0.363764
55.14706 0.842391 0.226061 00045065 1.355866 0233258 0.0001135 2.695744 0069296
57.3913 1.883075 0.8785 00516846 4409362 0.981136 0.0012072 6.355423 0687346
55.08772 1.236429 0.555719 0.4416299 2.976156 0.624865 0049293 2773325 0.600857
40.90909 0.867925 0.293951 0.0170916 1.479176 1.09336 0.0412596 1.025353 0.241434
38.14433 1.136216 0.430822 0.3033108 3023313 0565108 0.000306 4901766 0.59492
13.24786 1.005457 0.336821 0.9553344 1109125 0210213 0.1260952 1.450622 0313212
42.22222 0.646482 0.829652 0.0304121 2144563 0499891 1.110-05 4168457 0659649
15.58074 0.887858 0.247168 0625 0605337 0.326422 00923653 0.664477 0377662
15.35245 1.354883 0.234493 00060169 1148729 0.449674 0.3464434 1.046109 0.20613
16.59389 1.243177 0.281497 0.4375 0993192 0.234221 0.6643037 1.267403 0479661
16.6801 1.231962 0.36954 0.1034256 0877971 0.561423 0.4293699 1.070923 0.456856
20.93023 0.968973 0.470794 0.6187797 0.373047 0497327 0000686 0300522 0743839
81.81818 1.30961 0.482918 01060539 6.545266 0.647427 0.000154 9.062092 0597922
18.66667 1.17304 0.332141 0296675 1.146996 1368479 0.296675 1250631 1.242364
28.24176 0.986197 0.378524 0.6972496 3.137771 0.444296 00002761 4365947 0.341663
18.90244 0.942 0.386282 0.6624672 1.042147 0.242856 0763677 3.120632 0.202312
44.33962 0.746961 0.398982 444E-05 0.90611 0322438 0.0274032 1.201796 0.446562
20.91429 1.114657 0.268242 03297717 3.595856 0387989 0.0056739 3.135764 0308311
25.74627 0.784726 0.556233 02964631 1.941072 0453118 0024877 2.856925 047348
43.0303 1.051228 0.153254 0.3578261 3.399142 0.621972 00625 4.543992 0804589
36.92494 1.238706 0.309334 0.0900441 2.705998 0.997999 00059426 3.486668 0.71653
24.85714 0.696563 0.354593 0.0002441 0873866 0.394239 00651016 1113116 0.402894
17.28135 0.971916 0.307732 07515049 0.937539 0.153447 0.1634666 1306979 0.201769
19.56155 0.981782 0.4997D2 09194103 3.107429 0.510515 00078239 3.498451 0343663
33.67347 1.151309 0.476669 0.4582779 2.610443 0.613626 0.0154491 3.539745 0.916422
62.23776 0.721476 0.046847 0.0032687 1.331159 0389176 0.2144017 3.195369 0.528406
46.23116 1.335529 0.376182 0.0165782 4.071044 0.517156 112E-05 4.946965 0579555
53.76344 1.523003 0.241733 0.0005666 3.9735 0.602612 0.0009766 4.226144 0.6916
21.69118 1.196257 0.499483 0.1373665 0.713353 0360547 0.0018497 1715993 0.691086
53.46939 1.666969 0.181633 00001768 4.070146 0340142 2.885-05 4.270728 0.235607
33.28197 1.328366 0.280622 0.0160601 0.750151 0.456758 0.1076629 1.084646 0.033707
38.67925 2.339525 1.705012 0494 4967163 0752382 00006669 5.276421 06488
47.85714 0.984943 0.229807 0.7732803 2.827048 0.262665 2.065-07 3961251 0.95482
28 0.759355 0.657534 0.3126366 1393516 0.063048 00613242 2.115963 0.493526
27.69231 0.611032 0.397021 270E-07 0.947817 0.181766 0.0071035 1.868062 0.433897
30.4078 0.978475 0.537585 0.8965113 245728 0.593261 0.0083154 2.944606 0.662037
29.05569 1.4351 0.81286 0.5316989 4.332814 0.399891 0.0649655 4.030831 0.157902
39.28692 0.515588 0.843656 0.0021144 0.6635 .30365 0.0002922 0.787142 0.499883
24.79962 1.310653 0.767904 0.4724615 1.570161 0.931907 0.3025977 1.900436 0.772411
16.07477 0.609054 1.186849 0.246469 0.692773 0.161206 0.0026575 0.600518 0.842992
32.5 1.401466 0.278818 0.0398761 2.349795 0.462218 0.0101637 3.707999 0.375063
40.31008 1.209341 0.469429 0.2132029 5887609 0.59221 5635-08 6.924352 0.649171
27.66355 1.521052 0.861412 0.3484215 3.234318 0.655 0,0466966 5.043265 0771672
29.26829 1.091927 0.23322 0.293771 1.915942 0.338410 00049064 2.520743 0.607506
15.42857 0.780148 0.148658 0.0169044 0.994096 0,250669 0.8962366 0597473 0.756674
30.50847 2.017567 1.029917 0.1442065 6706982 0.714377 00002276 7.159304 0659366
23.2 0.718178 0.660928 0.1807677 1.217623 0.210773 0.3434273 1.521064 0.491197
46.50206 0.939134 0.253669 0.3765814 0.866708 0.194334 00261033 1.124384 0.360969
42.56757 0.561035 0.269208 5.04E-05 0.904662 0.266371 0.3125 0.770496 0.740227
44.37086 1.189206 0.334906 0.0966763 2.372D42 0.481176 0.0076125 2.789196 0.525725
53.33334 1.143116 0.588056 0.5057353 2.664728 0.465376 0.0007116 3.373152 0.539626
22.83737 1.077707 0.16977 0.386629 2.49569 0.480878 0.0420877 328739 0.453214
41.61074 1.588616 0.617223 0.0730954 2.46493 0470962 0.0035763 1023269 0645059
33,33333 1.305207 0.579915 00531219 5.156013 1.36457 4.395-05 5291402 1.331999
28.1198 0.568797 0.044792 0.0247297 0755315 0.62039 05163629 0796984 0.22566
25.97087 1.343171 0.029007 0.0015513 2.009387 0265239 00227652 1591036 043976
33.98876 1.676168 1786418 0.5455095 3122778 0.520259 00021674 4.541486 0514743
70.34483 2.79713 0.550535 00125265 1.199678 0402669 02966016 3962602 0.365669
16.18399 0.937838 0.30186 0.5792656 1.237269 021475 0.0693237 0351941 1.002473
42.2619 0.334023 0.63773 0.0002441 1.375822 0.39724 0001486 1.622514 0.624073
19.19771 1.580628 0.619966 02067068 2.304159 0.90919 0.150557 2794152 0.666304
51.88285 1.156699 0.776058 0.627433 274657 0.75906 00130126 3205741 0.596991
25.47528 1.348022 0.391818 0.015625 3.217466 0590741 0.0002686 3.529642 0.839054
38.07107 D.487568 0.137961 0.0006384 0.713065 0.236462 0.0251242 0728636 0.403697
35.71429 0.600276 0.353855 4.14E-05 1.010426 0.232691 0936477 1.375163 0.703576
19.21182 0.461024 0.437169 0.0046268 115529 0.332775 02520667 076319 0.569631
35.86957 1.343524 0.194285 0.03125 3.196009 0.427377 0.0002126 4.158412 0.723263
48.59335 0.957059 0.484712 0.6080712 3.306448 0.533767 00073567 5.9913 063796
17.04835 1.130043 0.300774 0.3276844 1.40175 0.407355 00565616 2.059305 0453447
37.78802 1.390803 0.337679 0.067115 5065662 0.510943 00005196 5632550 0.559054
72.41379 1.865069 0.402858 910E-06 4.57462 0415176 144E-09 5756974 0.420637
29.55224 1.142346 0.205271 0.1595653 1.684237 0.456006 00477095 2.935988 0.451667
25.24272 0.59365 0.376463 00018407 0.64177 0328059 00629004 0692403 043771
20.61856 1.765132 0.057721 0.0016523 0322906 0.194399 00041666 0.476651 1.69626
22.22222 1.183397 0.220437 0.1976026 2.247146 1.107326 0.0793661 3.249727 0.986715



















































































gi]888538 16 superoxide dismutase 2, mitochondrial [Bos taurus] 2747748 1.235636 0.493475 00829534 0.734209 0.227854 00007784 1.999054 0261175 7.18E-07 10 8 10
gill15432055 tyrosine 3-monooxygenaseltryptophan 5-monooxygenase activation protein, beta polypeptide [Bos taurus] 55.69106 1.422587 0.077752 174E-05 3.501318 0192254 2.94E-06 3.858543 0211649 319E-06 6 6 6
gil157785569 coatomer protein complex, subunit alpha [Bos taurus] 129085 1.316966 0.397573 00897317 2610025 0.473913 00029117 3.187685 0.565521 000271062 5 5 5
gil1199050D
4 
PREDICTED similar togrowth-anest-specioc protein (809 taurus) 7765276 0721107 0376862 0.0485911 0.697037 0.093336 0.03125 0.548286 0.769348 0.02458663 5 6 7
gil122692559 oncostatn M receptor [Bos taurus] 31.17284 1.280483 0.106645 0.0001005 0.6362 0270181 8.02E-05 1.042406 0.240358 0.47596106 9 9 8
gi76613071 PREDICTED similar to class mu glutathione S-transferase isoform 1 [Bos taurus] 5183486 1.338978 0.684998 0.125 3909715 0.427273 00005115 4.55274 0.491575 0.0625 5 5 5
gi]83715992 coatomer protein complex, subunit gamma 1 [Bos taurus] 18.7643 1.383876 0.198783 00552539 2835368 0.600945 00156205 3.367195 0.788878 002123441 3 4 4
gi|27806103 polypyrimidine tract binding protein 1 [Bos taurus] 18.39736 1.071288 0.177561 04383303 4928856 0.459518 00021435 7.534288 0.258851 000018219 3 4 4
gi|95147666 periostin, osteoblast specific factor [Bos taurus] 21.82280 667162 0.55327 01248816 0941027 00817 0.1268117 0.741324 0.575318 023030411 4 4 4
gi|77736071 heterogeneous nuclear rbonucleoprotein K [Bos taurus] 3189655 0892417 0420267 08583256 2468258 0.657117 00291513 3.461617 0.613798 001001715 4 4 4
gi|119914936 PREDICTED similar to histone Hix [Bos taurus] 4252336 0.902183 0.701122 08305065 1.304308 0.498831 01688872 5.633982 0.740719 000166614 5 5 5
gil6246D582 complement component 1, q subcomponent, A chain [Bos taurus] 40.57377 1213977 0.285166 0008303 0734811 0.255337 00001522 1.549626 0.505138 000198304 11 11 11
gil119902257 PREDICTED: similar to peptidyl-Pro cis trans isomerase isoform 1 [Bos taurus] 57.31707 -1.00065 1 -1 2222372 0.78119 0.1267682 .549673 0.608262 006165172 1 3 3
gil27806743 alpha-1-microglobulin/bikunin [Bos taurus] 33.23064 1.014587 0.191366 08085857 0.970377 0.158274 04552212 1.202043 0.120397 0.00293502 6 6 6
gil1990
42
80 PREDICTED: similar to collagen type 5 alpha 1 {Bos taurus] 22.42647 0.831915 0.302113 0180258 0927065 0.216521 00354010 0.83402 074081 0.98111659 17 17 17
gill 15494984 apolipoprotein D [Bos taurus] 34.39153 0.354994 0.444943 1 19E-08 1,046545 0.348715 0.5554434 0.452896 0.449429 3216-07 14 14 14
gi|77735583 S-adenosylhomocysteine hydrolase [Bos taurus] 37.037D4 -1.00065 1 -1 2728891 0.533151 0.1631087 -1 1 -1 1 2 1
gill 14051445 protein phosphatase 2A, regulatory subunit B [Bos taurus] 19.1356 0.808148 0.109661 03252149 2717641 0.488088 0.0365571 4.41776 0.505432 0.01803671 2 3 3
gi|1 14052264 phosphoglucomutase 3 (Bos taurus] 2121771 1.213355 0270846 02173425 2.652676 0.096038 0.001358 2.75446 0308063 0.0145299 3 3 3
gi41386729 high-mobility group box 1 {Bos taurus] 29.76744 0934584 0016017 0.0726401 3357907 0.782882 0.1962704 5.707625 0.760044 0.13755545 2 2 2
gil119904118 PREDICTED similar to Chain A, Neutrophil Gelatnase-Associated tipocalin IsA Novel BacteriostacAgentThat nereresith Siderophore- Mediated IronL 6 219182 0o31c243 00001014 0387581 0363147 0.0010616 0.18633 0.793478 000174783 5 5 5
gil119919315 PREDICTED: similar to latent transforming growth factor beta binding protein 3 [Bos taurus] 17.73504 0.754775 0406388 02250735 1112067 0.066451 0.0642077 0.708965 1.331028 0.5846554 3 3 3
gil119920682 PREDICTED: similar to adlican [Bos taurus] 15.83567 1.099632 0.772836 0789192 1131677 0.328484 04663631 1.191522 0.470687 045043484 3 3 3
gi|164452935 SWAP-70 protein [Bos taurus] 20.51282 1.12547 0.509696 0622627 3064104 0.674581 0.054061 3.790778 0.758144 004812702 3 3 3
gil155372051 hypothetcal protein LOC535277 [Bos taurus) 52.8168 1.476054 0685859 0.4539187 3102647 0.331506 0.0912452 3.180255 0.245301 00659195 2 2 2
gil27806085 peroxiredoxin 4 {Bos taurus] 4708029 0.886062 0.381269 01790651 1.576858 0.295458 5.216-05 2.110987 0.276311 6.08E-07 10 10 10
gi]27806087 probneatgirine-nchandleuome-nchrepaatprotem]Bostaurus 19.98504 1.028341 0.225889 0.791198 1766713 0.430917 0.082431 2.247018 0.285457 00193342 3 3 3
gil156523068 ubiquitin-activating enzyme E1 [Bos taurus] 14.27221 1835553 0.961293 0.4203646 5.673488 0.316458 0.057302 8.848527 0.510027 0.01141375 2 2 3
gil76631783 PREDICTED similar to chondrorho 6-sulohansterase ]Bos taurus] 29.64509 0.989903 0230848 0.901174 0.870173 0.15354 0.0717274 1.118471 0.131443 0.0914539 4 4 4
gil114051730 cell growth regulator with EF-hand domain 1 [Bos taurus] 30.15267 1.374686 0564551 0.2030251 1.244621 0.3458 0.1742345 1.469283 0.338737 0.04651187 4 4 4
gil119884990 PREDICTED similar to ceruloplasmin isotorm 1]Bos taurus] 14.24528 0.510658 0.346303 0.0112042 0.773488 0.184435 0.0209447 0.459270 0.556732 002741702 4 4 4
gi|156120555 glyoxalase domain containing 4 {Bos taurus] 34.56376 1.361714 0.523666 0.2793152 4272346 0.430063 7.496-05 4.233143 0.449098 9.27E-05 3 6 6
gij1 14326274 crystallin, zeta (quinone reductase) [Bos taurus] 34.84848 1.415376 0.253623 0.0760381 3465257 0.09736 0.0818 3.899744 0.13153 0.08149262 3 3 3
gil27806677 connective tissue growth factor [Bos taurus] 20.3434 0.557302 0.359124 0.000204 0.996824 0.101397 0.7113753 0.134078 0.741618 1.10-05 8 8 8
gill14053135 proteasome (prosome, macropain) subunit, alpha type, 6 {Bos taurus] 40.2439 0.99902 0.37092 0.9943883 3.892598 0.253461 0.0050758 4.470833 0.273579 0.00530201 2 3 3
gil278068
49 
melanoma inhibitory activity [Bos taurus] 39.23077 0.93442 0413171 0.5502078 0.74613 0.394438 0.0275114 1.870968 0.317091 844188343 7 7 7
gil114052350 WD repeat domain 1 [Bos taurus] 24.91748 1.328011 0.317688 0.0819609 2.835062 0.8448 0.0144696 3.231304 0.589377 0.01099513 4 4 4
gil278061
6
1 tissue inhibitor of metalloproteinase 1 [Bos taurus] 32.36719 1.30685 0.251035 01004857 0.847312 0.272364 0.567031 0.540126 1.701831 0.46123532 3 4 3
gil1 19905546 PREDICTED: similar to Cu/Zn superoxide dismutase [Bos taurus] 36.17021 1.751774 0.020838 0.0063299 3.824468 0.549542 6.88-05 3.578872 0.383382 0.019625 7 7 7
gi]94966811 alpha-i acid glycoprotein (Bos taurus] 37.12871 0.640945 0.68266 0.6848892 0.238141 0.21781 0.04784 0.180854 8.18886 0.03443773 2 2 2
gil156523084 matrin 3 [Bos taurus] 23.81017 1.160861 0.498817 0.3780607 2.281601 0.88777 0.125 3.118349 0.901589 0.120 5 5 5
gi]99028963 5' nucleotidase, ecto [Bos taurus] 17.07317 0.964298 0.151043 0.6027264 1.523897 0.150462 8.1120271 1.975657 8.391831 8.04815696 3 2 3
gi]27807517 settee (or osisteine] proteinase inhibitor, dade 8 (ocatbumin], member 9][Bos taurus] 33.06878 1.568132 1.134077 0.5672758 2.791528 1.382881 0.3732823 3.194459 1.677478 0.39216793 2 2 2
gil62460568 eukatyobo translaton elongaton factor 1 beta 2 [Sos tautus] 27.11111 1.042784 0.568523 0.9064535 3.033238 0.42681 0.0010695 4.09589 0.615496 1.016-05 2 5 9
gil147902079 glycyl-tRNA synthetase {Bos taurus] 21.92102 1.411195 0.087404 0.0789222 4.581574 0.30509 0.0084267 4.982354 0.274885 0.0046598 2 3 3
gi77735461 canopy 4 homolog [Bos taurus] 24.68619 1.163013 0494403 0.3315886 3.65057 065318 8.766-05 4.676185 0.764743 00078125 6 8 8
gi29135329 glutathione S-transferase pi {Bos taurus] 4285714 1.26077 0.144679 00182182 2.979707 0.11706 7.976-06 3.837103 0.287837 0.00610483 4 5 5
gi27805995 mannosidase, beta A, lysosomal [Bos taurus] 14.9033 8392585 0239537 00103341 0.768706 0.076163 0.0129617 0.490066 0.483761 00913343 3 3 3
gil1 14052595 galectin 3 binding protein [Bos taurus] 16.21622 1163616 0312811 0.258239 0855052 0.088827 0.0131883 0.725326 0.38382 009888402 4 4 4
gij77404434 hypoxanthine phosphonbosyltransferase 1 [Bos taurus] 20.6422 1.736061 0.481642 00224143 3252737 0.4512 0.0011055 4.128777 0.525803 0.08096119 5 5 5
gil11991
7
101 PREDICTED: hypothetical protein isoform 6 [Bos taurus] 2056834 0.879581 0.624866 0.5835043 1.916642 0333636 0.0145105 2.200812 0.459368 0.01577774 4 4 4
gi[76642911 PREDICTED: similar to IL-10-inducible chemokine [Bos taurus] 99 0.875858 0123182 0.2709402 0.800304 0299641 0.1833167 0.829947 1.195581 0.43601883 2 3 3
gil1 19903493 PREDICTED: similar to spectrin, beta, non-erythrocytic 1 isoform 1 [Bos taurus] 14.47313 0.713101 059002 0.4498234 1.833073 0.596717 0.2888106 2.515698 0.597666 0.1807333 2 2 2
gil156121073 ARP2 actin-related protein 2 homolog (Bos taurus] 23.09645 1.001828 0.697862 0.9881846 2.304177 0.029813 0.011229 2.067647 0.874D45 0.27182784 2 2 2
gil77735683 S100 calcium binding protein A2 [Bos taurus] 36.08247 -1.00065 1 -1 2.466222 0.120242 0.0028888 2.563626 0.158206 0.06438019 1 3 3
gill15497428 calcyphosine [Bos taurus] 28.54233 1.388068 0421027 03516481 3.522336 0.11175 0.0278185 4.282173 0.328754 0.00812933 2 2 3
gi|27807481 ubiquitin-like protein SMT3B [Bos taurus] 38.94737 1.348473 0.36111 00560946 3.350866 0.477124 0.625 4.313778 0.401973 00625 5 5 5
gi|1 16003917 ar upstream element-binding Protein Sos taurus] 19.44012 2.11329 0269365 01112784 4.654771 0.367708 0.0745735 8.61e61t8 0-326646 0.05383599 2 2 2
gi77736560 stathmin l/oncoprotein 18 [Bos taurus] 48.99029 1.092151 0325027 05704541 0995114 0342775 6.4828973 1496251 0.214272 004242202 3 3 3
gi|1154977 28 aconitase 1, soluble [Bos taurus] 12.26097 1.240157 0.17276 02382912 3423462 0.386158 0.0155636 4.481167 0.439657 0.01348308 2 3 3
gi]77736371 actin related protein 203 complex subunit 2 [Bos taurus 27.66667 1.018386 0.197026 0.8136051 2258753 0622534 0.0331859 296798 0.588514 0.01288204 4 4 4
gi[29135293 farnesyl diphosphate synthase [Bos taurus] 1898017 1.203639 0435333 03082513 3.539508 0.239562 00096248 3.779224 0.267713 0.00073658 4 4 4
gi]51036244 eukaryotic translation initiation factor 5A [Bos taurus] 24.02597 1453199 1.286417 0.5439189 2.954515 0170368 0.003964 3.754468 0.132889 0.00161227 3 3 3
gi]84000347 interleukin enhancer binding factor 2 (Bos taurus] 27.4359 1.828959 0.671820 01530618 2537814 0.533873 0.0154008 3.62311 0.465778 005411404 3 4 4
gil157073982 von Willebrand factor A domain containing 1 Bos taurus] 1684915 1.099628 0.131237 03810268 0807840 0.102784 0.1945011 1.090683 0.050353 017938155 2 2 2
gil114051892 UDP-N-acteylglucosamine pyrophosphorylase 1 [Bos taurus] 20.11494 1.226566 0282574 02136395 2.447533 0.459173 0.401649 2.107073 0.240058 0.0158773 3 3 3
giJ77735453 alcohol dehydrogenuse 5 class 111) chi polppepride [Sos taurus] 14.70588 1.048268 0.260757 0.6424549 2.946919 0.36427 0.0035499 3.528374 0.332388 0.00163491 4 4 4
gi]76609798 PREDICTED: similar to GalNAc-T5 [Bos taurus] 143617 1.02627 0.20103 08401129 1303342 0.415165 0.4245001 788229 0.273644 014437637 2 2 2
gil77735537 ephrin-Al [Bostaurus] 20.97061 113559 0.365597 0.327316 0.839321 0362003 0.1809834 1.18891 0.33226 0.1682474 5 5 5
gil1 14052973 glypican 1 [Bos taurus] 254025 1.210355 0.77746 053101 0.797344 0.122 0.011785 0.986551 0.435525 093417054 4 4 4
gi[76691395 PREDICTED: similar to mammary serum amyloid A3.2 [Bos taurus] 76.33588 0416971 0.352713 2.02E-08 0408124 0.374995 8.01-09 096142 0.234995 038254998 14 14 14
giJ77735939 proliferating cell nuclear antigen [Bos taurus] 33.33333 0.761819 0420592 02466368 1.739169 0431616 0.0869073 2.034908 0.234062 00694241 3 3 3
gi|27807275 matrix Gla protein [Bos taurus] 4466019 1.287522 0396059 00016206 0.754217 063986 0.0183724 1.280808 0662351 0.04100272 17 17 17
gil27806703 CD44 antigen [Bos taurus] 17.75956 1100475 0.406985 0406822 040386 0.32497 3.886-05 0.68014 0.502869 0.02643126 7 7 7
gil15727990
7 
parathymosin [Bos taurus] 28.43137 1744462 0.642378 0.0492541 3952378 0628303 0.0021777 4150371 0.681311 0.00252709 5 5 5
gil15612105
9 
biotinidase [Bos taurus) 8 0.814699 0455306 05260767 1.140688 0236245 6.3163806 1.005905 0.151722 0.94970084 2 3 2
gi[91680535 proteasome activator subunit 1 [Bos taurus] 35.34136 1.091096 0.459176 0.6840743 2735559 0.288460 0.0130874 4546808 0.418258 0.01200284 3 3 3
gi|75812956 GTP binding protein Rabla [Bos taurus] 28.01106 0667297 0.163042 0.0853354 4.239819 0.35D683 0.0012976 5.530162 0.377976 0.00097051 4 4 4
gil164420709 retinol binding protein 4. plasma [Bos taurus] 40.29851 0593539 0.486594 D.2726927 0637269 0.156723 0.2517599 0300645 0.06204 0.0183279 2 2 2
gill 39948301 branched chain aminotransferase 1, cytosulic 85 taurus] 17.61696 1.334924 0.373477 0.0414187 2335966 0576351 0.0014122 2.805883 0.64513 000088134 6 7 7
gil164420725 dipeptidyl peptidase Ill [Bos taurus] 20.13699 1.801793 0048435 0.0256006 4.015375 0217609 0.048973 4672917 0.390478 0.07862271 2 2 2
gi[76638716 PREDICTED: similar to ubpiguihon isotorm 12 [Boo taurus] 94.63760 1.204583 0.27885 0.0655101 2.015621 0.246148 0.0001837 2.392524 0.159873 6.926-06 6 6 6
gil122692375 hypothetical protein LOC783871 [Bos taurus]
gi|114052248 plastin 3 [Bos taurus]
gi|119906762 PREDICTED: carilage-derived morphogenetic protein 2 [Bos taurus
gil115495441 hexosaminidase A [Bos taurus]
gi119920091 PREDICTED similar to ventroptin [Bos taurus]
gil62177164 tumor protein, translationally-controlled 1 [Bos taurus]
gi]62751339 proteasome (prosome, macropain) subunit, beta type, 2 [Bos taurus]
gi78369310 stress-nduced-phosphoprotein 1 (Hsp70/Hsp9O-organizing protein) [Bos taurus]
gi|27806555 legumain [Bos taurus]
g|87080799 small inducible cytokine subfamily E. member 1 [Bos taurus]
gil77735431 ornithine aminotransferase [Bos taurus]
gill 15497922 hypothetical protein LOC505636 [Bos taurus]
gi]157279995 dipeptdyl-peptdase 7 [Bos taurus]
gil155372073 cullin-associated and neddylation-dissociated 1 [Bos taurus]
gil119917901 PREDICTED: similar to Carboxypeptdase X 2 (M14 family) [Bos taurus]
gil27806887 fusion (involved in t(1216) in malignant liposarcoma) [Bos taurus]
gil27806783 thioredoxin [Bos taurus]
gi|155372333 lectin, mannose-binding 2 [Bos taurus]
gi|84370199 6-phosphogiuconolactonase [Bos taurus]
gi|7836964 5 SH3 domain binding glutamic acid-rich protein like [Bos taurus]
gi|27805945 inositol(myo)-1(or 4)-monophosphatase 1 [Bos taurus]
giJ77735429 proteasome alpha 3 subunit [Bos taurus]
gi|77735823 ribosomal protein S20 [Bos taurus)





spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) [Bos taurus]
gi|1 14052270 chordin-like 2 [Bos taurus]
gi|126722829 BCL2-associated athanogene 3 [Bos taurus]
gi|114051291 tissue specific transplantation antigen P35B [Bos taurus]
gi]78042510 haloacid dehalogenase-like hydrolase domain containing 2 Bos taurus]
gil149642873 hyaluronan and proteoglycan link protein 3 {Bos taurus]
gil119930148 PREDICTED: similar to RIKEN cDNA 1600002004 gene, partal [Bos taurus]
gil278064
97 
plasminogen activator inhibitor-1 [Bos taurus]
gil1 15497482 zinc binding alcohol dehydrogenase, domain containing 1 [Bos taurus]
gil119879173 PREDICTED: similar to putative MAPK activating protein isoform 2 [Bos taurus
gill 15497442 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase [Bos taurus]
gil134085825 carboxypeptdase Z [Bos taurus]
gi|75832090 isocitrate dehydrogenase 1 (NADP+), soluble [Bos taurus]
gi27807129 thioredoxin reductase 1 [Bos taurus]
gil1 19908206 PREDICTED: hypothetcal protein [Bos taurus]
gil1 14052667 RAD23 homolog B [Bos taurus]
gil149642987 S100 calcium binding protein Al1 (calgizzarin) [Bos taurus]
gi|28461189 lectin, galactoside-binding, soluble, 1 (galectin 1) [Bos taurus]
gi27807075 S100 calcium-binding protein A4 [Bos taurus]
gi27806067 plasminogen activator, urokinase receptor [Bos taurus]
gil27806725 cathelicidin antimicrobial peptide [Bos taurus]
gi|27806273 chemokine (C-C motif) ligand 2D [Bos taurus]
gi|l 14052322 alpha-N-acetylgalactosaminidase [Bos taurus]
gil1 14050905 SERPINE1 mRNA binding protein 1 [Bos taurus]
gi]76669880 PREDICTED: similar to LRTS841 [Bos taurus]
gi|119915943 PREDICTED: similar to serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1 isoform 1 [Bos taurus]
gi119912825 PREDICTED: solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1 {Bos taurus]
gi76608584 PREDICTED: similar to KIAA0653 protein isoform 1 (Bos taurus]
gi|27807445 peroxiredoxin 5 precursor [Bos taurus)
gi|155371881 alanyl-tRNA synthetase [Bos taurus]
gi|1 15496898 Hi histone family, member D [Bos taurus]
gil119924945 PREDICTED similar to agrin [Bos taurus]
gil119922764 PREDICTED: similar to MSTP006 [Bos taurus]
gi61888866 tropomyosin 1 alpha chain [Bos taurus]
giJ60592784 hexokinase 1 [Bos taurus]
gi[76649536 PREDICTED: similar to fibulin 2 precursor, [Bos taurus]
gi27806923 brain ribonuclease [Bos taurus]
gi|119909757 PREDICTED: similar to E-selectin ligand-1 [Bos taurus]
gi158262747 glutamine-fhuctose-6-phosphate transaminase 1 [Bos taurus]
gi|27807193 platelet-activating factor acetylhydrolase, isoform lb, beta subunit 30kDa [Bos taurus]
gi|119907132 PREDICTED: similar to Hyoul protein [Bos taurus]
gi|82697343 cystatin B (stefin B) [Bos taurus]
gi|116004245 retinoblastoma binding protein 4 [Bos taurus]
gil14823
3 3
12 dermatan 4 sulfotransferase 1 [Bos taurus]
gil1 19915491 PREDICTED: similar to Complement C4-A precursor (Acidic complement C4) [Bos taurus]
gi78042520 eukaryotic translation initiation factor 4B [Bos taurus]
gil1 19894607 PREDICTED: similar to peptidoglycan recognition protein L [Bos taurus]
gi|157427940 activated RNA polymerase 11 transcription cofactor 4 [Bos taurus
gi|77735427 protein phosphatase 1, regulatory subunit 7 [Bos taurus]
gij77735717 proteasome (prosome, macropain) subunit, alpha type, 4 [Bos taurus]
gil29135303 glutaminyl-peptide cyclotransferase (glutaminyl cyclase) [Bos taurus]
gil117935057 dihydroxyacetone kinase 2 [Bos taurus]
gi|122692601 hypothetical protein LOC526913 [Bos taurus]
gil157151716 annexin A6 (Bos taurus]
gil27807521 prostaglandin H2 D-isomerase [Bos taurus]
gi|1 14051526 coactosin-like 1 [Bos taurus]
gi|76615127 PREDICTED: similar to Dihydrolipoamide dehydrogenase isoform 2 [Bos taurus]
gi|76671278 PREDICTED smiar to vesicle amine transport protein 1 isoform 1 [Bos taurus]
44.76744 0.552975 0.604769 00662065 1244118 0.095675 00077462 27926 0300125
25.03912 1.323663 0.526258 0.3153689 2.232197 0.526929 0.0634759 3044657 059854
18.51064 0.567102 0.548921 0083639 1.350388 0.033151 00001309 0.654959 035796
16.44613 -1.00065 1 -1 2.067133 0.989501 0.3774703 1.87352 0.796051
23.39956 0.937338 0.048121 0.0769204 068945 0.515165 0.2079753 087366 1.447548
35.46512 1.158834 0.443541 0.62196 2,340446 0.412916 0.1498302 3.121972 0.566442
29.35323 1.330207 0.274933 0.1225159 3.127191 0.379439 00006479 4.246609 0.660994
32.22836 1.341008 0.807716 03724710 3.140066 0.564662 00101359 3.704626 0525602
24.01848 0.768093 0.152944 0.1750179 0.975966 0.08125 05616646 0979913 0205985
37.57764 0.978151 0.51457 0.9427495 3.248512 1.009726 0.0440782 450022 0.875604
15.03417 1.395334 0.98313 04870478 2.029195 1041695 0.2346279 1919908 1320611
28.51711 -1.00065 1 -1 1.581124 0400711 0.2610647 226249 0236818
23.97541 0.857851 0.549094 06691034 1304726 0.197209 0.2269135 1.089601 0.096418
18.86179 0.695073 0.378225 02896027 2.907305 0.49621 01440313 3759088 0843245
18.60158 0.797696 0.095673 01288634 0.730217 0224571 02104108 0.684151 0102243
32.61719 1.181835 0.481151 0.606781 4238665 0.550486 01180872 5.516432 054895
42.85714 1.444023 0.440707 0.054952 3509945 0.475087 00010569 419445 0.412321
23.11978 1.153124 0.410591 0.4790391 127617 0.343735 0226436 1493062 0.605143
30.23256 0.576743 0.018861 0.0106797 1.205925 0040074 0.0688709 1254963 0.811092
47.36842 1.577395 0.086695 0059265 3.14094 0.4042 00038984 4378125 0516322
27.43682 1.400499 0.331543 0.1288063 2.957581 0692891 00602492 3363121 0.681528
38.82353 0.932204 0.22374 06348077 2.281576 0313706 0.1182173 2.446468 0.00794
31.09244 0.790159 0.17284 0.0290852 1.737038 0.268753 00099104 3.188097 0.532714
25.87719 0.927323 0.676895 0.8051482 2611393 0.755215 0.0874872 3160965 0.680789
16.58576 1.184876 0.388282 0537734 2947246 0.371875 01068734 3840887 0.388681
19.76744 0.884934 1.269861 0.798205 0.41275 0.65961 0.0776335 0.487832 0.680651
27.0855 2.802923 1.289169 03502997 3.458467 0048328 0.0122142 4.271478 0.13829
23.98754 1.654949 0.535261 01433048 4.137355 0278018 0.0061372 4.214638 0.236823
24.71042 0.94649 0.757689 0.9053114 3.266997 0.791617 00033087 4.125668 0317018
41.38889 1.158435 0.537488 0.4291358 1.01502 0.217778 0.625 1.241183 0.2373
38.37209 0.609115 0.452781 0.1114128 0.931329 050876 0.8898663 1754287 0.451165
16.41791 2.200635 0.29896 0.004716 4.486546 0380705 0.0014754 8.368697 0.330522
13.10541 -1.00065 1 -1 1.893992 0.327402 0.1582271 2.316179 0.902675
15.89649 1.426563 0.799612 0.5317789 3.512832 0.665082 0.0123022 5.059416 0.032401
13.85135 0.945259 0.440325 0.8357586 3.088379 0.800938 0.2143968 3.857588 0.686000
18.47826 0.559446 0.166333 0.0128532 0.856328 0.130455 0.0905337 1.188414 0.289823
24.63768 1.045861 0.344877 0.8372108 2.802093 0.576889 0.1841776 2.929273 0.27283
19.23848 1.282764 0.3450D6 0.3805389 2.327132 0.981346 0.3316377 25314 0.715079
17.80303 1.214952 0.224236 0.1830811 2.43674 0.887958 00547898 2.6914 1.083964
19.36274 -1.00065 1 -1 2757201 0.625255 0.1879261 3.188905 0.658176
29.12621 1.030253 0.247403 0.8497925 2.568362 0.112691 0.0374885 4.252827 0.107625
30.37037 1.224775 0.175201 0.0447682 220260 0.339462 0.8069073 2.735369 0.439069
42.57426 0.879406 0.024022 0.0878722 2.602672 0493875 0.1588096 3.749839 0.737501
16.36364 1.121041 0.414642 0.6754922 1.833391 0.813034 0.3733367 2.407823 1.479507
17.89474 0.1597 0.784296 0.0066379 1.138599 0.187596 0.1580967 0.329782 1.259486
19.79167 0.194847 0.555875 0.0179878 0.419872 0.220179 0.0100069 0.482231 0.146586
12.89538 1.139529 0.595913 0.8404207 1.51588 0.332239 0.0911832 1.883756 0.367761
27.27273 -1.00065 1 -1 3.400362 0.220987 0.0584873 5.344381 0.284973
22.9765 0.448547 0.945133 0.167938 0.759383 0.335878 0.1712008 1.831562 0.088643
24.41176 0.866515 0.14408 0.2903878 3.970274 0.119787 0.0272171 4866283 0.500872
29.61957 1.16955 0.347958 0.528402 1.937879 0.32838 0.1533487 1.906841 0.396522
12.87425 1.184635 0.264365 0.0080988 0.252437 0.804793 2.606-05 0.641921 082809
36.07306 1.113993 0.326673 0.4880402 4.136891 0171283 0.0023432 5.802393 0.11972
18.69835 1.087238 0.469583 0.7796875 3232799 0.34756 00922806 3.627258 0.063241
28.86598 0.849143 0.420366 0.5716697 2.006775 0033187 0.0150018 9.050744 0.149403
16.48301 0.866545 0.317657 05250638 0823302 1.139062 07801894 1.01548 0439552
25.0715 1.305384 0.165716 0.1887662 3.244213 0.394372 0.1041913 3.761606 0.031078
50.35211 0.833011 0.034991 0.0593724 1.718769 0.723139 0.3723729 1.984483 0.477072
11.88659 0.685052 0.923112 0.5561625 2.195976 0.321184 0.1267448 2182267 1.005376
9.444905 1.109473 0.049989 0.1483473 1.321788 0.510396 04727018 1.376373 0.520491
41.31736 0.723807 0.332298 0.0029219 0.96977 0.130105 02522524 0.273223 0656186
16.37131 1.093871 0.410077 0.7344326 2.581782 0169757 0.0560792 1.506366 1.445697
24.81645 1.231305 0.084642 0.1256687 2535182 0.377752 01259132 3.108689 0.51129
24.45415 1.027925 0.91947 09620578 2.814638 011982 00021668 4334730 0.218424
27.17283 -1.00065 1 -1 2.035217 0816025 0.3268293 2365465 0.387398
71.42857 1.478201 0.182256 0.0332131 2501006 0.120338 00030223 2.85596 0.131669
17.41176 -1.00065 1 -1 1.987514 0.601259 0.260174 2447641 0.257507
17.81915 0.740922 0.011548 00119886 0.728226 0.348724 03094067 1246645 0.505891
17.96785 0.166893 0.97678 0.1662811 1082212 0.420537 0743752 0.316188 2.318201
25.40984 -1.00065 1 -1 3.503268 0512061 0.1264097 2.816826 0333674
20.13536 4.792911 0.487863 0.0004903 0395206 0.772723 00175063 1.139641 0.698255
41.73228 1.13341 0.21623 0.4487548 4.359615 0183893 0.0025105 5755411 0.17363
25.83333 -1.00065 1 -1 3.783091 0.000171 4.036-05 5.134357 0.088936
27.20307 1.218217 0.382513 0.3274525 3.009222 0.61398 0046819 3.822741 0.658926
27.42382 -1.00065 1 -1 0.955946 0524784 0.8743152 0939491 0.711602
23.18339 1.770718 0.856066 0.4035772 2710145 0.889998 02540701 2.181308 0.368757
33.91813 -1.00065 1 -1 -1.00642 1 -1 5440118 0.813041
22.28826 0.875483 0.2842 0.5159396 1.580233 0.112174 0077197 1.94607 0.114224
35.6021 2.053996 0.214395 0.0139374 0.468867 0.252016 0.0169907 0277285 1.052004
30.28169 1.478547 0.347001 0.2615507 1.981741 0.060627 02472422 3.391487 0498548















































































gij76652407 PREDICTED similar to Chain A, Crystal Structure Of Human Rangapl-Ubc9 isoform 2 [Bos taurus]
gi27806129 ribosomal protein L24 [Bos taurus]
gil122692537 damage-specific DNA binding protein 1, 127kDa [Bos taurus]
gill991
73 7
8 PREDICTED similar to FAM20C protein [Bos taurus}
gi]119901084 PREDICTED: similar to CD109 [Bos taurus]
gi|41386699 heat shock 70kDa protein 2 [Bos taurus]
gi|157074012 EF-hand domain family, member D2 [Bos taurus]
gi|122692293 chloride intracellular channel 4 [Bos taurus]
gi]77735589 splicing factor, argininelserine-rich 2 [Bos taurus]
g]155372143 arginine-rich, mutated in early stage tumors [Bos taurus]
gil27805833 chemokine (C-X-C motif) ligand 5 [Bos taurus]
gill18151144 tenascin C [Bos taurus]
gil119914306 PREDICTED similar to 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase delta 1 (Phosphoinositide phospholipase C] ]PLC-deha-l ]Phospholpase
gi|77735633 cysteine-rich, angiogenic inducer, 61 [Bos taurus]
gi|158937293 fibroblast growth factor receptor 1 [Bos taurus]
gi|41386687 leukemia inhibitory factor (cholinergic differentiation factor) [Bos taurus]
gil115495701 pentraxin 3 [Bos taurus]
gill 15497506 LIM and cysteine-rich domains 1 [Bos taurus]
gi|27806365 UDP-glucose dehydrogenase [Bos taurus]
gi|155372327 tumor necrosis factor receptor superfamily, member 6b [Bos taurus]
gi|169658384 non-metastatic cells 1, protein (NM23A) expressed in [Bos taurus]
gi|119888815 PREDICTED: similar to GALE protein isoform 2 [Bos taurus]
gi|76607797 PREDICTED similar to cis Golgi-localized calcium-binding protein isoform 2 [Bos taurus]
gi|62752D12 ribosomal protein L18 [Bos taurus]
gi|147902328 thymopoietin [Bos taurus]
gil27807361 nuclease sensitive element binding protein 1 [Bos taurus]
gil1 19895504 PREDICTED: similar to heterogeneous ribonucleoprotein AO [Bos taurus]
gir77736367 poly(rC)-binding protein 2 [Bos taurus]
gi]77736353 dimethylarginine dimethylaminohydrolase 2 [Bos taurus]
gi|1 14051796 glucosidase, beta, acid (includes glucosylceramidase) [Bos taurus]
gi62751960 nbosomal protein S26 [Bos taurus]
gil1 19879493 PREDICTED: similar to limbic system-associated membrane protein 6c- [Bos taurus]
gil145279649 tumor necrosis factor alpha [Bos taurus]





eukaryotic translation initiation factor 4A isoform 1 [Bos taurus]
gil28461231 ATPase, He transporting, lysosomal accessory protein 1 [Bos taurus)
gil119895
7
32 PREDICTED: similar to synaptopodin [Bos taurus]
gi|114 05 142 3 ubiquitin carboxyl-terminal esterase Li [Bos taurus]
gir76633778 PREDICTED: similar to syndecan 4 [Bos taurus]
gl1 54707892 Clq and tumor necrosis factor related protein 5 [Bos taurus]
gil1 53791208 immunoglobulin superfamily containing leucine-rich repeat [Bos taurus]
gil1 19890624 PREDICTED: similar to insulin responsive sequence DNA binding protein- [Bos taurus]
gil27806675 cystatin C [Bos taurus]
gil164259354 reticulon 4 isoform 2 [Bos taurus]
gil115497820 parvalbumin [Bos taurus)
gir84000233 hypothetical protein LOC517857 [Bos taurus]
gi|27806297 biliverdin reductase B (flavin reductase (NADPH)) [Bos taurus]
gi|77736489 high-mobility group nucleosome binding domain 1 [Bos taurus]
gil1 15497074 esterase D/formylglutathione hydrolase [Bos taurus]
gil77735391 regakine 1 precursor [Bos taurus]
gil62460528 nascent polypeptide-associated complex alpha subunit [Bos taurus]
gill 15497050 isopentenyl-diphosphate delta isomerase [Bos taurus]
gil77735825 cathepsin K [Bos taurus]
gi77735687 proteasome (prosome, macropain) subunit, beta type, 6 [Bos taurus]
gi|27806823 osteomodulin [Bos taurus]
gij82697405 LSM3 homolog, U6 small nuclear RNA associated [Bos taurus]
gil115497398 neuron derived neurotrophic factor [Bos taurus]
gil119879765 PREDICTED: similar to eukaryotic translation initiation factor 4 gamma, 1 [Bos taurus]
gi|82697365 ribosomal protein S19 [Bos taurus]
gil15
7
954420 angiopoietin-like 2 [Bos taurus]
gir84000197 FK506 binding protein 3, 25kDa [Bos taurus]
gi|41386683 beta-2-microglobulin [Bos taurus]
giI62751407 fast skeletal myosin light chain 2 [Bos taurus]
gill 19919943 PREDICTED: similar to methyl-CpG-binding protein 2 isoform 1 [Bos taurus]
gi]77736355 RAN, member RAS oncogene family [Bos taurus]
gi|149642675 ribosomal protein S17 [Bos taurus]
gi|45430009 fumarylacetoacetate hydrolase domain containing 2A [Bos taurus]
gi|154152039 scrapie responsive protein 1 [Bos taurus]
gi|119907227 PREDICTED: hypothetical protein LOC535533 isoform 2 [Bos taurus]
gi|84000371 H2A histone family, member V [Bos taurus]
giJ27807173 S100 calcium binding protein A10 [Bos taurus]
gill 19927320 PREDICTED similar to laminin B2, partial [Bos taurus]
gil7662D955 PREDICTED: hypothetical protein [Bos taurus]
giJ77736063 dynactin 2 (p50) [Bos taurus]
gi|149642591 0100 calcium binding protein Al [Bos taurus]
giJ78369246 acireductone dioxygenase 1 [Bos taurus]
gi]77735889 mesoderm development candidate 2 [Bos taurus]
gill 14052282 nuclear casein kinase and cyclin-dependent kinase substrate 1 [Bos taurus]
gil1 19888616 PREDICTED: similar to beta 1,3-N-acetylglucosaminyltransferase 7 [Bos taurus]
gil115497034 ubiquitin specific peptidase 14 [Bos taurus]
gil27806277 calpain, small subunit 1 [Bos taurus]
gi|27806265 leukocyte cell derived chemotaxin 1 precursor [Bos taurus]
27.8481 0.838683 0.297707 076523 1.892648 0.828082 023114 2775658 0.962135
31.84713 0.299926 0.348412 0.0896313 1.559483 0.354058 0.240169 6.89452 0.560858
12.45614 1.110984 0.044019 0.027213 2.412275 0.407136 0.0330273 3.087672 0.31851
24.71783 0.76106 0.07298 0.0827319 0.747602 0043851 0.045987 0.604188 0.095755
36.22449 1.019964 0.426654 0.680915 0.94923 0409485 0.6351143 1.113193 0.444676
34.54834 0.843417 0.785543 0.5746141 1769436 0913078 0.078125 2786537 0.968469
24.38017 1.793432 0.112593 00600325 2865644 041333 0.1217369 4361099 0846208
27.27273 1.17274 0.328963 01946439 2.710524 0261827 0.0002585 3.301008 0318316
33.48416 1.270996 0.145926 00547751 7.86308 0443527 0.0073721 8.410554 0.399028
18.43575 0.848986 1.101397 0.9118423 3.28157 1175707 0.2887952 3.836271 1819622
23.21429 0.179465 0.263135 00476897 0670318 0245752 0.1034332 0.27815 0.496713
50.91638 D.770316 0.294486 00256867 0602405 0.356736 00089668 1431962 1.303577
15.621 1.035261 0.323216 08653991 2.394548 0.291299 0.103929 2.95617 0.266369
10.20942 0.883789 0.51206 0.7074747 1745372 0533266 02821737 053295 2.306675
12.56098 1.753452 0.47468 0.0421556 0559447 0521762 0.2614632 1122839 0.125486
17.82178 -1.00065 1 -1 0.963503 0190164 0.6378362 0.331646 0.726595
29.58115 1.670089 0.348366 00667453 1.193437 0490979 04771401 2.573371 0.426845
27.27273 1.321589 0.146172 0.1604673 2.747591 0.409624 00206214 2530716 0.39146
12.75304 1.648265 0.581918 0.3305285 4.526757 016537 0.0342841 5.402224 0.035946
30.06757 0.677278 0.157293 0025035 1.419267 0240222 00700653 1.789695 0.171036
51.97368 1.599096 0.496178 01421363 3221894 0487525 00066466 5113621 0.525556
14.39394 1.003638 0.243785 0.9764014 367117 1123597 0.1024996 4.28586 0.971872
13.68876 0.873921 0.473286 05486248 1459335 0521968 02172251 2.065455 0.464456
45.74468 -1.00065 1 -1 4234364 0.124859 00270982 5.293795 0.185178
24.86911 1.629695 0.244807 01535627 1171980 0.032739 0.0668263 1.915535 0.39931
28.7037 0.913776 0.424419 0.580643 257372 0.355249 00046603 4.140374 0.414895
18.72131 1.612215 0.242052 0.0388583 2692241 0.504924 0.0396778 4.291759 0.545594
23.20917 -1.00065 1 -1 2838597 0370689 0.0228783 4.3053 0.029314
23.85965 -1.00065 1 -1 -1.00642 1 -1 4.459772 0.743368
15.67164 0.764494 0.202429 02246044 1.254877 0.384624 04501166 1.678967 0.156796
42.6087 0.485585 0.151816 00652849 1.730674 0.56823 0.3025819 3.148392 0.620932
16.17977 1.159068 0.19806 0.204879 0798589 011301 0.0361716 1.088801 0.253514
6.837607 14.20984 1.293349 0.0096325 0911562 0.678383 0.8157827 14.54193 1.193093
66.79587 0.849069 0.201162 0.3441443 3.886245 0.072836 0.0168176 4.959856 0.14599
40.64039 1.16605 0.353513 0.3926128 4233965 0.197121 0.0030011 4.463149 0.121149
16.88034 0.960254 0.077019 0.3130112 1.005032 0.197032 0987851 1.422343 0.092712
12.58503 -1.00065 1 -1 2.424683 1.728491 0.4877888 3.240050 1.513455
13.88889 0.962528 0.00119 00690604 1.689114 0.859838 0.3554163 2.089131 0.997176
17.08543 0.683179 0.248639 0.0617444 0.418593 0.797848 0.1108239 0.821749 0.63134
21.39918 0.847331 0.101863 0.1856581 1.392054 0.068518 0.0658721 0.832781 0.214649
11.91589 0.83523 0.581162 0.2152827 0.591791 0.597903 0.0273438 0.929361 0.662288
10.12048 0.901494 0.025889 0.0770335 0.820672 0.319856 0.4170883 0.784367 0.215142
35.81081 0.311661 0.505464 0.1332276 040507 0.032231 00110491 0.347844 0.310227
9.49868 0.777559 1.6576 0.8083492 1.871928 1.281245 0.5037745 0.998028 2.136357
36.36364 1.014075 0.188671 0.9088892 4.286481 0.434321 00928578 2.549938 0.347009
23.75 1.171824 0.508378 0.6403982 3306598 0281712 0.073567 4.85265 0.352999
18.93204 1.564585 0.63012 01331828 2.125048 0.58417 0.0344776 3.034521 0.605806
32.67327 D.444938 0.555178 0.2062116 1.943734 1161423 0.4539377 2.284475 1.615261
12.76596 -1.00065 1 -1 4369147 0504538 0.1362306 -1 1
18.47826 0.451793 0.098061 0.0384317 0667916 0.53123 0.3602041 0.388718 1.36881
13.02326 1.830435 0.724095 0.3382421 4.504433 0.378398 0.0783849 5.934570 0.025173
27.1777 0.877947 0.778639 0.7897649 1.459049 0.325729 0.256461 2.013007 1.231721
35.62874 0.934242 0.047902 0.2097279 2.224044 0.048229 0.0189731 4.633014 0.04837
32.21757 1.333942 0.047645 0.0515986 3050473 032389 0.0905222 3.477498 0.235773
14.45498 0.774023 0.249999 00593557 1.07641 0153721 02961305 1.225383 0056163
31.37255 1.468764 0.902448 05450427 3.680527 0607336 0.1436591 4.276493 0.263572
39.05326 0.670412 0.278612 02091807 0997721 0.16174 09305859 1548858 0.502267
18.13773 1.564344 0.75853 04416059 5483087 0106958 0.01968 7244449 0.08588
35.17241 -1.00065 1 -1 1.692251 0.653953 03518414 6243338 0.798797
16.22718 1.028046 0.593377 0.9198322 1139332 0241889 0.3285328 1.277148 0.47329
24.55357 0.812919 0.853254 0.7084508 1.916825 0.544387 0.2499603 2.67173 0.989421
39.83051 1.416328 0.47085 0.0759663 083683 0.320825 0.1371149 2.344783 0.035110
19.18605 1.240037 0.337093 02527990 3.986864 0.165871 00023171 4.063859 0.358809
25.71943 -1.00065 1 -1 -1.00642 1 -1 8006162 0.471435
22.68519 0.739306 0.430781 0307744 2.028151 0204308 0.0903641 2.630704 0.148516
32.59259 0.542396 0.748698 0.3436696 1.800149 1.235928 04900739 2.454942 0.030363
26.11465 1.274767 0.170997 02121555 1.709406 0619099 03311537 1.565225 0837969
45.91837 0.738699 0.312672 00186276 0421795 0.242594 003125 028535 0.680972
13.22141 -1.00065 1 1 2202432 0.346186 01358267 2750132 0.03182
48.4375 0.760566 0458467 0182695 1.609169 0324879 00251315 4.178997 0.122533
38.14433 D.839503 0.497589 02675871 2623931 0360347 9788-09 3993368 0.422779
13.90729 1.083504 0.254515 0.6386092 0965657 0045925 0.317017 1.357422 0.088716
59.52381 0.694827 0.419084 0.3265113 1135705 0147721 0.3436365 2.488608 0.160546
16.62531 -1.00065 1 -1 2.792355 0.054156 0.0165552 3.203302 0.807278
17.02128 0.991839 0.070916 0.6413485 3.244039 0.087176 00232301 4.796569 0.248085
27.93296 1.213911 0.401982 03527036 255191 0.258428 00121312 2.915009 0.114788
28.87931 1.077581 0.23601 0.6374274 3.852189 0.986506 0.2201164 4.933039 0.775939
32.09876 -1.00065 1 -1 1.82684 0.790179 0.170527 4.057833 0.901211
14.25061 .524025 0.197044 0.1436533 0.892664 0.34249 05050319 1.373841 0.052724
19.02834 1.273419 0.057796 0.074474 3.178216 0.41429 0.1112683 4.085951 0460966
18.63116 -1.00065 1 -1 -10642 1 1 4.924903 0.174657



















































































gi|119909677 PREDICTED: similar to MGC84382 protein (Bos taurus]
giI122692323 ysozyme [Bos taurus]
gil75812914 macrophage migration inhibitory factor (glycosylation-inhibiting factor) [Bos taurus]
gill 15496488 SEC22 vesicle trafficking protein homolog B [Bos taurus]
gill 15497346 adaptor-related protein complex 2, beta 1 subunit [Bos taurus]
9i|76629502 PREDICTED: simiartoTGOLN2 protein [Bostaurus]
gi|76635454 PREDICTED: similar to OAF homolog (Drosophila) [Bos taurus]

























0.7429104 2.026587 1.22306 0.4508602 2.810786 1.083154
0.5397527 1.160912 0.324298 0.5340143 2.758603 0.059322
0.0186749 3.646303 0.546461 8.86E-05 3.957525 0.598624
0.4800242 3.392663 0.687048 0.1720918 4.493164 0.881982
0.2969266 1.574513 0.063904 0.0444805 2.047706 0.037289
0.677674 1.543475 0.159946 0.1154222 1.40067 0.171665
0.1659524 0.974144 0.157536 0.7457215 2.663787 0.08286








gi|119888979 PREDICTED: similar to heparan sulfate proteoglycan 2 (perlecan) [Bos taurus]
giJ76610126 PREDICTED similar to fibronectin 1 isoform 4 preproprotein isoform 12 [Bos taurus]
gil16441442
7 
collagen, type 11, alpha 1 isoform 2 [Bos taurus]
gil307942
8
D albumin [Bos taurus]
gil34098396 Chondroitn ABC endolyase 1 precursor (Chondroitin ABC lyase 1) (Chondroitinase ABC) (Chondroitin sulfate endolyase) (Chondroits ABC elroinase)
gil41386685 thrombospondin 1 [Bos taurus]
gil119890645 PREDICTED similar to alpha 3 type VI collagen isoform 5 precursor isoform 1, partial [Bos taurus]
gil1 19900891 PREDICTED: hypothetical protein LOC540664 [Bos taurus]
gil27806761 aggrecan 1 [Bos taurus]
gi|119901095 PREDICTED similar to collagen, type XII, alpha 1 isoform 1 [Bos taurus]
gi|l 15495027 heat shock 7DkDa protein 5 [Bos taurus]
gi|119887130 PREDICTED similar to Collagen, type VI, alpha 1 isoform 1 [Bos taurus]
gi|119913814 PREDICTED similar to melanoma-associated chondroitin sulfate proteoglycan 4 [Bos taurus]
gi|119890597 PREDICTED similar to alpha 3 type VI collagen, partial [Bos taurus]
gi|119919153 PREDICTED: similar to AHNAK nucleoprotein [Bos taurus]
gill10347570 vimentin [Bos taurus]
gi|1 14051163 collagen, type XI, alpha 2 [Bos taurus]
gi|119892686 PREDICTED similar to P63 protein [Bos taurus]
gi|119914559 PREDICTED: similar to filamin B. beta (actin binding protein 278) isoform 7, partial [Bos taurus]
gil148238040 actinin, alpha 4 [Bos taurus]
gi[77404182 lamin A/C [Bos taurus]
gi|l56120777 nidogen 2 [Bos taurus]
gil60592792 heat shock 90kD protein 1, alpha [Bos taurus]
gil1482303
7
4 protein disulfide isomerase-associated 3 [Bos taurus]
gil119894520 PREDICTED similar to cartilage oligomeric matrix protein isoform 1 [Bos taurus]
gi|164452943 gelsolin a [Bos taurus]
gi|99028969 complement component 3 [Bos taurus]
gi|27806501 prolyl 4-hydroxylase, beta subunit [Bos taurus]
gi|153791660 extracellular matrix protein 1 [Bos taurus]
gil119889734 PREDICTED: similar to Collagen alpha-l(XI) chain isoform 1 [Bos taurus]
gil115497814 nucleobindin 1 [Bos taurus]
gil119888668 PREDICTED: similar to Cartilage matrix protein precursor (Matrilin-1) [Bos taurus]
gil27807447 matrix metalloproteinase 2 [Bos taurus]
gi|87196501 enolase 1 [Bostaurus]
gil95147674 complement factor B [Bos taurus]
gil119906908 PREDICTED: similar to matrix metalloproteinase-3 [Bos taurus]
gi|7663014 3 PREDICTED: similar to matrilin-3 [Bos taurus]
gill14050715 moesin [Bos taurus]
gi|1 14326226 protein disufide isomerase-associated 4 [Bos taurus]
gi]122692297 chibnase 3-like 1 [Bos taurus]
gl155372023 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 [Bos taurus]
gi]27807289 annexin A2 [Bos taurus]
gil156120795 quiescin Q6 sulfhydryl oxidase 1 [Bos taurus]
gil27805853 cartilage linking protein 1 [Bos taurus]
gi|1 19921375 PREDICTED: similar to RP1 1-525G3.1, partial [Bos taurus]
gi|41386780 UDP-glucose pyrophosphorylase 2 [Bos taurus]
gil119901238 PREDICTED: similar to laminin alpha 4 [Bos taurus]
gi|1 15497900 eukaryotc translation elongation factor 2 [Bos taurus]
giJ61888856 triosephosphate isomerase 1 [Bos taurus]
gil27807263 heat shock protein 90kDa beta, member 1 [Bos taurus]
gil147906412 hypothetical protein LOC615490 [Bos taurus]
gir61845535 PREDICTED: similar to emilin (Bos taurus]
gi|76607158 PREDICTED similar to Melanotransferrin precursor (Melanoma-associated antigen p97) (CD228 antgen) 905 taurus]
gi|27806469 peptidylprolyl isomerase B {Bos taurus]
gi]116003881 collagen, type 111, alpha 1 [Bos taurus]
gil115497210 complement component 1. s subcomponent [Bos taurus]
giJ77735551 phosphoglycerate kinase 1 [Bos taurus]
gil27806147 secreted protein, acidic, cysteine-rich [Bos taurus]
gi|110350683 biglycan [Bos taurus]
gij75832054 actin, beta [Bos taurus]
gi|119919953 PREDICTED similar to filamin [Bos taurus]
gi|115495019 procollagen-proline, 2-oxoglutarate 4-dioxy genase (proline 4-hydroxylase), alpha polypeptide I [Bos taurus]
gi|27806559 lactate dehydrogenase A [Bos taurus]
gi|115496702 collagen, type VI, alpha 2 [Bos taurus]
gi|119902010 PREDICTED: similar to LOC512571 protein [Bos taurus]
gi|27806477 lysyl hydroxylase precursor [Bos taurus]
gi|76253709 heat shock 70kDa protein 8 [Bos taurus]
gil1 19919157 PREDICTED: hypothetical protein [Bos taurus]
gi|77404252 collagen, type 1, alpha 1 [Bos taurus]
gi|62988316 follistatin-like 1 [Bos taurus]
gi|77404217 phosphoglycerate mutase 1 (brain) [Bos taurus]
gi|156523168 matrilin 2 [Bos taurus]
gi|27807367 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide [Bos taurus]
gi|27806723 catreticulin [Bos taurus]
gi|148238309 aldolase C, fructose-bisphosphate [Bos taurus]
gir77404273 glyceraldehyde-3-phosphate dehydrogenase [Bos taurus]
gill14052136 FK506 binding protein 9 [Bos taurus]
gi]76621011 PREDICTED: similar to Cartilage intermediate layer protein 2 precursor (CILP-2) [Bos taurus]
gi]27806941 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 [Bos taurus]
gil94966763 haptoglobin [Bos taurus]
gi|27806697 chondroadherin [Bos taurus]
%Cov mean 115 stdl15l1pualue 115:11stl1 1lluel161meanl17 stdl171lpcaluell7l4Nopepl11 Nopep 16 upept1?
26.34935 0.837063 0.403478 1.9DE-i5 0.95259 0.373037 00088365 0998097 0.883258 0000136975 247 258 255
44.75021 0.463156 0.480728 1.36E-93 1.052178 0.423887 0.0007858 0484351 0.840485 2.82E-93 598 591 589
55.00705 0.854572 0.495462 6.13E-35 0.840488 0.589894 3.08E-96 0.535849 0.830221 4.770-111 743 739 744
85.66722 2.45993 0.479478 2.04E-111 0883801 0.495928 1.49E-18 09846 1091581 0.974578433 674 650 68
52.88932 1 0.419691 0.989830327 1 0387833 0.3194828 1 0.320736 0436577998 219 220 225
47.69231 0.73053 0.493838 1.57E.31 1.057974 0.33551 7.05E-06 0.951059 0.737226 0200718485 275 280 281
45.04037 0.582081 0.538468 5.40E-19 1107817 0,499157 0.0086458 0.957857 0.81187 0034312499 110 110 112
32.81527 0.849801 0.104069 0194181551 1.112003 0.377122 0.7060237 1.162073 0.126294 0.229409638 2 2 2
17.40438 0.752685 0.512405 0 0816278 0.43587 2.38E-49 0744753 0806282 552E-39 671 879 895
22.98335 0.719242 0.381935 1.72E-13 0982038 0.345564 0.2847857 1153545 0388945 928E-06 59 64 68
63.35878 1.109696 0.480298 0024460731 2823067 0.642853 0 277909 0682487 0 108 116 126
42.64849 0.622398 0.325312 721E-55 1.008858 0.301594 0.023367 0.874573 0379201 533E-17 334 343 339
24.45019 1.040585 0.249999 0.047922995 0.928117 0283046 0.0002174 0.927416 0425555 0076052035 74 74 75
36.76471 0.62676 0.480739 8.58E-11 1010198 0.290596 0.857575 104808 0377368 0038908652 79 81 81
41.59497 1.039134 0.370255 06078493 3.092819 0.743213 1310-07 2.638091 0.733315 5700-07 12 17 17
62.23176 1.380347 0492979 1.490-10 2.542251 0886741 0 2.738 0.713441 8390-14 65 71 74
40.14977 0.686068 0.464923 4990-29 1113795 0.347323 4410-08 1.629073 0.646425 3.730-36 307 323 333
67.06282 0.906607 0.321133 0000194084 3.247247 0.734753 0 2.653344 0.745841 0 80 87 88
27.82132 1.194375 0.540658 0.006403559 1.848702 0.363359 7.370-14 1.74755 0497287 2430-12 37 37 36
47.63996 1.26428 0.394529 0000114481 2578089 0.812227 0 2.664101 0694165 0 40 43 46
59.26573 1.217868 0.359493 5030-06 2.17346 0.466516 0 2.624695 0.54318 0 43 43 43
32.64368 0.808751 0.343373 8150-12 0.908361 0.298581 5.870-08 0.955872 0.576384 0707942141 81 63 84
47.3397 1.205972 0.474195 000537598 2.949889 0.538509 3330-15 3260966 0.579182 2560-06 28 29 29
62.57426 1.0893 0.446279 0109789208 3.817216 0.748355 0 3.793069 0.691047 0 67 86 86
46.03175 0.818788 0.487005 4.580-07 0827782 0.533429 7.250-09 0.551296 1.118423 1420-10 88 86 86
40.97311 0.695187 0.386157 1150-14 1.649112 0.580126 7.88E-07 1348877 0.557911 1770-06 58 59 59
28.95846 1.063743 0.280662 0074060176 0.811825 0.384343 2.840-12 0.356582 0.903084 2310-10 33 33 32
66.47059 1.073538 0.345317 0.008549401 3.010583 0.583446 0 2.977922 06411 0 81 89 90
54.54546 0.338604 0.455412 0 0815204 0.344116 1.88E-09 0.306434 0899426 1.230-11 59 60 61
31.97578 0.839092 0.38777 827E-13 0.847742 0.337052 222E-18 0.711882 0.505987 6350-18 146 146 147
60.12658 1.121138 0.374925 0.000237774 1.011852 0.356226 0.5324485 0.883468 0.302727 4.810-05 78 77 77
50.73529 0.835415 0.390752 1.870-11 0.803501 0.338838 0 0.959839 0552348 0.866595362 125 125 133
55.06808 0.761708 0.557064 2.990-08 0739579 0.450868 6.17E-10 0.440702 0635573 7.55E-11 55 56 56
60.36866 1.041078 0.58665 0393765163 2.791033 0.721168 0 3407778 0.805833 0 65 68 69
43.88962 0.6658 0.400061 0 0.58171 0.479446 0 0.717888 0.478212 2.101114 98 00 105
37.10692 0.379018 0.633204 0 1.006669 0.293237 0.739739 0.80568 0.306294 1.76E-08 81 81 81
50.97002 0.56015 0.453447 0 0.588751 0.493742 0 0.831069 0.762416 0.000940778 104 105 104
52.513 1.033309 0.317744 0.761636645 1.700946 0.484271 1.820-5 1.727707 0.454487 1.60-06 15 16 17
44.32348 1.173791 0.603892 004049287 2.897887 0.799682 2.77E-12 2.8862 0.777428 1.466-13 31 33 36
53.70844 0.355438 0.422411 3010-117 0.5802 0.28437 1.070-119 0.322687 0.443066 2.590-118 706 729 719
36.08924 1.008474 0.263717 0796128801 2.369590 0.441774 2.22E-14 2.565107 0.42218 4.44E-16 27 28 28
63.71682 0.864522 0.449534 002005348 1.620062 0.561806 1.300-06 1.719897 0.64929 3.190-07 27 27 29
45.14991 0.885577 0.576208 0.00094702 166031 0.408226 0 2.953609 0.547068 2.43E-13 52 63 71
50.64746 0.877402 0.365959 3.3-07 0.935443 0.383396 2.310-07 0.975970 0.305248 0.397689938 113 113 118
23.35423 0.810071 0.469326 0.003648842 0.819274 0.593539 0.0105995 0.902332 0.48741 0.013061608 27 28 28
48.8189 1.035136 0.322768 0388958428 2.778324 0.534484 4.440-16 2.508068 0.654265 1.740-12 31 32 31
21.79417 1.092885 0.561388 0.304105828 0796267 0.304242 3.800-05 0.832184 0.345183 0.004018315 21 21 21
36.71329 1.176607 0.423182 0010127881 2.801989 0.578151 1.320-12 2.58226 0.607902 1.35E-11 24 26 26
72.69076 1.374135 0.51317 3.290-07 3.010825 0.60713 0 2.84055 0.664001 0 45 70 71
38.80597 0.947458 0.348699 0.34980025 3010549 0.575034 5.790-10 3.428719 0.729066 2.900-09 19 19 19
37.52809 0.610225 0.662467 5.600-10 0.877448 0.350422 6.520-05 1.077281 0.858107 0807656019 51 53 53
30.04926 0.90724 0.350471 0.008698904 0990708 0.313715 0.5207495 0.891227 0429387 0.040499183 38 38 39
33.55886 1.171926 0.320153 0001172306 1.171209 0.318859 0.0142498 0.980021 0.53173 0.933285925 28 26 26
75.48077 0.775224 0.405526 1100-09 1.497094 0.508777 2.23E-08 1.26326 0.381398 373E-10 63 63 63
42.90587 0.728525 0.476838 3.680-08 1.435887 0.461725 4.93E-06 1.348145 0.735978 0.00842754 54 54 54
28.77698 0.825658 0.276615 2.8-07 0681547 0.260751 2.220-16 0.586669 0340813 2.220-16 39 39 39
65.94724 1.014866 0.457414 0.787327151 3.25846 0.813019 2.200-14 2.909108 0960754 3.190-11 31 36 35
52.30263 1.112631 0.432879 0000437327 0.433091 0.455733 0 0.267344 0.904945 0 103 103 103
53.11653 0.90193 0.361646 3.30-05 1943041 0496503 0 1.452485 0.547575 0 102 116 114
47.46667 1.142032 0.488555 0009011311 3.081512 0.857538 0 2.87937 0.85164 0 62 67 67
18.10017 1.119296 0.299691 0095124695 1617911 0.446145 0.0002908 2.246832 0578947 1970-05 12 12 12
42.50936 0.962406 0.370927 0510699563 2836113 0.724586 3920-08 3161361 0.881849 1.330-08 21 22 22
61.44578 1.095854 0.396579 013030691 2.451282 0.68869 6230-09 2.131829 0.74977 6410-08 22 24 26
48.74591 0.672606 0.454125 1.036-06 1.329379 0.349184 2850-08 1142093 0302527 0.006284216 26 20 26
44.40298 1.167611 0.372884 0.001632762 3468224 0.44042 0 2.93251 0.500255 0 32 35 37
48.76033 1.014552 0.303548 0650464916 0.97276 0.340762 0.0345908 1.026278 0.288379 0.201064286 40 43 42
33.69231 0.941139 0.884305 0.206054688 1.833408 1.178599 0.0136719 1.933138 1.566201 0.088752455 11 11 11
30.6163 1.057389 0.447895 0423419308 2.443185 0.80538 2630-09 2.379748 0.58095 1.23E-09 20 22 22
42.72044 0.588984 0.431925 1.700-05 0838006 0.491821 0.0245361 0.423029 0958062 0.000610352 14 14 14
49.83713 0.920442 0.311904 0006624735 0.892288 0271447 1.330-15 0.295712 1.0329 3.570-08 40 40 40
61.02362 1.290904 0.353771 1800-06 3140921 0.546255 0 2.441112 0599982 1.200-14 32 35 35
31.10647 0.622527 0.379856 1560-07 0764861 0.24757 5.710-07 0711202 0.52512 000068081 20 20 20
61.22449 1.352603 0.55751 0000570644 3000337 0.625155 3.350-14 274531 0596008 1.580-14 30 30 31
37.88969 1.191075 0.373938 0013218783 3.972464 0.640949 3020-11 3033952 0901157 3.250-07 17 20 19
42.85714 1.040839 0.319976 1 2.175947 0.71009 00002261 2.069744 0.669801 0000177336 10 12 12
40.84084 1.284868 0.298604 4.930-05 4767639 0457855 3.33E-14 4.94648 0.055547 4.830-13 19 19 19
32.92683 0.952533 0.353901 0700480746 3.459247 0.833595 1.040-14 2866455 0.815351 2.930-13 34 36 36
24.6473 0897385 0.315468 0.006546787 0.871611 0.355929 0.00078 0.904995 0.38123 0.047402976 35 36 38
39.18269 0.654795 0.323534 6.920-11 0863964 0.268318 9.840-05 0.688005 0.338425 1.01E-08 29 28 28
45.63591 0.480795 0.458112 1.130-11 0188748 0.806206 7.330-15 0.155989 0.921258 7.970-14 28 26 26
48.75346 0.627942 0.422765 0 1.134407 0.298218 288-07 1.558928 0.401822 2.090-16 99 103 102
gi|157074106 lamin B1 [Bos taurus] 4027304 1125927 0.427507
gi|27806907 clusterin [Bos taurus] 31.89006 0.994265 0459222
gi|27806257 collagen, type 1, alpha 2 [Bos taurus] 42.0088 0.572324 0.327987
gi|164450489 AE binding protein 1 [Bos taurus] 22.82051 0791002 0.481149
gi|61828365 PREDICTED: similar to Tropomyosin 3 isoform 1 [Bos taurus] 6572581 1.203989 0.533307
gi|156718112 latent transforming growth factor beta binding protein 1 [Bos taurus] 22.34679 0477334 0.39839
gi|27807207 plasminogen activator inhibitor type 1, member 2 [Bos taurus] 34.50882 0.747163 0.406881
gi|27806853 lumican [Bos taurus] 41.22807 0.957583 0.452189
gil115498012 glycogen phosphorylase, liver [Bos taurus) 3184499 0.935102 0.333769
gi]82751849 Parkinson disease (autosomal recessive, early onset) 7 [Bos taurus) 5978836 1167313 0.482983
gil27807437 matrix metalloproteinase 9 [Bos taurus] 3244382 0845298 0.356417
gi|76253900 GDP dissociation inhibitor 2 [Bos taurus] 4874157 1 008134 0404379
gil155371895 sema domain, immunoglobulin domain (1g), short basic domain. secreted, (semaphon) 3C [Bus taurus] 3475366 0.656269 041703
gir76682880 PREDICTED similar to nucleolin-related protein NRP isoform 1 [Bos taurus] 3972222 1146393 0.255354
gi]38566696 serum amyloid A 3 [Bos taurus] 72.51908 0448264 0.570317
gi27806781 vitrin [Bos taurus] 32.97546 0799637 0423876
gil156121245 insulin-like growth factor binding protein 7 [Bos taurus] 5567376 0.774017 0.289178
gi|78369242 alpha-actinin [Bos taurus] 3733184 1.397087 0398414
gi|119903231 PREDICTED similar to lysyl oxidase-like 3 protein [Bos taurus] 29.65426 0872476 0356122
gi|119903133 PREDICTED hypothetical protein [Bos taurus] 37.06294 0.673846 0.235276
gi|77736401 thrombospondin 4 [Bos taurus] 28.72008 0946067 0666918
gi|120474983 annexin A5 [Bos taurus] 54.91713 091483 0.369929
gi27805949 inhibin beta A [Bos taurus] 3764706 1.07804 0.333489
gij40254 806 heat shock 70kDa protein 1A [Bos taurus] 3588144 1.09679 0438155
gil1 19895885 PREDICTED similar to EGF4ike repeats and discoidin I-like domains 3 [Bos taurus] 2645161 0.773023 0.352321
gi|164420731 transaldolase 1 [Bos taurus] 52.22552 1.238868 0.37494
gi|155371863 histone cluster 1, Hld [Bos taurus] 6063349 0.851828 0.328314
gi|168804008 tubulin, alpha, ubiquitous [Bos taurus] 42.79379 0.965033 0.308589
gil156120479 aldolase A [Bos taurus] 39.83516 1.456509 0.8686
gil1 14051756 heterogeneous nuclear ribonucleoprotein A2/B1 [Bos taurus] 43.10851 1.261221 0.429936
gil27806489 proenkephalin [Bos taurus] 60.8365 0.900143 0.625208
gil1 14053121 reticulocalbin 3, EF-hand calcium binding domain [Bos taurus] 36.89024 0952057 0.602992
gi]27806085 peroxiredoxin 4 [Bos taurus] 56.93431 0.88498 0258455
gil115497328 procollagen C-endopeptidase enhancer 2 [Bos taurus] 39.06346 0.70963 0.290526
gi|119912215 PREDICTED: hypothetical protein isoform 2 [Bos taurus] 1933682 1.171852 0.346696
gi]94966781 eukaryotic translation elongation factor 1 gamma [Bos taurus] 2888364 1.172907 0.475952
gi[27806351 ezrin [Bos taurus] 36.8881 0.965646 0.296138
gi|119918578 PREDICTED: smilar to vinculin isoform meta-VCL isoform 1 [Bos taurus] 361552 1.206622 0.426321
gi|119331178 SPARC related modular calcium binding 1 [Bos taurus] 29.7235 0833238 0.325341
gi[76253701 decorin [Bos taurus] 39.72222 0.909011 0.434115
gil1 14052653 procollagen C-endopeptidase enhancer [Bos taurus] 40.79823 0.727481 0.485901
gil68299807 eukaryobc translation elongation factor 1 alpha 1 [Bos taurus] 43.93939 0.903605 0.225695
gi]115496892 non-metastatic cells 2, protein (NM23B) expressed in [Bos taurus] 5855263 1.066869 0.557906
gi76670918 PREDICTED: similar to histone H4 [Bos taurus] 70.87379 0.779528 0.307805
gil115495641 aldo-keto reductase family 1, member Al (aldehyde reductase) [Bos taurus] 49.30789 1.181813 0.431983
gil154707890 lysyl oxidase-like 2 [Bos taurus] 2209302 0.801612 0.381171
gill14051505 serpin peptdase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1) [Bos taurus] 354067 0633137 0.478665
gil114051908 FK506 binding protein 10, 65 kDa [Bos taurus] 3859348 0.745777 0700688
gi|118601868 heat shock 90kDa protein 1, beta [Bos taurus 4323204 1.179926 0432622
gi|119900887 PREDICTED: similar to collagen XXVil proalpha 1 chain precursor; preproprotein [Bos taurus] 24.28717 0711018 0.35738
gi|94966765 glucose phosphate isomerase [Bos taurus] 26.75045 1.337168 0.39997
gi|30794292 lactotransferrin [Bos taurus] 27.11864 0.372085 0.501949
gi|119917101 PREDICTED: hypothetical protein isoform 6 [Bos taurus] 25.71042 1.018847 0.342963
gil1 15496400 dthydropyrimidinase-like 2[Bos taurus] 23.07692 1.099276 0.41174
gil15707396 reticulocalbin 1, EF-hand calcium binding domain [Bos taurus] 37.16012 0.930906 0.492291
gil27806197 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide [Bos taurus] 06.47059 1.278383 0.321317
gi|27805991 latent transforming growth factor beta binding protein 2 [Bos taurus] 1477331 0.540961 0606565
gi|27806623 fibromodulin [Bos taurus] 28 0859221 0.363144
gil119887291 PREDICTED similar to peroxidasin homolog [Bos taurus] 175049 0770344 0.231358
gil1 19915902 PREDICTED similar to Thioredoxin domain-containing protein 5 precursor (Thioredoxin-like protein p46) (Endoplasmic reboutum protein ERpd6) isoform 1 [Bust 3971292 0.997541 0.50088
gil78369310 stress4nduced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein) [Bos taurus] 290976 1.506858 0.390306
gil119892775 PREDICTED similar to myosin. heavy polypeptide 9. non-muscle [Bos taurus] 22.79898 1202307 0.357698
gi|41386727 protein kinase C substrate 80K-H [Bos taurus] 19.88743 1.219497 0.313394
gi|1 19908681 PREDICTED: similar to superficial zone protein [Bos taurus] 23.88721 0.632282 0.948914
gi27805823 dermatan sulfate proteoglycan 3 [Bos taurus] 24.29907 0.778807 0270498
gi|119888620 PREDICTED: similar to alpha 1 type XVI collagen [Bos taurus] 23.00062 0.761568 0.540382
gil139949116 slit-like 2 [Bos taurus] 2734027 1052909 0.806197
gi 27805983 leukocyte cell-derived chemotaxin 2 [Bos taurus] 5761589 0.478727 0.264371
gil27806317 annexin A6 [Bos taurus] 48.62385 1-333883 0.500675
gil148223509 osteoprotegerin [Bos taurus] 3706468 0765069 033217t
gi|119917871 PREDICTED: similar to serin protease with IGF-binding motif [Bos taurus] 2507375 0.676009 0208364
gi|119903961 PREDICTED similar to Protein disulfide isomerase associated 6 isoform 7 [Bos taurus] 3395932 0.964435 0657748
gi|31341666 mannosidase, alpha, class 2B, member 1 [Bos taurus] 2102102 082622 0.327152
gil1 15496067 nucleobindn 2 [Bos taurus] 41.20482 0916578 0.272702
gi|30794358 versican [8os taurus] 12.18574 1.108672 0436888
gi76613223 PREDICTED: similar to chitiase [Bos taurus} 3255814 0.396545 0195772
gi77736275 calumenin [Bos taurus] 39.36508 0.969705 0.682093
gil28461273 glutathione S-transferase M1 [Bos taurus] 55.9633 1.308305 0.483219
gil1 16004023 phosphoglucomutase 1 [Bos taurus] 24.91103 1.026151 0.396244
gil1 15497628 reticulocalbin 2, EF-hand calcium binding domain [Bos taurus] 29653 1.162354 0.492613
gi]27807349 complement component 1 inhibitor [Bos taurus] 22.86325 1132734 0.364022






















































































































































































































































gi|78369510 ribonuclease/angiogenin inhibitor 1 [Bos taurus]
gill 18151330 tyrosine 3-monooxygenaseltryptophan 5-monooxygenase activation protein, theta polypeptide [Bos taurus]
gi[41386719 milk fat globule-EGF factor 8 protein [Bos taurus]
gi[119919898 PREDICTED: hypothetical protein [Bos taurus]
gi|2780 6561 lactate dehydrogenase B [Bos taurus]
gil156121049 dimethylarginine dimethylaminohydrolase 1 [Bos taurus]
gil1 15497174 3-phosphoadenosine 5'-phosphosulfate synthase 2 [Bos taurus]
gi|119895049 PREDICTED: similar to Lamin 92 [Bos taurus]
gi76635416 PREDICTED: similar to coat protein delta-cop isoform 1 [Bos taurus]
gil12927
7
510 superoxide dismutase 3, extracellular [Bos taurus]
gil27806401 secreted phosphoprotein 1 [Bos taurus]
gi|149773543 steroid-sensitive protein 1 [Bos taurus]
gi|27806679 colony stimulating factor 1 (macrophage) [Bos taurus]
gi|51491841 transketolase [Bos taurus]
gi|119913642 PREDICTED: similar to KIAA0051 [Bos taurus]
gi]119908661 PREDICTED: similar to Laminin gamma-i chain precursor (Laminin 62 chain) [Bos taurus]
gi]78369298 stromal cell derived factor 4 [Bos taurus]
gi|7581294 0 phosphatidylethanolamine binding protein [Bos taurus]
gill1405
27 3
1 tubulin, beta polypeptide [Bos taurus]
gi|27806739 apolipoprotein E [Bos taurus]
gi|27 80864 D peptidoglycan recognition protein 1 [Bos taurus]
gil27807167 peroxiredoxin 6 [Bos taurus]
gil1 14053333 fibrinogen-like 2 [Bos taurus]
gi|82697375 histone H2B-like [Bos taurus]





PREDICTED: similar to Syncrip protein [Bos taurus]
gi]71037405 heat shock 27kDa protein 1 [Bos taurus]
gi|1 16003813 amyloid beta A4 protein [Bos taurus)
gi|119901059 PREDICTED: similar to COL9A1 protein, partial [Bos taurus]
giJ76611607 PREDICTED: similar to C1QC protein isoform 1 [Bos taurus]
gi[75832065 TIMP metatlopeptidase inhibitor 2 [Bos taurus]
gi|1 19896006 PREDICTED: similar to mannosidase, alpha, class 2A, member 1 [Bos taurus]
gi|148230364 heterogeneous nuclear ribonucleoprotein D [Bos taurus]
gi27805977 keratin 10 [Bos taurus]
gi]27806095 protein S, alpha [Bos taurus]
gil119900517 PREDICTED: similar to KtAAl027 protein [Bos taurus)
gil66792902 vanin 1 [Bos taurus]
gil1 19917901 PREDICTED: similar to Carboxypeptidase X 2 (M14 family) [Bos taurus]
gil125991942 Sec23 homolog A [Bos taurus]
gi|84579853 lipopolysaccharide binding protein [Bos taurus]
gil1 13205970 glial fibrillary acidic protein [Bos taurus]
gi[27806541 matrix metalloproteinase 1 [Bos taurus]
gi[78369684 platelet-derived growth factor receptor-like protein [Bos taurus]
gi]27807517 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6 [Bos taurus]
gil1 15496928 EGF-containing fibuhn-ike extracellular matrix protein 2 [Bos taurus]
gi]95006989 ribonuclease, RNase A family, 4 [Bos taurus]
gi|28875793 thrombospondin 2 [Bos taurus]
gi|27806449 dystroglycan 1 [Bos taurus]
gi62751777 cofilo 1 (non-muscle) [Bos taurus]
giJ27807469 peroxiredoxin 2 [Bos taurus)
gi|77404209 eukaryotic translation initiation factor 4A2 [Bos taurus]
gil11405112
9 
retinoic acid receptor responder (tazarotene induced) 2 [Bos taurus]
gil156121
3 27 
galectin 3 [Bos taurus]
gi27806813 pleiotrophin [Bos taurus]
gi|95147666 periostin, osteoblast specific factor [Bos taurus]
gi|119919662 PREDICTED: similar to LOC539445 protein [Bos taurus]
gi|77735541 valosin-containing protein [Bos taurus]
gi|60592767 ribosomal protein, large, PO [Bos taurus]
giJ77735461 canopy 4 homolog [Bos taurus]
gil27806829 osteoglycir [Bos taurus]





coatomer protein complex, subunit alpha [Bos taurus]
gij61808545 PREDICTED: similar to histone H2A isoform 1 [Bos taurus]





44 eukaryotic translation initiation factor 5A [Bos taurus]
gi|75832045 HLA-B associated transcript 1 [Bos taurus]
gi|41386707 vascular cell adhesion molecule 1 [Bos taurus]
gil1 19915070 PREDICTED: similar to CUB and EGF containing protein [Bos taurus]
gil134085613 alpha 1 type XVIII collagen [Bos taurus]
gi|1 15497294 canopy 2 homolog [Bos taurus]
gilo14053135 proteasome (prosome, macropain) subunit, alpha type, 6 [Bos taurus]
gil1 19894807 PREDICTED: interleukin enhancer binding factor 3 isoform 2 [Bos taurus]
gil164518
97
8 diazepam binding inhibitor [Bos taurus]
gi|73853762 annexin I [Bos taurus]
gill14051157 complement component 1, q subcomponent, B chain [Bos taurus]
gi|7804549 1 fascin homolog 1, actin-bundling protein [Bos taurus]
gi|78045555 acidic (leucine-rich) nuclear phosphoprotein 32 family, member B [Bos taurus]
gi|157427782 insulin-like growth factor binding protein 5 [Bos taurus]
gi]27807007 insulin-like growth factor binding protein 3 [Bos taurus]
gi|129270171 gremlin-1 [Bos taurus]
gi|1 19926480 PREDICTED: similar to Meteorin, glial cell differentiation regulator-like [Bos taurus]
gi78042524 thioredoxin domain containing 4 (endoplasmic reticulum) [Bos taurus]
29.38597 1.126192 0.324758 0.300595249 2.622966 0.510622
55.91837 1.199329 0.39451 0101012132 3005314 0.519199
33.48946 D.79112 0.202064 7.496-06 0.640309 0364921
26.28571 0.775134 0.46563 0011395109 0.944692 0.50241
47.60479 1.508136 0.342936 0.000392235 4.069971 0942095
39.29825 1.237758 0.3963 0.156403106 3.70924 0.5117
31.21951 0.949886 0.251807 0.439653794 2.902697 0.571167
35.92715 1.020326 0.212387 0.720053349 1.944109 0.311161
27.0057 1.193124 0.247001 0.091502996 3.559594 0.440376
41.49378 0.926996 0.387711 0.376073329 0.701524 0.257354
45.68345 0.720812 0.458792 0.000291367 2.779999 0.444469
20.96436 0.605496 0.607317 0056229617 1.622905 0.402909
27.07581 2.070581 0.802553 0001457649 070331 0.456362
27.60835 1.028374 0.531252 0.920956016 4.020656 0.641951
22.83019 1.436444 0.503329 0.033195974 3797069 0.730459
21.33858 0.926587 0.285185 0392433702 0903793 0363619
32.67606 1.012411 0.517378 0.92627127 1.250975 0444424
49.73262 1.099546 0.353673 0116220906 2.426716 0.401752
22.2973 1.038783 0.49663 0.759217249 2.469264 0.572251
45.88608 0.733549 0.252604 0.000341695 0.704996 0.346392
46.31579 0.639251 0.33389 0.000409542 0792692 0.299915
48.66071 1.323234 0.296632 000390625 4067222 0.399759
44.89796 0.749614 0.318248 0.013672157 0.396909 0629676
78.57143 0.778357 0.309967 0.0359793 1.529371 0213163
19.6281 1.617291 0.439488 3.916-09 3.6169 0.629535
31.11702 0.824457 0.443684 0299776229 2.991697 0.520536
41.66667 0.930182 0.428426 0.517012213 3426523 0670677
15.68345 1.404063 0.335795 0.002337023 0.975401 0.270109
19.71253 0.699285 0.338444 9.736-05 1.053999 0.397699
25.36765 0.734554 0.67762 0.054991937 1.132333 0.506994
33.18182 0.65191 0.497802 3.996-05 1.974962 1141225
18.42795 0.999529 0.28011 0.997929406 0.999099 0.355969
35.62092 1.082545 0.371005 0.643733331 2.312701 0.562955
23.95437 0.714804 0.141639 0.000401162 0.599967 0.423997
22.66667 0.691925 0.320239 0.125 0.496097 0.097204
22.2747 0.848161 0.076552 0033191021 1.644241 0.656075
17.64706 0.405888 0.843808 1.756-09 1.392702 0.34499
26.51715 0.686724 0.290136 0.014026424 0.973799 0.077667
1809896 1.12328 0.277486 0.245595267 2.345791 0229969
23.07692 0.248446 0.43585 1.966-05 0.424693 0.313313
52.1028 1.142308 0.609279 0.517790539 3.051097 0.456294
26.01279 0.421773 0.29099 0.000139795 0.947792 0.321252
36.8 0.980503 0.400557 0.842916695 1.023016 0.299
31.21693 1.448994 0.534954 0.391170505 2.369377 0.703193
31.37698 0.776944 0.283558 0.045796595 0.906221 0.29523
59.86394 0.470833 0.438507 4.976-11 0.75013 0.403742
13.84615 0.843256 0.307429 0.059936619 1.339209 0.502969
14.07821 0.874871 0.407648 01159614 0947697 0.425033
71.08434 1.299646 0.549125 0072047296 3.503711 0.532703
39.19598 1.246076 0.520799 0.156919757 3.716369 0.697934
21.86732 1.360362 0.492577 0.01996463 3.009031 0.617036
50 0.588901 0.517981 0.000100372 0.619703 0.599036
36.60377 1.050061 0.481141 0.473661304 2.929179 0.742356
38.69048 0.458214 0.616786 1236-06 1.57945 0.397929
23.62003 0.620313 0.577812 0.056077025 1.377917 0.137072
16.21271 1.032594 0.352598 0.77993524 4.090764 0.960567
28.0397 1.600285 0.979663 0015625 2.430097 0.402511
46.22642 0.939665 0.34456 0.521179669 2.692939 0.68635
12.5523 0.961306 0.529227 0.971797147 2.619545 0.902403
34.11371 1.043169 0.513296 0.659518694 1.094649 0420726
22.91667 0.68501 0.310794 0017260013 099271 0.251514
20.75163 1.102223 0.276264 0.315996319 2.719342 0416479
62.30769 0.694453 0.450515 0003090092 0973912 0.060754
42.67783 1.064069 0.347332 0.637719162 2.676727 0.590959
24.02597 0.993644 1.03353 0.990709602 2.223171 1.207639
28.27103 1.04593 0.454598 0.675319797 3.090223 0959097
20.43302 0.896205 0.529789 0.59039496 0.455245 0.197909
10.2719 0.702824 0.509628 0.058640939 0.99664 0376304
19.15456 1.108286 0.310159 03426475 0963963 0.209996
33.51648 0.901592 0.387093 0.439693459 2.414472 0.569202
31.30081 1.161236 0.344706 0147267129 2524294 0.693279
17.3913 1.005649 0.464716 0.963199927 2.214517 052779
79.31035 1.461292 0.433004 0.000649227 4.737242 0.6969
36.12717 0.760038 0.297116 004109943 1193621 0.197493
22.67206 0.661922 0.425196 5 576-07 1013925 0.390959
22.10953 1.222581 0.434414 0.02120626 2.319909 0.44932
34.09962 1.171976 0.326434 0.111557495 3.344199 0.549291
49.07749 0.954689 0.404841 0.706974927 0.917127 0.419721
35.05155 0.746612 0.194963 0.000490913 1.504305 0.199503
63.58696 0.752901 0.895 0.45527291 0.954642 0.354793


































































































































































gi|77736203 malate dehydrogenase 1, NAD (soluble) [Bos taurus]
gi27806415 scinderin [Bos taurus]
gi56119114 purine nucleoside phosphorylase [Bos taurus]
gi]77736471 SH3 domain binding glutamic acid-rich protein like 3 (Bos taurus]
gi]45429977 staphylococcal nuclease and tudor domain containing 1 {Bos taurus]
gil28603774 Rho GDP dissociation i hibitor (GDI) alpha [Bos taurus]
gil62460494 hemoglobin, gamma [Bos taurus]
gi|77735429 proteasome alpha 3 subunit {Bos taurus]
gi|62460582 complement component 1. q subcomponent, Achain [Bos taurus]
gi|156523068 ubiquitin-acvating enzyme E1 [Bos taurus]
gi61888850 adenylate kinase 1 (Bos taurus]
gi(119914274 PREDICTED hypothetical protein isoform 1 [Bos taurus]
gi|27805999 matrix metalloproteinase 13 [Bos taurus]
gi157074098 leprecan 1 [Bos taurus]
gi1156120501 heat shock 70kD protein binding protein [Bos taurus]
gi115497728 aconitase 1, soluble (Bos taurus]
gil119907132 PREDICTED similar to Hyout protein [Bos taurus]
gi77735539 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide il [Bos taurus]
gil119901144 PREDICTED: similar to malate dehydrogenase decarboxylase (NADP+) (Bos taurus]
gil157954420 angiopoietin-like 2 [Bos taurus]
gi2780750
3 
ribosomal protein S27a [Bos taurus]
gill 14052264 phosphoglucomutase 3 [Bos taurus]
gi|139948301 branched chain aminotransterase 1, cytosolic [Bos taurus]
gi28603770 capping protein (actin filament) muscle Z-line, beta (Bns taurus]
gi]88853816 superoxide dismutase 2, mitochondrial [Bos taurus]
gi|119908402 PREDICTED: similar to Calsyntenin-1, partial [Bos taurus]
gi|27806673 cathepsin L2 [Bos taurus]
gi|119919488 PREDICTED: similar to cathepsin 0 isoform 1 [Bos taurus]
gil119894607 PREDICTED similar to peptidoglycan recognition protein L (Bos taurus]
gi]77404434 hypoxanthine phosphoribosyltransferase 1 [Bos taurus]
gil27806553 microtubule-associated protein 4 [Bos taurus]
gil27807445 peroxiredoxin 5 precursor [Bos taurus]
gil27806671 cathepsin B [Bos taurus]
gi|27807523 ribosomal protein P2 [Bos taurus]
gi|76610312 PREDICTED: similar to neuropilin 2 isoform 8 [Bos taurus]
gil27806637 fibrillin 1 (Bos taurus]
gir27807209 alpha-2-plasmin inhibitor [Bos taurus]
gi}83715992 coatomer protein complex, subunit gamma 1 [Bos taurus]
gi|27806139 secreted frizzled-related protein 1 [Bos taurus)
gil119919689 PREDICTED: similar to RNA binding motif protein, X-linked isoform 5 [Bos taurus]
gill 15497086 cortactin (Bos taurus]
gi|134085635 glyoxalase I [Bos taurus]
gil1 19890932 PREDICTED similar to Laminin beta-1 chain precursor (Laminin B1 chain) [Bos taurus]
gil56710317 keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types) (Bos taurus]
gi|76620378 PREDICTED: similar to cytokine-like protein C17 [Bos taurus]
gi|155372035 nidogen 1 [Bos taurus]
gi|75832090 isocitrate dehydrogenase 1 (NADP+), soluble [Bos taurus]
gi|27806447 prosaposin [Bos taurus]
gi|78369645 SH3 domain binding glutamic acid-rich protein like [Bos taurus]
gi|1 15494984 apolipoprotein 0 [Bos taurus]
gi|119922764 PREDICTED: similar to MSTP006 [Bos taurus]
gil153791208 immunoglobulin superfamily containing leucine-rich repeat [Bos taurus]
gil28461189 lectin, galactoside-binding, soluble, 1 (galectin 1)[Bostaurus]
gi]29135329 glutathione S-transferase pi [Bs taurus]
gi|1 15497078 splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing factor) [Bos taurus]
gi|119924055 PREDICTED: similar to p167 isoform 4 {Bos taurus]
gi|119879765 PREDICTED similar to eukaryotic translation initiation factor 4 gamma, 1 [Bos taurus]
gi|1 16004039 peptidylprolyl isomerase C (cyclophilin C) [Bos taurus]
gil27806783 thioredoxin [Bos taurus]
gi]78369458 proteasome (prosome, macropain) subunit, alpha type, 1 {Bos taurus]
gil1 19908208 PREDICTED: similar to Calpain 2, (m/l1) large subunit isoform 3 [Bos taurus]
gi|77736071 heterogeneous nuclear ibonucleoprotein K (Bos taurus]
gi|84000347 interleukin enhancer binding factor 2 [Bos taurus]
gi|41386760 CD14 antigen [Bos taurus]
gi|115495555 endoplasmic reticulum protein 29 [Bos taurus]
gi|78369232 phosphorylase, glycogen, brain [Bos taurus]
gi|27806081 peroxiredoxin 1 [Bos taurus]
gi|77736371 actin related protein 203 complex subunit 2 [Bos taurus]
gi|41386798 poly(A) binding protein, cytoplasmic 1 [Bos taurus]
gi}61888866 tropomyosin 1 alpha chain [Bos taurus]
gi|78042498 phosphoglycerate dehydrogenase [Bos taurus]
gil27806751 alpha-2-HS-glycoprotein [Bos taurus]
gir77736343 ErbB3-binding protein 1 [Bos taurus]
gi|27807377 glutamic-oxaloacetc transaminase 2, mitochondrial (aspartate aminotransferase 2) [Bos taurus]
gi]62177164 tumor protein, translationally-controlled 1 [Bos taurus]
gij41386729 high-mobility group box 1 [Bos taurus]
gi(164420709 retinol binding protein 4, plasma [Bos taurus]
gi]27806487 serine (or cysteine) proteinase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1(Bos taurus]
gi|119924945 PREDICTED: similar to agrin [Bos taurus]
gi]82524405 US01 homolog, vesicle docking protein [Bos taurus]
gi|76651183 PREDICTED similar to histone H3 [Bos taurus)









































































































































































































































































































































gi|119912531 PREDICTED: similar to mannose receptor, C type 2 {Bos taurus]
gi|114051730 cell growth regulator with EF-hand domain 1 [Bos taurus]
gi|77735425 proteasome alpha 7 subunit [Bos taurus]
gi|119905546 PREDICTED: similar to Cu/Zn superoxide dismutase [Bos taurus]
gil27807147 C-type lectin domain family 3 member A [Bos taurus]
gil119892706 PREDICTED similar to chondroitn 4-0-sulfotransferase [Bos taurus]
gil1 19906216 PREDICTED: similar to Eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) isoform 1 [Bos taurus]
gi|148232266 fibulin 1 [Bos taurus]
gi|166706929 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) [Bos taurus]
gil1 15497888 nuclear distribution gene C homolog [Bos taurus]
gi]62460514 angiopoietin-like 7 [Bos taurus]
gi]84370163 SET translocation (myeloid leukemia-associated) [Bos taurus]
gi|62751847 ribosomal protein LlOa [Bos taurus]
gi|119919151 PREDICTED similar to AHNAK nucleoprotein isoform 1 [Bos taurus]
gil14052350 WD repeat domain 1 [Bos taurus]
gi|125630701 collagen triple helix repeat containing 1(Bos taurus]
gi|76613946 PREDICTED: similar to Histone H1.5 [Bostaurus]
gill 19904280 PREDICTED: similar to collagen type 5 alpha 1 [Bos taurus]
gill 16003917 far upstream element-binding protein [Bos taurus]
gil148228060 stem cell growth factor [Bos taurus]
gil28461187 myosin, light chain 6, alkali, smooth muscle and non-muscle [Bos taurus]
gil134085825 carboxypeptidase Z [Bos taurus]





ribosomal protein S20 [Bos taurus]
gil1 19920777 PREDICTED: similar to collagen, type IX, alpha 2 [Bos taurus]
gi|157785567 calnexin [Bos taurus]
gi|125991882 phospholipase C, delta 1 [Bos taurus]
gill 14326274 crystallin, zeta (quinone reductase) [Bos taurus]
gi77735583 S-adenosylhomocysteine hydrolase [Bos taurus]
gil119923009 PREDICTED similar to put. HMG-17 protein [Bos taurus]
gi|119907521 PREDICTED: similar to NuMA protein [Bos taurus]
gil158937293 fibroblast growth factor receptor 1 [Bos taurus]
gil114052384 heterogeneous nuclear ribonucleoprotein Al [Bos taurus]
gi]77736141 extracellular matrix protein 2, female organ and adipocyte specific [Bos taurus]
gi|27807389 bucentaur [Bos taurus]
gil27807481 ubiquitin-like protein SMT3B [Bos taurus]
gir27807075 S100 calcium-binding protein A4 [Bos taurus]
gill
226 92 55 9 
oncostatin M receptor [Bos taurus]
gi]91680535 proteasome activator subunit 1 [Bos taurus]
gil76633778 PREDICTED: similar to syndecan 4 [Bos taurus]
gi]45430017 apolipoprotein A- binding protein [Bos taurus]
gi|164448628 carboxypeptidase X [Bos taurus]
gi|1 15496724 heat shock protein, alpha-crystallin-related, B6 [Bos taurus]
gil27807275 matrix Gta protein [Bos taurus]
gi|155372143 arginine-rich. mutated in early stage tumors [Bos taurus]
gi|164420791 transforming growth factor, beta 2 [Bos taurus]
gil28603812 epsilon subunit of coatomer protein complex [Bos taurus]
gi|119917542 PREDICTED: similar to tolloid-like 2 protein isoform 2 [Bos taurus]
gi|27806419 seryl-tRNA synthetase [Bos taurus]
gi|78042520 eukaryotic translation initiation factor 48 [Bos taurus]
gi|61097917 cystatin E/M [Bos taurus]
gil27806743 alpha-1-microglobuhn/bikunin [Bos taurus]
gill 14051347 cytidine monophosphate (UMP-CMP) kinase 1, cytosolic [Bos taurus]
gil27806279 caldesmon 1 [Bos taurus]
gi|29135295 aspartate aminotransferase 1 [Bos taurus]
gi|155371881 alanyt-tRNA synthetase [Bos taurus]
gill 19908206 PREDICTED: hypothetical protein [Bos taurus]
gi|1 15496906 acidic ([eucine-rich) nuclear phosphoprotein 32 family, member E [Bos taurus]
gill 19901449 PREDICTED: similar to PDNP1 [Bos taurus]
gil 114051291 tissue specific transplantation antigen P35B [Bos taurus]
gi|7804256 4 CNDP dipeptidase 2 [Bos taurus]
gil116004251 granulin [Bos taurus]
gil76614948 PREDICTED similar to pepbdyl-Pro cis trans isomerase isoform 1 [Bos taurus]
gi]77736257 protein phosphatase 1, catalytic subunit, beta isoform [Bos taurus]
gi|l 19909677 PREDICTED: similar to MGC84382 protein [Bos taurus]
gi|164448698 chaperonin containing TCP1, subunit 3 [Bos taurus]
gi|165905571 leucine aminopeptidase 3 [Bos taurus]
gi|156120555 glyoxalase domain containing 4 [Bos taurus]
gi|123858766 prefoldin subunit 2 [Bos taurus]





complement component 1, r subcomponent [Bos taurus]
gil148233312 dermatan 4 sulfotransferase 1 [Bos taurus]
giJ77736509 S-phase kinase-associated protein 1 [Bos taurus]
gil115495701 pentraxin 3 [Bos taurus]
gi|1 16812902 hemoglobin alpha chain [Bos taurus]
gil156120327 thrombospondin 3 [Bos taurus
gi|27806825 peptidylglycine alpha-amidating monooxygenase [Bos taurus]
gi|154152039 scrapie responsive protein 1 [Bos taurus]
gil119904972 PREDICTED: similar to Collagen alpha-2(iv) chain [Bos taurus]
gi|77735597 FK506-binding protein 4 [Bos taurus]
gil 19914266 PREDICTED: similar to cartilage-associated protein (CASP) [Bos taurus]







































































































































































































































































































































gi|115497736 olfactomedin-like 3 [Bos taurus]
gi|119888815 PREDICTED: similar to GALE protein isoform 2 [Bos taurus]
9184370199 6-phosphogluconolactonase [Bos taurus]
gi82697343 cystatin B (stefin B) [Bos taurus]
gi|29135293 farnesyl diphosphate synthase [Bos taurus]
gi|77736061 NSFLI (p97) cofactor (p47) [Bos taurus]
gi[115495441 hexosaminidase A[Bostaurus
gi[115497820 parvalbumin [Bos taurus]
gil119915943 PREDICTED: similar to serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1 isoform 1 [Bos taurus]
gil149642605 drebrin-like [Bos taurus]
gil119925682 PREDICTED similar to adlican [Bos taurus]
gill 54152127 olfactomedin-tike 21 [Bos taurus]
gi83035095 high-mobility group box 2 [Bos taurus]
gi|27806555 legumain [Bos taurus]
gi|122692375 hypothetical protein LOC783871 [Bos taurus]
gi|27805927 heat shock lOkDa protein 1 [Bos taurus]
gi|119901068 PREDICTED: similar to Collagen, type IX, alpha 1. partial [Bos taurus]
gi|27805981 ribosomal protein SA [Bos taurus]
gi77735725 cathepsin H [Bos taurus]
gi|84000203 esophageal cancer related gene 4 protein [Bos taurus]
gil1 19895711 PREDICTED similar to cytokine-like protein ZCYTD7 isoform 1 [Bos taurus]
gil119914936 PREDICTED similar to histone Hlx [Bos taurus]
gil27806677 connective tissue growth factor [Bos taurus]
gil119901084 PREDICTED: similar to CD109 [Bos taurus]
gi|119914223 PREDICTED: similar to KIAA2019 protein [Bos taurus]
gi|115497124 asparagine synthetase [Bos taurus]
gi|77735669 lysyl-tRNA synthetase [Bos taurus]
gil119907290 PREDICTED: hypothetical protein [Bos taurus]
gil119896208 PREDICTED: similar to PRDX3 protein [Bos taurus]
gil119919315 PREDICTED: similar to latent transforming growth factor beta binding protein 3 [Bos taurus]
gi[78045531 aspartyl-tRNA synthetase [Bos taurus]
gi|114051185 programmed cell death 5 [Bos taurus]
gij149773586 lectin, mannose-binding, 1 [Bos taurus]
gi]77736560 stathmin l/oncoprotein 18 [Bos taurus]
gi[77736489 high-mobility group nucleosome binding domain 1 [Bos taurus]
gi|84000165 complementfactor I[8os taurus]
gil119919951 PREDICTED: similar to glucose-6-phosphate dehydrogenase G6PD [Bos taurus]
gil27805805 fatty acid binding protein 5 [Bos taurus]
gi[77735927 3-hydroxybutyrate dehydrogenase, type 2 [Bos taurus]
gi1149642873 hyaluronan and proteoglycan link protein 3 [Bos taurus]
gil1 15432055 tyrosine 3-monooxygenaseltryptophan 5-monooxygenase activation protein, beta polypeptide [Bos taurus]
gil1 19906919 PREDICTED: similar to ribosomal protein L6-tike [Bos taurus]
gi|155371891 ADAM metallopeptidase with thrombospondin type I motif, 1 [Bos taurus]
gi|76642911 PREDICTED: similar to IL-104nducible chemokine [Bos taurus]
gill 15496496 matrix-remodelling associated 8 [Bos taurus]
gil27806001 matrix metalloproteinase 14 [Bos taurus]
gil1 14052322 alpha-N-acetytgalactosaminidase [Bos taurus]
gil1 57279907 parathymosin [Bos taurus]
gi]41386699 heat shock 70kDa protein 2 [Bos taurus]
gil115496734 proteasome (prosome, macropain) 260 subunit, non-ATPaose, 5 [Bos taurus]
gi]62461611 ribosomal protein 012 [Bos taurus)
gil119904908 PREDICTED: similar to CDEP [Bos taurus]
gil27806703 CD44 antigen [Bos taurus]
gill 14051578 histidyl-tRNA synthetase [Bos taurus]
gil27805945 inositol(myo)-l(or 4)-monophosphatase 1 [Bos taurus]
gi|14790207 9 glpcyl-tRNA synthetase [Bos taurus]
gi|62460568 eukaryotic translation elongation factor 1 beta 2 [Bos taurus]
gi|169658384 non-metastatic cells 1, protein (NM23A) expressed in [Bos taurus]
gi|155372073 cullin-associated and neddylation-dissociated 1 [Bos taurus]
gi|28461173 elastin [Bos taurus]
gi|157074012 EF-hand domain family, member D2 [Bos taurus)
gi|62751650 poly(rC) binding protein 1 [Bos taurus]
gij47564074 hypothetical protein LOC407769 [Bos taurus]
gill25991938 cadherin 11, type 2 [Bos taurus]
gil119909757 PREDICTED: similar to E-selectin ligand-1 [Bos taurus]
gil119909718 PREDICTED: similar to KIAA0015 [Bos taurus]
gil134085807 capping protein (actin filament) muscle Z-line, alpha 1 [Bos taurus]
gil1 14051892 UDP-N-acteylglucosamine pyrophosphorylase 1 [Bos taurus]
gi|70778754 adenine phosphoribosyltransferase [Bos taurus]
gill 19890624 PREDICTED: similar to insulin responsive sequence DNA binding protein-1 [Bos taurus]
gil62460548 sushi-repeat-containing protein. X-linked 2 [Bos taurus]
gil27806265 leukocyte cell derived chemotaxin 1 precursor [Bos taurus]
gil27806093 endothelial protein C receptor [Bos taurus]
gil 14051423 ubiquitin carboxyl-terminal esterase L1 [Bos taurus]
gi|87196507 unactive progesterone receptor, 23 kD [Bos taurus]
gi[76641864 PREDICTED: hypothetical protein isoform 1 [Bos taurus
gi[27807173 S100 calcium binding protein A10 [Bos taurus]
gill 14053237 GDP-mannose pyrophosphorylase B [Bos taurus]
gi)64370167 ADP-ribosylation factor-like 3 [Bos taurus]
gi176691395 PREDICTED: similar to mammary serum amyloid A3.2 [Bos taurus]
gi[77735515 leukotriene A4 hydrolase [Bos taurus]


















































































































































































































































































































































































































gil157073982 von Willebrand factor A domain containing 1 [Bos taurus]
gil77735861 vacuolar protein sorting 29 [Bos taurus]
gi77735805 leucine zipper transcription factor-like 1 [Bos taurus]
gil27806849 melanoma inhibitory activity [Bos taurus]
gil27806297 biliverdin reductase B (flavin reductase (NADPH)) [Bos taurus]
gil145279649 tumor necrosis factor alpha [Bos taurus]
gi|119888578 PREDICTED: hypothetical protein [Bos taurus]
gi|1 15497946 LanC lantibiotic synthetase component C-like 1 [Bos taurus]
giJ84000233 hypothetical protein LOC517857 [Bos taurus]
gi|77735537 ephrin-A1 [Bos taurus]
gi|119884774 PREDICTED similar to profilin 1 [Bos taurus]
gi|27806161 tissue inhibitor of metalloproteinase 1 [Bos taurus]
gi|1199213 84 PREDICTED similar to Oxysterol-binding protein 1 [Bos taurus]
giJ780
4
2510 haloacid dehalogenase-like hydrolase domain containing 2 [Bos taurus]
gi]77735687 proteasome (prosome, macropain) subunit, beta type 6 [Bos taurus]
gi|41386683 beta-2-microglobulin [Bos taurus]
gi|164414726 thymosin beta 4 [Bos taurus]
gi|27806365 UDP-glucose dehydrogenase [Bos taurus]
gi|77735683 S100 calcium binding protein A2 [Bos taurus]
gi|75812956 GTP binding protein Rabla [Bos taurus]
gi|77735697 threonyl-tRNA synthetase [Bos taurus]
gi| 114053301 receptor accessory protein 5 [Bos taurus]
gil126722829 BCL2-associated athanogene 3 [Bos taurus]
gi|148235020 cold shock domain protein A [Bos taurus]
gil114053087 glutathione S-transferase M3 [Bos taurus]
gi|149642641 D-dopachrome tautomerase [Bos taurus]
gi]77404290 ribosomal protein S3 [Bos taurus]
gil123959772 leucine rich repeat neuronal 1 [Bos taurus]
gil77735465 D component of complement (adipsin) [Bos taurus]
giJ76608584 PREDICTED: similar to KIAA0653 protein isoform 1 [Bos taurus]
gi[27806273 chemokine (C-C motif) ligand 20 [Bos taurus]
gil1 19927320 PREDICTED: similar to laminin B2, partial [Bos taurus]
gij78042550 glutaredoxin 3 [Bos taurus]
gil119879173 PREDICTED: similar to putative MAPK activating protein isoform 2 [Bos taurus]
gil76652407 PREDICTED: similar to Chain A, Crystal Structure Of Human Rangap1-Ubc9 isoform 2 [Bos taurus]





tryptophanyl-tRNA synthetase [Bos taurus]
gi[76635398 PREDICTED: similar to DDX6 protein isoform 1 [Bos taurus]
gil29135323 sialyltransferase 1 [Bos taurus]
gi[76631783 PREDICTED: similar to chondroitin 6-sulfotransferase [Bos taurus]
gill 14052973 glypican 1 [Bos taurus]
gil122692293 chloride intracellular channel 4 [Bos taurus]
gi77735939 proliferating cell nuclear antigen [Bos taurus]
gi|1 19910239 PREDICTED: similar to gamma-adaptin [Bos taurus)
gi|47564098 cell division cycle 10 [Bos taurus]
gi|84000371 H2A histone family, member V [Bos taurus]
gi|134085671 histone cluster 1, Hi c [Bos taurus]
gi78042544 galactosidase, beta 1 [Bos taurus]
gi[84000197 FK506 binding protein 3, 25kDa [Bos taurus]
gil2780584
7 
crystallin, lambda 1 [Bos taurus]
gil1 15497422 glucosamire (N-acetyl)-6-sufatase [Bos taurus]
gi|77736031 chaperonin containing TCP1, subunit 6A [Bos taurus]
gil122692521 DEAH (Asp-Glu-Ala-His) box polypeptide 36 [Bos taurus}
gi|76635454 PREDICTED: similar to OAF homolog (Drosophila) [Bos taurus]
gi|77736207 growth factor receptor-bound protein 2 [Bos taurus]
gi|77735815 rrbosomal protein L30 [Bos taurus]
giJ62751458 endoplasmic reticulum thioredoxin superfamily member. 18 kDa [Bos taurus]
gi45430019 ribosomal protein L12 [Bos taurus]
gil27806083 peroxiredoxin 3 [Bos taurus)
gi62751982 proteasome (prosome, macropain) subunit, alpha type. 5 [Bos taurus]
gi|155371989 methionine adenosyltransferase 11, alpha [Bos taurus]
gi|1 14052601 hypothetical protein LOC530784 [Bos taurus]
gi|149642987 S100 calcium binding protein Al1 (calgizzarin) [Bos taurus]
gil76669880 PREDICTED: similar to LRTS841 [Bos taurus]
gi|77736139 proteasome (prosome, macropain) subunit, beta type, 3 [Bos taurus]
gi|119901198 PREDICTED: similar to Man9-mannosidase [Bos taurus]
gil122692459 ABI gene family, member 3 (NESH) binding protein [Bos taurus]












































































0.583065838 2.722416 1.0707180.335263055 0.613421 0.5701

























































































































0.0913148 0.629888 04801530.4636148 1411991 1.011494
0.449906825
0.147658919
0.2143126160.052742037
0.075396343
0.007001955
0.044667797
0.005336706
0.148761828
0.122131253
9.02E-06
0.163511214
0.184405477
0.039430197
0.005036076
0.057707358
0.000146953
0.029986705
0.030923861
0.100036468
0.016719328
0.015547378
0.108541195
0.019243706
0.204676729
0.007936662
0.086514746
0.089630587
0.124535298
0.03125
0.09457953
0.538829433
0.038702029
0.017431026
0.080679787
0.121591531
0.436910788
0.944212072
0.210607741
0.099640677
0.204752902
0.227727609
0.106078454
0.162961893
0.226181408
0.050063854
0.002966252
0.351888895
0.015323242
0.107723999
0.647913246
0.101084937
0.399893253
0.192449106
0.0784065
0.025621412
0.059500004
0.25454044
0.349964129
0.64873546
0.230181937
0.0899961980.002049768
0.097124639
0.152654038
0.035564114
0.307839705
0600944594
